const DRUGS = {

autonomic: [
{
    group: "Parasympathetics",
    color: "auto",
    drugs: [
      {
        name: "Cholinomimetics (Direct)",
        summary: "Direct muscarinic agonists — bethanechol for urinary retention/ileus, pilocarpine for glaucoma/Sjögren's dry mouth",
        tier: 1,
        aka: "Bethanechol, Carbachol, Pilocarpine, Methacholine",
        tags: ["Glaucoma", "Ileus", "Xerostomia"],
        moa: "Directly bind and activate **muscarinic (M) receptors** → ↑ parasympathetic tone",
        use: "Bethanechol: postop ileus, urinary retention. Pilocarpine: glaucoma (↑ aqueous outflow), Sjögren syndrome (dry mouth). Methacholine: challenge test for asthma diagnosis",
        se: "**DUMBBELLS**: Diarrhea, Urination, Miosis, Bradycardia, Bronchospasm, Emesis, Lacrimation, Salivation",
        ci: "Asthma (bronchospasm risk), peptic ulcer, bowel obstruction",
        pk: "",
        pearl: "Pilocarpine is the classic **glaucoma drug that constricts the pupil** — it opens the trabecular meshwork. Bethanechol does NOT cross the BBB (quaternary amine)."
      },
      {
        name: "Acetylcholinesterase Inhibitors",
        summary: "↑ ACh by blocking breakdown — neostigmine for MG, donepezil for Alzheimer's, physostigmine reverses anticholinergic toxicity",
        tier: 1,
        aka: "Neostigmine, Physostigmine, Pyridostigmine, Edrophonium, Donepezil, Rivastigmine",
        tags: ["Myasthenia Gravis", "Alzheimer's Disease", "Reversal Agent"],
        moa: "Inhibit **AChE** → ↑ ACh at both muscarinic and nicotinic synapses",
        use: "Neostigmine/pyridostigmine: myasthenia gravis. Edrophonium: diagnosis of MG (Tensilon test). Donepezil/rivastigmine: Alzheimer's dementia. Physostigmine: atropine/anticholinergic overdose (crosses BBB)",
        se: "Cholinergic excess (DUMBBELLS), bradycardia, lacrimation, urination, GI cramping",
        ci: "Bowel/bladder obstruction, severe bradycardia",
        pk: "Edrophonium: ultra-short acting (2 min). Neostigmine/pyridostigmine: don't cross BBB. Physostigmine: crosses BBB (tertiary amine)",
        pearl: "**Organophosphate poisoning** = irreversible AChE inhibition. Treat with **atropine** (blocks muscarinic effects) + **pralidoxime** (regenerates AChE if given early, before 'aging')."
      },
      {
        name: "Muscarinic Antagonists (Anticholinergics)",
        summary: "Can't see/spit/pee/poop — atropine for bradycardia, ipratropium for COPD, benztropine for drug-induced Parkinsonism",
        tier: 1,
        aka: "Atropine, Scopolamine, Ipratropium, Tiotropium, Oxybutynin, Benztropine, Glycopyrrolate",
        tags: ["Asthma", "COPD", "Motion Sickness", "Parkinson's Disease"],
        moa: "Competitively block **muscarinic receptors** → ↓ parasympathetic tone",
        use: "Atropine: bradycardia, organophosphate poisoning, pre-op to dry secretions. Scopolamine: motion sickness. Ipratropium/tiotropium: COPD. Oxybutynin: overactive bladder. Benztropine: drug-induced Parkinsonism",
        se: "**Can't see, spit, pee, or poop. Hot as a hare, dry as a bone, red as a beet, mad as a hatter**: mydriasis, dry mouth, urinary retention, constipation, hyperthermia, anhidrosis, flushing, delirium",
        ci: "Narrow-angle glaucoma (↑ IOP), BPH, tachycardia",
        pk: "Ipratropium/tiotropium: inhaled — minimal systemic effects (quaternary)",
        pearl: "**Classic toxicity trap:** elderly patient with confusion, dilated pupils, urinary retention, dry flushed skin = anticholinergic toxicity. **Reverse with physostigmine** (crosses BBB, unlike neostigmine)."
      },
    ]
  },
{
    group: "Sympathetics",
    color: "auto",
    drugs: [
      {
        name: "Epinephrine & Norepinephrine",
        summary: "Epi: first-line anaphylaxis (IM lateral thigh) + cardiac arrest. NE: first-line vasopressor in septic shock",
        tier: 1,
        aka: "Epinephrine (Adrenaline) · Norepinephrine (Levophed)",
        tags: ["Anaphylaxis", "Septic Shock", "Cardiac Arrest"],
        moa: "**Epinephrine:** α1/α2 + β1/β2 agonist — full adrenergic activation. **Norepinephrine:** α1/α2 + β1 agonist — primarily vasoconstrictive (minimal β2)",
        use: "Epinephrine: anaphylaxis (IM first-line), cardiac arrest (IV/IO), croup (nebulized racemic), co-administered with local anesthetics (↑ duration). NE: first-line vasopressor in septic shock",
        se: "Hypertension, tachycardia, arrhythmias, tissue necrosis (extravasation — use central line for NE). Epinephrine: hyperglycemia (β2 → glycogenolysis)",
        ci: "Avoid in cocaine/amphetamine toxicity (synergistic HTN). NE: hypovolemia before adequate resuscitation",
        pk: "Epinephrine IM lateral thigh: fastest absorption for anaphylaxis. NE: IV only, short t½, central venous access preferred",
        pearl: "**Epinephrine in anaphylaxis:** α1 → vasoconstriction (↑BP, ↓laryngeal edema); β1 → ↑HR/contractility; β2 → bronchodilation + ↓ mediator release. IM lateral thigh > IM deltoid > subcutaneous. Never delay — give immediately."
      },
      {
        name: "Dopamine & Dobutamine",
        summary: "Dopamine: dose-dependent (renal→cardiac→vasoconstriction). Dobutamine: ↑ contractility in cardiogenic shock, used in stress echo",
        tier: 1,
        aka: "Dopamine (Intropin) · Dobutamine (Dobutrex)",
        tags: ["Cardiogenic Shock", "Heart Failure", "Vasopressors"],
        moa: "**Dopamine:** dose-dependent — low (1–3 µg/kg/min): D1 → renal vasodilation; mid (3–10): β1 → ↑ contractility; high (>10): α1 → vasoconstriction. **Dobutamine:** β1 > β2 → ↑ contractility + mild vasodilation",
        use: "Dopamine: bradycardia with hypotension, cardiogenic shock. Dobutamine: cardiogenic shock/acute decompensated HF (↑ CO without ↑ afterload), stress echocardiography",
        se: "Dopamine: tachyarrhythmias, ischemia at high doses. Dobutamine: tachycardia, hypotension (β2 vasodilation), can precipitate ischemia in CAD",
        ci: "Dobutamine: HOCM (↑ outflow obstruction), uncorrected hypovolemia",
        pk: "Both IV infusion only. Dobutamine preferred over dopamine in cardiogenic shock (less arrhythmogenic, more predictable β1 effect)",
        pearl: "**Dobutamine stress echo:** Used in patients who can't exercise — ↑ HR + contractility unmasks ischemia (regional wall motion abnormalities). Does NOT reliably increase BP — if BP support also needed, add NE."
      },
      {
        name: "Phenylephrine & Isoproterenol",
        summary: "Phenylephrine (pure α1) → ↑ BP + reflex bradycardia. Isoproterenol (pure β) → ↑ HR, used as bridge in severe bradycardia",
        tier: 1,
        aka: "Phenylephrine (pure α1) · Isoproterenol (pure β1/β2) · Albuterol (β2-selective)",
        tags: ["Vasopressor", "Bradycardia", "Asthma"],
        moa: "**Phenylephrine:** pure α1 → vasoconstriction only (no β → no tachycardia). **Isoproterenol:** pure β1/β2 → ↑ HR + bronchodilation. **Albuterol:** β2-selective → bronchial smooth muscle relaxation",
        use: "Phenylephrine: hypotension without tachycardia (e.g., spinal anesthesia), nasal decongestant. Isoproterenol: severe bradycardia/AV block (bridge to pacing), torsades de pointes. Albuterol: acute asthma rescue, hyperkalemia (shifts K+ into cells)",
        se: "Phenylephrine: reflex bradycardia (baroreceptor response to ↑ BP). Isoproterenol: severe tachycardia, arrhythmias. Albuterol: tremor, tachycardia, hypokalemia",
        ci: "Isoproterenol: ischemic heart disease (↑ O2 demand). Phenylephrine: severe hypertension",
        pk: "Albuterol inhaled — onset 5 min. Phenylephrine: also available topical/nasal spray",
        pearl: "**Phenylephrine causes reflex bradycardia** — pure α1 raises BP → baroreceptors sense ↑ MAP → vagal response → HR drops. This makes it useful when you want BP support without worsening tachycardia, e.g., SVT with hypotension."
      },
      {
        name: "Beta Blockers (β-blockers)",
        summary: "First-line for HF, post-MI, HTN, rate control in AF — metoprolol β1-selective; avoid in asthma and cocaine chest pain",
        tier: 1,
        aka: "Metoprolol, Atenolol (β1-selective) · Propranolol, Carvedilol, Labetalol (non-selective)",
        tags: ["HTN", "HF", "Post-MI", "Arrhythmia"],
        moa: "Competitively block **β-adrenergic receptors** → ↓ HR, ↓ contractility, ↓ renin, ↓ AV conduction",
        use: "HTN, angina, HF (carvedilol/metoprolol/bisoprolol — evidence-based), post-MI, rate control (SVT/AF), hyperthyroidism, essential tremor, migraine prophylaxis, performance anxiety. Propranolol: pheochromocytoma (only after α-blockade)",
        se: "Bradycardia, AV block, fatigue, **masks hypoglycemia**, bronchospasm (non-selective), cold extremities, sexual dysfunction, ↑ triglycerides",
        ci: "Asthma/COPD (non-selective), decompensated HF, bradycardia, AV block. **Never use alone in pheo** (unopposed α → hypertensive crisis)",
        pk: "β1-selective (Atenolol, Metoprolol, Esmolol): safer in asthmatics. Carvedilol/labetalol: α+β blockade. Esmolol: ultra-short IV",
        pearl: "**Pheochromocytoma trap:** never give β-blocker without α-blocker first — blocking β2 (vasodilation) with intact α1 causes severe paradoxical hypertension. Always give **phenoxybenzamine first**."
      },
      {
        name: "Alpha Blockers (α-blockers)",
        summary: "Prazosin/tamsulosin: HTN + BPH. Phentolamine: pheochromocytoma. Key SE: first-dose orthostatic hypotension",
        tier: 2,
        aka: "Prazosin, Doxazosin, Terazosin (α1) · Phenoxybenzamine (irreversible α1/α2) · Phentolamine (competitive α1/α2)",
        tags: ["HTN", "BPH", "Pheochromocytoma"],
        moa: "**α1 blockade** → vasodilation (↓ SVR). Prazosin/doxazosin: competitive. Phenoxybenzamine: irreversible (surgical prep for pheo)",
        use: "Prazosin: HTN, PTSD nightmares. Doxazosin/terazosin: BPH. Phenoxybenzamine: pheochromocytoma preoperative (given 1–2 weeks before surgery)",
        se: "**First-dose orthostatic hypotension** (tell patient to take first dose at bedtime), reflex tachycardia, nasal congestion, inhibition of ejaculation",
        ci: "",
        pk: "",
        pearl: "**BPH pharmacology:** α1-blockers (prazosin) relax smooth muscle for immediate symptom relief. 5α-reductase inhibitors (finasteride) shrink the gland but take months. For acute relief → α-blocker first."
      },
    ]
  },
  {
    group: "Local & Neuromuscular Pharmacology",
    color: "neuro",
    drugs: [
      {
      name: "Local Anesthetics",
      summary: "Block Na⁺ channels (use-dependent) — amides metabolized by liver, esters by plasma esterases. Don't work in acidic tissue. Epinephrine prolongs effect",
      tier: 1,
      aka: "Amides (Lidocaine, Bupivacaine, Mepivacaine) · Esters (Procaine, Benzocaine, Tetracaine, Cocaine)",
      tags: ["Anesthesia", "Nerve Block", "Arrhythmia"],
      moa: "Bind and block **voltage-gated Na⁺ channels** (inner pore, charged form) → prevent membrane depolarization → no action potential. **Use-dependent block** — more effective in rapidly firing neurons (pain fibers >> motor fibers). Small myelinated > small unmyelinated > large myelinated fibers (pain first, proprioception last)",
      use: "Local/regional anesthesia (infiltration, nerve block, spinal/epidural). Lidocaine IV: ventricular arrhythmias (Class IB). Cocaine: only local anesthetic that is also a vasoconstrictor (only one used as topical nasal/ENT anesthetic — also causes euphoria/abuse)",
      se: "CNS: initial excitation (tinnitus, metallic taste, perioral numbness, seizures) → then CNS depression. Cardiovascular: arrhythmias, hypotension. **Bupivacaine:** severe cardiotoxicity — binds cardiac Na⁺ channels with high affinity (treat with lipid emulsion rescue — Intralipid). Methemoglobinemia: benzocaine, prilocaine (treat with methylene blue)",
      ci: "Acidic/infected tissue (protonated form cannot enter channel). **Amide allergy:** rare — use ester instead. Ester allergy (PABA metabolite): common — use amide. **Cocaine:** not for injection (vasoconstriction → tissue necrosis)",
      pk: "**Amides (lidocaine, bupivacaine):** metabolized by **hepatic CYP450** — longer duration. **Esters (procaine, cocaine):** metabolized by **plasma pseudocholinesterase** — shorter duration. Adding **epinephrine** causes local vasoconstriction → ↓ systemic absorption → prolongs block + ↓ toxicity. Never add epi to ring-block digits/nose/penis (end arteries → ischemic necrosis)",
      pearl: "**Why don't local anesthetics work in abscesses?** Infected tissue is acidic (pH ~6.0). Local anesthetics cross membranes in uncharged (base) form, then protonate inside the cell to block the channel. At low pH, drug is protonated in the extracellular space and **cannot cross the membrane** → no block. Classic Step 1 mechanism question."
    },
      {
      name: "Neuromuscular Blocking Agents",
      summary: "Succinylcholine (depolarizing): rapid intubation, hyperkalemia risk, malignant hyperthermia. Non-depolarizing (vecuronium, rocuronium): reversed by neostigmine or sugammadex",
      tier: 1,
      aka: "Depolarizing: Succinylcholine (Anectine) · Non-depolarizing: Rocuronium, Vecuronium, Atracurium, Pancuronium, Cisatracurium",
      tags: ["Intubation", "Paralysis", "Malignant Hyperthermia"],
      moa: "**Succinylcholine (depolarizing):** acts as ACh at nicotinic NMJ → sustained depolarization → initial fasciculations → flaccid paralysis (membrane cannot repolarize while drug occupies receptor). **Non-depolarizing:** competitive antagonism at nicotinic NMJ → no fasciculations, no initial depolarization → flaccid paralysis",
      use: "Succinylcholine: rapid sequence intubation (RSI — ultrashort-acting, fastest onset ~60 sec). Non-depolarizing: prolonged paralysis for ICU/surgery. Rocuronium: RSI alternative when succinylcholine contraindicated",
      se: "**Succinylcholine:** **hyperkalemia** (K⁺ efflux during depolarization — dangerous in burns, crush injury, denervation, prolonged immobility — can → fatal arrhythmia). **Malignant hyperthermia** (with halothane — ryanodine receptor mutation → uncontrolled Ca²⁺ release → rigidity, hyperthermia, rhabdomyolysis — treat with **dantrolene**). Bradycardia (especially in children — pretreat with atropine). Non-depolarizing: no hyperkalemia, prolonged effect in renal/hepatic failure (except atracurium — Hofmann elimination)",
      ci: "Succinylcholine: **hyperkalemia risk states** (burns >24h post, crush injury, spinal cord injury >3 days, prolonged immobility, denervating conditions). Pseudocholinesterase deficiency (prolonged paralysis)",
      pk: "Succinylcholine: **ultra-short** (metabolism by plasma pseudocholinesterase, ~10 min). Rocuronium: ~30–60 min, reversed by **sugammadex** (encapsulates drug directly). Vecuronium: hepatic elimination. Atracurium/cisatracurium: Hofmann elimination (spontaneous pH/temperature-dependent → organ-independent → safe in renal/hepatic failure)",
      pearl: "**Reversal of non-depolarizing agents:** Neostigmine (AChE inhibitor → ↑ ACh at NMJ → competes with drug, must give with atropine/glycopyrrolate to prevent bradycardia) OR sugammadex (directly encapsulates rocuronium/vecuronium — complete reversal, no need for anticholinergic). **Sugammadex is revolutionizing RSI** — rocuronium + sugammadex can replace succinylcholine for RSI while avoiding hyperkalemia/malignant hyperthermia risk."
    },
      {
      name: "Barbiturates",
      summary: "Phenobarbital: seizures + sedation. Thiopental: IV anesthesia induction. Strong CYP450 inducers — many drug interactions. Overdose: respiratory depression (no reversal agent)",
      tier: 1,
      aka: "Phenobarbital · Primidone · Thiopental (ultra-short IV) · Pentobarbital · Amobarbital",
      tags: ["Seizures", "Sedation", "Anesthesia", "CYP Induction"],
      moa: "Bind **GABA-A receptor** (at barbiturate site, distinct from benzodiazepine site) → **increase duration** of Cl⁻ channel opening (vs. benzos which ↑ frequency). At high doses: directly activate GABA-A without GABA → full CNS depression",
      use: "Phenobarbital: **tonic-clonic seizures, status epilepticus** (second-line after benzos), neonatal seizures. Thiopental: IV induction of anesthesia (largely replaced by propofol). Phenobarbital: neonatal hyperbilirubinemia (induces hepatic conjugation). Butalbital: tension headache (combination products)",
      se: "**Respiratory depression** (dose-dependent, no reversal agent — unlike benzos/opioids — requires supportive care). CNS depression, sedation, cognitive impairment. **CYP450 induction** → ↓ efficacy of OCP, warfarin, antiretrovirals, steroids. Tolerance and physical dependence. **Teratogenic** (neural tube defects, cardiac malformations). Intravenous: severe tissue necrosis if extravasation (highly alkaline)",
      ci: "Porphyria (↑ ALA synthase → ↑ porphyrin synthesis → acute attack). Severe respiratory depression. Pregnancy (teratogenic)",
      pk: "Strong **CYP450 inducers** (3A4, 2C9, 2C19) — most significant inducer class in pharmacology. Phenobarbital: long t½ (~100h), renally excreted. Thiopental: ultra-lipophilic → rapid CNS penetration but rapid redistribution to fat → short clinical effect despite long t½",
      pearl: "**Barbiturates vs. Benzodiazepines at GABA-A:** Benzos ↑ **frequency** of Cl⁻ opening; barbiturates ↑ **duration** of Cl⁻ opening. At overdose, barbiturates can open the channel directly without GABA — explaining why barbiturate overdose is more lethal than benzo overdose and has no antidote. This distinction (frequency vs. duration) is a classic Step 1 question."
    },
      {
      name: "Amphetamines & Methylphenidate",
      summary: "ADHD: reverse NE/DA transporters → flood synapse. Methamphetamine: severe cardiovascular effects + neurotoxicity. Cocaine comparison: same net effect, different mechanism",
      tier: 1,
      aka: "Amphetamine (Adderall) · Methylphenidate (Ritalin, Concerta) · Dextroamphetamine · Lisdexamfetamine (Vyvanse) · Methamphetamine",
      tags: ["ADHD", "Narcolepsy", "Stimulants", "Abuse"],
      moa: "**Amphetamines:** enter presynaptic terminal → **reverse NE and DA transporters (NET, DAT)** → force NE/DA out of vesicles into synapse (carrier-mediated efflux) + block reuptake → ↑↑ synaptic NE/DA/5-HT. **Methylphenidate:** blocks DAT and NET reuptake (no reversal of transport — more like cocaine mechanism). **Cocaine:** blocks DAT/NET/SERT reuptake only (no reversal — cannot release transmitter)",
      use: "ADHD (both amphetamines and methylphenidate), narcolepsy (amphetamines), binge eating disorder (lisdexamfetamine). Methamphetamine: rarely used medically (obesity — off-label)",
      se: "**Cardiovascular:** HTN, tachycardia, arrhythmias, ↑ risk MI/stroke with chronic abuse. CNS: insomnia, anxiety, irritability, psychosis (mimics schizophrenia with chronic use — due to ↑↑ DA). **Growth suppression** in children (reduced appetite). Hyperthermia. Dependence/withdrawal (fatigue, depression, hypersomnia). **Methamphetamine:** more neurotoxic — dopaminergic neuron destruction, severe dental decay, skin picking",
      ci: "Structural heart disease, severe HTN, hyperthyroidism. **MAOIs** (hypertensive crisis — serotonin syndrome if combined). Glaucoma (↑ IOP via mydriasis)",
      pk: "Most are Schedule II controlled substances. Lisdexamfetamine is a prodrug (lysine conjugate) — must be cleaved in GI tract → abuse-deterrent. Methylphenidate available in immediate and extended-release formulations",
      pearl: "**Amphetamine vs. Cocaine mechanism comparison:** Both ↑ synaptic DA/NE, but amphetamines **reverse** the transporter (push DA out) while cocaine **blocks** the transporter (prevent reuptake). Net effect similar but mechanism different — classic Step 1 distinction. Also note: cocaine is the only local anesthetic AND sympathomimetic — it blocks Na⁺ channels AND inhibits NE/DA reuptake. In cocaine overdose, treat HTN/arrhythmias with **benzos or phentolamine** — NEVER β-blockers alone (unopposed α1 → worse hypertension)."
    }
    ]
  }
],

cv: [
{
    group: "Heart Failure & Renin-Angiotensin",
    color: "cv",
    drugs: [
      {
        name: "ACE Inhibitors",
        summary: "First-line HF/post-MI/CKD/HTN — block angiotensin II, reduce proteinuria. CI: pregnancy (fetotoxic), bilateral RAS, hyperkalemia",
        tier: 1,
        aka: "Lisinopril, Enalapril, Captopril, Ramipril (-pril suffix)",
        tags: ["HTN", "HF", "DM Nephropathy", "Post-MI"],
        moa: "Inhibit **ACE** → ↓ angiotensin II → vasodilation + ↓ aldosterone → ↓ Na/water retention. Also ↑ bradykinin (→ cough/angioedema)",
        use: "HTN, HF (↓ afterload/preload), post-MI (↓ remodeling), **diabetic nephropathy** (↓ efferent arteriole tone → ↓ glomerular pressure → ↓ proteinuria), CKD with proteinuria",
        se: "**CAPTOPRIL**: Cough (most common, bradykinin-mediated), Angioedema (rare but life-threatening), Proteinuria, Taste changes, hYperkalemia, hypOtension (first-dose), Pregnancy contraindicated, Renal failure (bilateral RAS), Increased creatinine",
        ci: "**Pregnancy (teratogenic — renal agenesis)**, bilateral renal artery stenosis, hyperkalemia, angioedema history",
        pk: "Captopril: shortest acting. Enalapril: prodrug (enalaprilat is active)",
        pearl: "**Dry cough** (bradykinin accumulation) occurs in 10–15% — switch to ARB if intolerable. **Key distinction:** ARBs do NOT cause cough or angioedema because they don't raise bradykinin."
      },
      {
        name: "ARBs (Angiotensin Receptor Blockers)",
        summary: "Same indications as ACEi but no bradykinin → no cough. Preferred when ACEi causes cough. CI: pregnancy",
        tier: 1,
        aka: "Losartan, Valsartan, Irbesartan (-sartan suffix)",
        tags: ["HTN", "HF", "DM Nephropathy"],
        moa: "Block **AT1 receptors** directly → same end effects as ACEi but WITHOUT ↑ bradykinin",
        use: "Same as ACEi. First-line when ACEi causes cough or angioedema. Losartan also lowers uric acid (useful in gout + HTN)",
        se: "Hyperkalemia, hypotension, renal failure. **No cough.** Rare angioedema (still possible via bradykinin-independent pathway)",
        ci: "Pregnancy, bilateral renal artery stenosis, hyperkalemia",
        pk: "",
        pearl: "**ACEi vs ARB on Step 1:** both are first-line for DM nephropathy and HF. ACEi → cough (bradykinin ↑). ARB → no cough. Both are **absolutely contraindicated in pregnancy** (fetal renal toxicity)."
      },
    ]
  },
{
    group: "Diuretics",
    color: "cv",
    drugs: [
      {
        name: "Loop Diuretics",
        summary: "Furosemide: block Na/K/2Cl in TAL → most potent diuretic. Cause hypokalemia + metabolic alkalosis. Work even in renal failure",
        tier: 1,
        aka: "Furosemide, Bumetanide, Torsemide, Ethacrynic acid",
        tags: ["HF", "Edema", "Hypercalcemia"],
        moa: "Inhibit **Na-K-2Cl cotransporter (NKCC2)** in thick ascending loop of Henle → ↓ Na/K/Cl reabsorption → massive diuresis",
        use: "Acute pulmonary edema, HF, cirrhotic ascites, nephrotic syndrome, hypercalcemia, hypertensive emergency",
        se: "**Oh DANG:** Ototoxicity (dose-dependent, especially with aminoglycosides), Dehydration, hyperuricemia/gout, hyperglycemia, **hypokalemia**, metabolic alkalosis, hypomagnesemia, hyponatremia. Sulfa allergy risk (except ethacrynic acid)",
        ci: "Anuria, sulfa allergy (use ethacrynic acid instead), hypovolemia",
        pk: "Ethacrynic acid: non-sulfa — safe in sulfa allergy. Furosemide: best IV for acute situations",
        pearl: "**Loop diuretics = Lose calcium.** Thiazides = retain calcium. This is why loops treat hypercalcemia and thiazides treat hypocalciuria (kidney stones from Ca2+ wasting). Memorize this distinction — it's tested constantly."
      },
      {
        name: "Thiazide Diuretics",
        summary: "HCTZ: only diuretic that ↑ Ca²⁺ — used for kidney stones and nephrogenic DI. Causes HyperGLUCaemia electrolyte effects",
        tier: 1,
        aka: "Hydrochlorothiazide (HCTZ), Chlorthalidone, Metolazone",
        tags: ["HTN", "Nephrolithiasis", "DI"],
        moa: "Inhibit **NaCl cotransporter (NCC)** in early DCT → ↓ Na/Cl reabsorption",
        use: "HTN (first-line), HF, nephrogenic diabetes insipidus (paradoxically ↓ urine), calcium nephrolithiasis (↓ urinary Ca2+ → prevents stones)",
        se: "**HyperGLUCaemia:** Hyperglycemia, hyperLipidemia, hyperUricemia (gout), hyperCalcemia, **hypokalemia**, hyponatremia, metabolic alkalosis",
        ci: "Gout, sulfa allergy, hypokalemia",
        pk: "Metolazone: works even in low GFR — useful in refractory HF when combined with furosemide",
        pearl: "**Thiazides are the only diuretic that INCREASES calcium.** Use for: hypercalciuria/kidney stones. Conversely, loops are used for hypercalcemia. Also: thiazides paradoxically treat nephrogenic DI by reducing ECF volume → ↑ proximal tubule reabsorption."
      },
      {
        name: "K+-Sparing Diuretics",
        summary: "Spironolactone (aldosterone antagonist) for HF/ascites/hyperaldosteronism. Triamterene/amiloride block ENaC — all cause hyperkalemia",
        tier: 2,
        aka: "Spironolactone, Eplerenone (aldosterone antagonists) · Triamterene, Amiloride (ENaC blockers)",
        tags: ["HF", "Hyperaldosteronism", "Liver Cirrhosis"],
        moa: "Spironolactone: **aldosterone receptor antagonist** in collecting duct → blocks Na reabsorption and K+ secretion. Triamterene/amiloride: directly block ENaC",
        use: "Spironolactone: HF (↓ mortality), hyperaldosteronism (Conn syndrome), cirrhotic ascites, hirsutism/PCOS. Amiloride: Liddle syndrome (gain-of-function ENaC)",
        se: "**Hyperkalemia** (dangerous — avoid with ACEi/ARBs). Spironolactone: **gynecomastia**, menstrual irregularities (anti-androgen effect). Eplerenone: fewer anti-androgen SEs",
        ci: "Renal failure, hyperkalemia, concurrent ACEi + K+-sparing = dangerous hyperkalemia",
        pk: "Spironolactone: anti-androgenic (competes at androgen receptor). Eplerenone: more selective, less anti-androgen",
        pearl: "**Spironolactone in HF:** RALES trial showed it reduces mortality in severe HF. Remember it causes gynecomastia — if that's intolerable, switch to eplerenone. Also the treatment of choice for **primary hyperaldosteronism (Conn syndrome)**."
      },
      {
        name: "Carbonic Anhydrase Inhibitors",
        summary: "Acetazolamide: metabolic acidosis, altitude sickness, glaucoma, idiopathic intracranial hypertension — causes hypokalemia + acidosis",
        tier: 2,
        aka: "Acetazolamide",
        tags: ["Glaucoma", "Altitude Sickness", "Metabolic Alkalosis"],
        moa: "Inhibit **carbonic anhydrase** in PCT → ↓ H+ secretion → ↓ HCO3- reabsorption → metabolic acidosis + alkaline urine",
        use: "Glaucoma (↓ aqueous humor), altitude sickness prevention, metabolic alkalosis, pseudotumor cerebri, some epilepsies",
        se: "**Hyperchloremic metabolic acidosis**, hypokalemia, sulfa allergy, paresthesias (tingling extremities), renal stones (alkaline urine → Ca phosphate stones)",
        ci: "Sulfa allergy, hepatic cirrhosis (↓ NH3 excretion → encephalopathy)",
        pk: "",
        pearl: "**Classic board question:** Climber going to high altitude → prescribe acetazolamide prophylactically. MOA: metabolic acidosis compensatorily increases breathing (↑ ventilation), which helps acclimatize. Also remember: it causes **paresthesias** — a giveaway SE."
      },
    ]
  },
{
    group: "Anti-Hypertensives",
    color: "cv",
    drugs: [
      {
        name: "Calcium Channel Blockers (CCBs)",
        summary: "Dihydropyridines (amlodipine): HTN/angina. Non-DHP (verapamil/diltiazem): rate control in AF. Verapamil most constipating",
        tier: 1,
        aka: "Dihydropyridines: Amlodipine, Nifedipine, Nicardipine · Non-DHP: Verapamil, Diltiazem",
        tags: ["HTN", "Angina", "Arrhythmia"],
        moa: "Block **L-type voltage-gated Ca2+ channels**. Dihydropyridines: vascular smooth muscle → vasodilation. Non-DHP: also cardiac (↓ HR, ↓ AV conduction)",
        use: "DHP: HTN, angina (vasospastic/Prinzmetal), Raynaud's. Non-DHP: rate control in AF/AFl, SVT, angina. Nimodipine: subarachnoid hemorrhage (prevents vasospasm)",
        se: "DHP: peripheral edema, reflex tachycardia, flushing, headache, gingival hyperplasia. Non-DHP: **bradycardia, AV block, constipation**, negative inotropy",
        ci: "Non-DHP: AV block, cardiogenic shock, pre-excitation syndromes (WPW). Don't combine non-DHP with β-blocker (↑ bradycardia/AV block risk)",
        pk: "Verapamil and diltiazem act on heart AND vessels. Amlodipine: long-acting, good for chronic HTN",
        pearl: "**The key distinction:** Nifedipine (DHP) → mainly vessels → reflex tachycardia. Verapamil (non-DHP) → mainly heart → bradycardia, constipation. Verapamil + β-blocker = **complete heart block risk**."
      },
      {
        name: "Hydralazine & Direct Vasodilators",
        summary: "Hydralazine: direct arterial vasodilator for HTN in pregnancy and HF (with nitrates). Causes drug-induced lupus",
        tier: 2,
        aka: "Hydralazine · Minoxidil · Nitroprusside (sodium nitroprusside)",
        tags: ["HTN Emergency", "HF", "Pregnancy HTN"],
        moa: "Hydralazine: directly relaxes **arteriolar smooth muscle** (↑ cGMP). Minoxidil: opens K-ATP channels → hyperpolarization → ↓ Ca entry → vasodilation. Nitroprusside: releases NO → ↑ cGMP → arterial AND venous dilation",
        use: "Hydralazine: HTN in pregnancy (safe; First-line for eclampsia), HF in African Americans (+ nitrate, BiDil). Minoxidil: severe refractory HTN, topical for alopecia. Nitroprusside: hypertensive emergency (IV), acute HF",
        se: "Hydralazine: **drug-induced lupus** (anti-histone Ab), reflex tachycardia, fluid retention, headache. Minoxidil: **hypertrichosis** (body hair growth), fluid retention, pericardial effusion. Nitroprusside: **cyanide toxicity** (especially with renal failure/prolonged use) — metabolized to cyanide; treat with sodium thiosulfate + hydroxocobalamin",
        ci: "Hydralazine: severe tachycardia, CAD (reflex tachycardia ↑ O2 demand). Nitroprusside: renal failure (cyanide accumulation)",
        pk: "Nitroprusside: must be light-protected (photodegrades). Immediate onset/offset — ideal for hypertensive emergency with minute-to-minute titration",
        pearl: "**Drug-induced lupus (DIL) drugs — 'HIPMC':** Hydralazine, INH, Procainamide, Minocycline, Chlorpromazine. DIL features: ANA positive, **anti-histone antibodies** (not anti-dsDNA), no renal/CNS involvement, resolves on stopping drug."
      },
    ]
  },
{
    group: "Antiarrhythmics",
    color: "cv",
    drugs: [
      {
        name: "Adenosine",
        summary: "Drug of choice for terminating SVT — transient AV block. Very short t½ (10 sec). Blocked by theophylline, potentiated by dipyridamole",
        tier: 1,
        aka: "Adenocard",
        tags: ["SVT", "Diagnosis", "ACLS"],
        moa: "Activates **A1 adenosine receptors** on AV nodal cells → ↑ K+ conductance (hyperpolarize) + ↓ cAMP → profound, transient AV node block → terminates reentrant SVT",
        use: "First-line for **acute SVT termination** (AVNRT, AVRT). Also used diagnostically to unmask atrial flutter or identify accessory pathways. Adenosine is NOT effective for A-fib or V-tach",
        se: "**Transient chest pain/flushing**, dyspnea, sense of impending doom (very brief — 10 sec). Bronchospasm (avoid in asthma). Bradycardia/AV block (desired, transient)",
        ci: "Asthma/COPD (bronchospasm), 2nd/3rd degree AV block, Wolff-Parkinson-White with pre-excitation (may accelerate conduction in accessory pathway)",
        pk: "**Half-life ~10 seconds** — extremely short (inactivated by red blood cells and vascular endothelium). Must be given as rapid IV push followed immediately by normal saline flush. Use central or antecubital vein",
        pearl: "**Adenosine pearls:** (1) Methylxanthines (theophylline, caffeine) block adenosine receptors → ↓ efficacy → may need higher dose. (2) Dipyridamole inhibits adenosine uptake → ↑ adenosine effects → use lower dose. (3) If adenosine breaks SVT but it recurs, use verapamil for longer-lasting AV block."
      },
      {
        name: "Class IA Antiarrhythmics",
        summary: "Quinidine/procainamide/disopyramide: block Na+ + K+ channels → ↑ QRS + QT. Quinidine: torsades + cinchonism (tinnitus)",
        tier: 2,
        aka: "Quinidine, Procainamide, Disopyramide",
        tags: ["Atrial Fibrillation", "VT", "WPW"],
        moa: "Block **Na+ channels (intermediate kinetics)** + K+ channels → ↑ AP duration, ↑ ERP, ↑ QT interval",
        use: "AF, AFl, WPW (accessory pathway), ventricular tachycardia",
        se: "**Quinidine:** cinchonism (tinnitus, headache, visual changes), thrombocytopenia, torsades de pointes (QT prolongation). **Procainamide:** drug-induced lupus (anti-histone antibodies). **Disopyramide:** strong anticholinergic effects",
        ci: "QT prolongation, torsades history",
        pk: "",
        pearl: "**Procainamide → Drug-Induced Lupus (DIL).** Think: PRocainamide = PRo-lupus. ANA positive, anti-histone antibodies. Lupus symptoms resolve with drug cessation. Other DIL drugs: Hydralazine, INH, Minocycline, Chlorpromazine — 'HIPMC'."
      },
      {
        name: "Class IB Antiarrhythmics",
        summary: "Lidocaine/mexiletine: block Na+ channels in ischemic tissue only — post-MI ventricular arrhythmias. ↓ QT interval",
        tier: 2,
        aka: "Lidocaine, Mexiletine, Phenytoin",
        tags: ["Post-MI VT", "Ventricular Arrhythmia"],
        moa: "Block **Na+ channels (fast on/off)** — preferentially bind depolarized/ischemic tissue. ↓ AP duration. Minimal effect on normal tissue",
        use: "Acute ventricular arrhythmias (especially post-MI). Mexiletine: oral lidocaine equivalent for chronic VT",
        se: "Lidocaine: CNS toxicity (tinnitus, seizures, sedation at toxic doses), cardiovascular depression",
        ci: "",
        pk: "Lidocaine: IV only (extensive first-pass). Mexiletine: oral",
        pearl: "**IB drugs love ischemic tissue.** Lidocaine has fast off-rate — it dissociates rapidly from normal resting channels but stays bound to rapidly firing ischemic channels (use-dependent block). **Overdose:** '1-5-1' — cardiac depression, then CNS signs, then grand mal seizure."
      },
      {
        name: "Class IC Antiarrhythmics",
        summary: "Flecainide/propafenone: most potent Na+ blockers — atrial arrhythmias only. CI in structural heart disease (↑ mortality — CAST trial)",
        tier: 2,
        aka: "Flecainide, Propafenone",
        tags: ["Atrial Fibrillation", "SVT"],
        moa: "Block **Na+ channels (slow kinetics)** → markedly ↑ PR and QRS duration. Potent Na+ channel blockade",
        use: "SVT, AF/AFl in structurally normal hearts",
        se: "**Proarrhythmic** — can convert AF into AFL with 1:1 conduction. Post-MI arrhythmia risk (CAST trial: ↑ mortality in post-MI patients)",
        ci: "**Structural heart disease, post-MI** — absolutely contraindicated (CAST trial proved this)",
        pk: "",
        pearl: "**CAST trial (1989):** Flecainide and encainide suppressed PVCs post-MI but INCREASED mortality. Classic lesson: treating arrhythmias doesn't always improve outcomes. If exam mentions IC + structural heart disease = wrong choice."
      },
      {
        name: "Class III Antiarrhythmics",
        summary: "Amiodarone: broadest antiarrhythmic (all classes) but pulmonary/thyroid/hepatic toxicity. Sotalol/ibutilide also prolong QT",
        tier: 1,
        aka: "Amiodarone, Sotalol, Ibutilide, Dofetilide",
        tags: ["Atrial Fibrillation", "VT", "VF"],
        moa: "Block **K+ channels** → ↑ AP duration, ↑ ERP, ↑ QT interval. Amiodarone also blocks Na+, Ca2+, β-receptors (class I/II/III/IV properties)",
        use: "Amiodarone: AF, VT, VF, WPW — drug of choice in cardiac arrest. Sotalol: also has β-blocker activity",
        se: "**Amiodarone toxicity (PALE):** Pulmonary fibrosis (#1 cause of death), liver toxicity, thyroid dysfunction (↑ or ↓ — contains iodine), corneal microdeposits, blue-gray skin discoloration, neuropathy, photosensitivity. Half-life: **40–55 days**",
        ci: "QT prolongation (torsades risk), thyroid disease (relative)",
        pk: "Amiodarone: extremely lipophilic, massive Vd, t½ ~40–55 days — levels persist months after stopping",
        pearl: "**Amiodarone has EVERYTHING:** it's class I, II, III, AND IV. Contains 37% iodine by weight → thyroid effects. Pulmonary toxicity on CXR = bilateral infiltrates. Must monitor **LFTs, TFTs, PFTs, eye exam** regularly."
      },
      {
        name: "Digoxin",
        summary: "↑ vagal tone (rate control in AF) + ↑ contractility — narrow therapeutic window, toxicity precipitated by hypokalemia",
        tier: 1,
        aka: "Digoxin (Digitalis)",
        tags: ["HF", "AF Rate Control"],
        moa: "Inhibits **Na/K-ATPase** → ↑ intracellular Na+ → ↑ Na-Ca exchange → ↑ intracellular Ca2+ → ↑ contractility. Also ↑ vagal tone → ↓ HR/AV conduction",
        use: "HF with reduced EF (↑ contractility). AF rate control (↑ vagal tone). NOT used for acute decompensated HF",
        se: "**Toxicity:** GI (nausea, vomiting, anorexia — earliest signs), visual disturbances (yellow-green halos), **any arrhythmia** (PAT with block is classic), hyperkalemia",
        ci: "AV block, WPW (enhances accessory conduction), hypokalemia/hypomagnesemia (↑ toxicity), renal failure",
        pk: "Narrow therapeutic index (0.5–0.8 ng/mL therapeutic, >2 = toxic). Renally cleared. t½ ~36 hrs",
        pearl: "**Hypokalemia potentiates digoxin toxicity** because K+ and digoxin compete for the same Na/K-ATPase binding site. Low K+ → more digoxin binding → toxicity. Classic vignette: patient on loop diuretic (loses K+) + digoxin → digoxin toxicity. Treat with **digoxin-specific Fab antibodies**."
      },
    ,
      {
  name: "Ranolazine & Ivabradine",
  summary: "Ranolazine: late INa inhibitor → anti-anginal without ↓ HR/BP. Ivabradine: If channel blocker → ↓ HR only. Used in HFrEF with sinus rhythm when β-blocker max'd. Both avoid hemodynamic compromise",
  tier: 2,
  aka: "Ranolazine (Ranexa) · Ivabradine (Corlanor)",
  tags: ["Angina", "Heart Failure", "Rate Control"],
  moa: "**Ranolazine:** inhibits **late INa** (late inward sodium current) during prolonged cardiac depolarization → ↓ intracellular Na⁺ → ↓ Ca²⁺ overload (via Na⁺/Ca²⁺ exchanger) → ↓ myocardial O₂ demand + ↑ diastolic relaxation. Does NOT significantly ↓ HR or BP. **Ivabradine:** blocks **If (funny) current** (pacemaker current in SA node, HCN channels) → ↓ spontaneous depolarization rate → ↓ HR. Sinus node-specific — NO effect on contractility, conduction, or BP",
  use: "Ranolazine: **chronic stable angina** refractory to standard therapy (add-on to β-blockers/CCBs/nitrates). Ivabradine: **HFrEF (EF ≤35%)** with sinus rhythm + resting HR ≥70 bpm despite maximally-tolerated β-blocker (reduces hospitalization for worsening HF — SHIFT trial). Inappropriate sinus tachycardia",
  se: "Ranolazine: **QT prolongation** (avoid with other QT-prolonging drugs), constipation, dizziness, nausea. **CYP3A4 substrate** — significant interactions with strong inhibitors (ketoconazole, diltiazem, verapamil). Ivabradine: **bradycardia**, visual phosphenes (transient flickering — If channels also in retina), AF (↑ atrial fibrillation risk — contraindicated if AF present)",
  ci: "Ranolazine: significant hepatic impairment, QT prolongation, strong CYP3A4 inhibitors. Ivabradine: **atrial fibrillation/flutter** (relies on sinus rhythm), severe bradycardia, hypotension, SSS, 3rd-degree AV block, pacemaker-dependent",
  pk: "Ranolazine: CYP3A4 and 2D6 metabolism — multiple drug interactions. Ivabradine: CYP3A4 metabolism. Both oral agents",
  pearl: "**Ivabradine mechanism is unique:** It slows HR without touching contractility, blood pressure, AV conduction, or bronchial tone — unlike β-blockers, CCBs, or digoxin. This makes it valuable when β-blocker dose is limited by hypotension or bronchospasm. Also: If channels are present in the retina → ivabradine causes **phosphenes** (bright flashes/halos, especially in low-light conditions) — a characteristic but benign side effect."
}
    ]
  },
{
    group: "Vasodilators & Special CV Agents",
    color: "cv",
    drugs: [
      {
        name: "Milrinone & Nesiritide",
        summary: "Milrinone: PDE3 inhibitor → ↑ cAMP → ↑ contractility + vasodilation ('inodilator'). Nesiritide: recombinant BNP → ↑ cGMP → vasodilation in acute HF",
        tier: 2,
        aka: "Milrinone (Primacor) · Nesiritide (Natrecor)",
        tags: ["Acute HF", "Cardiogenic Shock", "Inodilator"],
        moa: "**Milrinone:** inhibits **phosphodiesterase III (PDE3)** → ↑ cAMP in cardiomyocytes and vascular smooth muscle → ↑ contractility (inotrope) + vasodilation (↓ preload + afterload). **Nesiritide:** recombinant human BNP → binds natriuretic peptide receptors → ↑ cGMP → venodilation + mild diuresis",
        use: "Milrinone: acute decompensated HF (short-term IV infusion), cardiogenic shock when dobutamine insufficient. Nesiritide: acute decompensated HF (dyspnea relief, adjunct to diuretics)",
        se: "Milrinone: **arrhythmias** (ventricular tachyarrhythmias — major concern), hypotension, thrombocytopenia. Nesiritide: hypotension (primary concern), possible renal impairment",
        ci: "Milrinone: hypertrophic obstructive cardiomyopathy (HOCM), severe hypotension",
        pk: "Milrinone: renally cleared — reduce dose in renal failure. Both IV only. Milrinone: half-life ~2–3 hours",
        pearl: "**Milrinone = 'inodilator'** — simultaneously ↑ contractility AND ↓ afterload (unlike dobutamine which primarily ↑ contractility). Key exam distinction: dobutamine works via β1 (useful in heart transplant patients pre-transplant); milrinone works downstream of β receptor (remains effective in patients taking β-blockers)."
      },
      {
        name: "Aliskiren",
        summary: "Direct renin inhibitor — inhibits first step of RAAS. Combined with ACEi/ARB: ↑ hyperkalemia + renal failure risk. CI in diabetes with ACEi/ARB",
        tier: 2,
        aka: "Tekturna",
        tags: ["HTN", "RAAS Inhibitor"],
        moa: "Directly inhibits **renin** → ↓ angiotensinogen → angiotensin I conversion → ↓ angiotensin II + ↓ aldosterone. Attacks RAAS at the first enzymatic step",
        use: "Hypertension (typically second-line or add-on therapy when ACEi/ARB insufficient alone)",
        se: "Hyperkalemia, diarrhea (most common GI SE), angioedema (rare), ↑ creatinine",
        ci: "**Combination with ACEi or ARB in diabetic patients** (ALTITUDE trial — ↑ renal failure, hyperkalemia, stroke). Pregnancy (fetotoxic)",
        pk: "Poor oral bioavailability (~2.5%). High-fat meal ↓ absorption. Long t½ (~24 hours)",
        pearl: "**RAAS drug comparison:** ACEi blocks conversion of Ang I → Ang II. ARB blocks Ang II receptor. Aliskiren blocks renin (first step). Combining any two RAAS agents ↑ hyperkalemia and renal failure risk — only the ACEi + ARB combination is most strongly contraindicated."
      },
      {
        name: "Mannitol",
        summary: "Osmotic diuretic → ↓ ICP and IOP. Not absorbed → stays in tubule → pulls water by osmosis. Given IV. Contraindicated in CHF/anuria (volume overload risk)",
        tier: 1,
        aka: "Osmitrol",
        tags: ["↑ ICP", "Cerebral Edema", "Glaucoma", "Osmotic Diuretic"],
        moa: "Freely filtered at glomerulus but **not reabsorbed** → acts as osmotic agent in tubule → draws water into urine → ↓ plasma osmolarity expansion → ↓ brain water content + ↓ ICP. Also ↑ renal blood flow",
        use: "Acute ↑ ICP (cerebral edema, head trauma, stroke with herniation). Acute angle-closure glaucoma (emergency). Promotes excretion of toxic substances (renal tubule flushing). Oliguria prophylaxis before surgery",
        se: "**Initial volume expansion** → dangerous in CHF (fluid overload before diuresis). Electrolyte disturbances (hyponatremia with large doses). Pulmonary edema if given too rapidly in cardiac patients",
        ci: "CHF, pulmonary edema, anuria (can't excrete → volume overload), severe dehydration",
        pk: "IV only (not absorbed orally). Rapidly distributed to extracellular space. Renal excretion unchanged",
        pearl: "**Mannitol vs Hypertonic Saline for ↑ ICP:** Both used for cerebral edema but different mechanisms — mannitol acts via osmotic diuresis (removes volume). Hypertonic saline (3% NS) acts by ↑ plasma osmolarity + direct water draw from brain without diuresis (preferred if hyponatremia or volume depletion). Mannitol is contraindicated in CHF."
      },
      {
        name: "Magnesium Sulfate",
        summary: "Class V antiarrhythmic — First-line for torsades de pointes and eclampsia/pre-eclampsia. Mechanism: Ca²⁺ channel antagonism + membrane stabilization",
        tier: 1,
        aka: "MgSO₄",
        tags: ["Torsades de Pointes", "Eclampsia", "Preeclampsia", "Hypomagnesemia"],
        moa: "Blocks **L-type Ca²⁺ channels** + displaces Ca²⁺ from binding sites → membrane stabilization. ↓ neuromuscular transmission (blocks ACh release at NMJ). ↓ catecholamine release. Mechanism in arrhythmia: restores normal AP kinetics in cells with prolonged QT",
        use: "**Torsades de pointes** (drug of choice — terminates and prevents recurrence). **Pre-eclampsia/eclampsia** (prevents/treats seizures — superior to diazepam). Refractory VF (adjunct). Hypomagnesemia. Severe acute asthma (bronchodilation). Refractory hypokalemia (Mg2+ needed to retain K+)",
        se: "Toxicity correlates with Mg2+ levels: loss of patellar reflexes (first sign, ~7 mEq/L) → respiratory depression (~10 mEq/L) → cardiac arrest. Flushing, hypotension, somnolence",
        ci: "Myasthenia gravis (worsens NMJ block). Renal failure (↓ excretion → accumulation)",
        pk: "IV for acute treatment. Excreted by kidneys — accumulates in renal failure. Antidote: **calcium gluconate IV** (reverses Mg toxicity)",
        pearl: "**Mag toxicity reversal = calcium gluconate.** Classic board scenario: pre-eclamptic patient on MgSO4 infusion → respiratory depression + absent deep tendon reflexes. Give IV calcium gluconate immediately. Monitor patellar reflexes (first to disappear) and urine output during infusion."
      },
    ]
  },
{
  group: "Dyslipidemia",
  color: "cv",
  drugs: [
    {
      name: "Statins (HMG-CoA Reductase Inhibitors)",
      summary: "Inhibit cholesterol synthesis — first-line for LDL lowering. Key SE: myopathy/rhabdomyolysis (↑ with CYP3A4 inhibitors + fibrates)",
      tier: 1,
      aka: "Atorvastatin, Rosuvastatin",
      tags: ["Hypercholesterolemia", "CV Risk Reduction"],
      moa: "Inhibit **HMG-CoA reductase** → ↓ LDL, ↓ VLDL, mild ↑ HDL",
      use: "First-line for LDL reduction and CV event prevention",
      se: "**Myopathy/Rhabdomyolysis** (risk ↑ with fibrates), hepatotoxicity",
      ci: "Pregnancy (teratogenic), active liver disease",
      pk: "Lovastatin/simvastatin: CYP3A4 substrates",
      pearl: "**Statin + fibrate = rhabdomyolysis risk**. Statins also have **pleiotropic effects** (anti-inflammatory)."
    },
    {
      name: "Fibrates & Niacin",
      summary: "Fibrates: ↓ TGs via PPARα. Niacin: ↑ HDL most, ↓ TGs, causes flushing (use aspirin). Both increase statin myopathy risk",
      tier: 1,
      aka: "Gemfibrozil, Fenofibrate · Niacin",
      tags: ["Hypertriglyceridemia", "HDL"],
      moa: "**Fibrates:** activate **PPARα** → ↑ LPL → ↑ TG clearance. **Niacin:** inhibits hormone-sensitive lipase → ↓ hepatic VLDL synthesis → **↑↑ HDL**",
      use: "Fibrates: **hypertriglyceridemia** (TGs > 500). Niacin: raising HDL",
      se: "**Fibrates:** myopathy, gallstones. **Niacin:** **flushing** (prostaglandin-mediated), hyperglycemia, hyperuricemia",
      ci: "Gemfibrozil + statin (high rhabdo risk)",
      pk: "Aspirin blocks niacin-induced flushing by inhibiting COX",
      pearl: "Niacin is the **only drug that significantly raises HDL**."
    }
  ]
}
],

blood: [
  {
    group: "Anticoagulants (Coagulation Factors)",
    color: "blood",
    drugs: [
      {
        name: "Heparin (UFH & LMWH)",
        summary: "UFH: activates antithrombin → inhibits IIa + Xa, monitor aPTT, reversed by protamine. LMWH: Xa only, preferred in pregnancy",
        tier: 1,
        aka: "Unfractionated Heparin (UFH) · Enoxaparin, Dalteparin (LMWH) · Fondaparinux",
        tags: ["DVT/PE", "ACS", "Safe in Pregnancy"],
        moa: "**UFH:** activates antithrombin III → inhibits **IIa (thrombin) and Xa**. **LMWH:** preferentially inhibits **Xa** (less anti-IIa). Fondaparinux: Xa only",
        use: "DVT, PE, ACS, bridging therapy. LMWH/heparin: safe in pregnancy (don't cross placenta)",
        se: "**HIT (Heparin-Induced Thrombocytopenia):** Type I = non-immune, mild. Type II = immune-mediated (IgG vs PF4-heparin) → paradoxical **THROMBOSIS**. Osteoporosis with long-term use",
        ci: "Active bleeding, HIT history",
        pk: "UFH: monitor **aPTT**. LMWH: monitor anti-Xa levels. Reversal: **Protamine sulfate** (reverses UFH completely; only partial for LMWH)",
        pearl: "**HIT type II:** platelets fall 5–10 days after starting heparin. Stop all heparin IMMEDIATELY; switch to **argatroban or bivalirudin** (direct thrombin inhibitors). NEVER give warfarin alone initially in HIT."
      },
      {
        name: "Warfarin",
        summary: "Inhibits vit K-dependent factors II/VII/IX/X — monitor INR, teratogenic, reversed by PCC or vitamin K. Drug interactions via CYP2C9",
        tier: 1,
        aka: "Coumadin",
        tags: ["Atrial Fibrillation", "DVT/PE", "Prosthetic Valves"],
        moa: "Inhibits **vitamin K epoxide reductase** → ↓ γ-carboxylation of factors II, VII, IX, X, and proteins C and S",
        use: "AF (stroke prevention), DVT/PE treatment, mechanical heart valves, hypercoagulable states",
        se: "**Bleeding** (most common). **Warfarin skin necrosis:** protein C/S deficiency patients → paradoxical clotting in first days. **Teratogenic (embryopathy)**",
        ci: "Pregnancy (fetal warfarin syndrome), active bleeding",
        pk: "Monitored by **INR** (target 2–3 for AF/DVT). Multiple drug interactions via **CYP2C9**",
        pearl: "**Warfarin reversal:** Minor bleeding → hold + vitamin K PO. Serious bleeding → IV vitamin K + **4-factor PCC** or FFP."
      },
      {
        name: "Direct Oral Anticoagulants (DOACs)",
        summary: "Dabigatran (anti-IIa) + rivaroxaban/apixaban (anti-Xa): no monitoring, fixed dosing. Reversal: idarucizumab vs andexanet alfa",
        tier: 1,
        aka: "Dabigatran (IIa inhibitor) · Rivaroxaban, Apixaban, Edoxaban (Xa inhibitors)",
        tags: ["Atrial Fibrillation", "DVT/PE", "Fixed Dosing (No INR Monitoring)"],
        moa: "**Dabigatran:** direct thrombin (IIa) inhibitor. **Rivaroxaban/Apixaban:** direct factor Xa inhibitors",
        use: "Non-valvular AF, DVT/PE. Advantages: no INR monitoring, fewer drug interactions",
        se: "Bleeding. Dabigatran: GI side effects (most common)",
        ci: "Mechanical heart valves (DOACs inferior), severe renal failure (dabigatran)",
        pk: "Dabigatran: renal clearance. Rivaroxaban/apixaban: hepatic clearance",
        pearl: "**Reversal agents:** Dabigatran → **Idarucizumab**. Factor Xa inhibitors → **Andexanet alfa**."
      }
    ]
  },
  {
    group: "Antiplatelets (Platelet Aggregation)",
    color: "blood",
    drugs: [
      {
        name: "Aspirin (Antiplatelet)",
        summary: "Irreversibly inhibits COX → ↓ TXA2 for 7–10 days. Reye syndrome in kids + viral illness. Overdose: mixed resp alkalosis + met acidosis",
        tier: 1,
        aka: "Acetylsalicylic acid (ASA)",
        tags: ["ACS", "Stroke Prevention", "Post-Stent"],
        moa: "Irreversibly inhibits **COX-1 and COX-2** → ↓ thromboxane A2 (TXA2) synthesis. Effect lasts platelet lifespan (7–10 days)",
        use: "ACS (immediate 325 mg chewed), secondary stroke prevention, post-coronary stent",
        se: "**GI bleeding/ulcers** (↓ PGE2). **Reye syndrome** (children + viral illness). Tinnitus (overdose)",
        ci: "Children with viral illness, active GI bleeding",
        pk: "Antiplatelet dose: 81 mg. Effect is irreversible",
        pearl: "**Aspirin overdose:** Early respiratory alkalosis followed by late metabolic acidosis (uncoupling oxidative phosphorylation). Treat with sodium bicarb to alkalinize urine."
      },
      {
        name: "P2Y12 & GP IIb/IIIa Blockers",
        summary: "Clopidogrel (prodrug, CYP2C19) + ticagrelor: DAPT post-stent/ACS. Clopidogrel + omeprazole interaction — use pantoprazole",
        tier: 1,
        aka: "Clopidogrel (Plavix), Ticagrelor · Abciximab, Eptifibatide",
        tags: ["ACS", "Post-Stent", "PCI"],
        moa: "P2Y12 inhibitors: block **ADP receptor (P2Y12)**. GP IIb/IIIa inhibitors: block final common pathway (prevents fibrinogen binding)",
        use: "Dual antiplatelet therapy (DAPT): post-stent, ACS",
        se: "Bleeding. **Ticagrelor: dyspnea** (unique side effect)",
        ci: "Clopidogrel + PPIs (omeprazole inhibits CYP2C19 activation)",
        pk: "Clopidogrel: prodrug → requires **CYP2C19** activation",
        pearl: "**PPI Interaction:** Omeprazole inhibits CYP2C19 → ↓ clopidogrel activation. Use pantoprazole for GI protection instead."
      },
      {
        name: "PDE3/PDE5 Inhibitors (Antiplatelet)",
        summary: "Cilostazol/Dipyridamole: ↑ cAMP in platelets → inhibit aggregation + vasodilation. Cilostazol used for claudication; Dipyridamole for stroke prevention",
        tier: 2,
        aka: "Cilostazol (Pletal) · Dipyridamole (Persantine)",
        tags: ["Intermittent Claudication", "Stroke Prevention", "PAD"],
        moa: "Inhibit **phosphodiesterase (PDE3 in platelets/vessels)** → ↑ cAMP → (1) **Inhibit platelet aggregation**. (2) Direct **vasodilation**",
        use: "Cilostazol: **intermittent claudication** (symptom relief in PAD). Dipyridamole: **secondary stroke prevention** (combined with aspirin), cardiac stress testing",
        se: "Headache, palpitations, diarrhea, dizziness. **Coronary steal** (dipyridamole)",
        ci: "**Heart Failure of any severity** (cilostazol — associated with reduced survival)",
        pk: "Cilostazol: CYP3A4 substrate",
        pearl: "**Cilostazol is the 'claudication drug'**—it improves walking distance in PAD. High-yield CI: **never use in HF**. Dipyridamole causes **coronary steal**—dilating normal vessels and shunting blood *away* from stenosed ones."
      }
    ]
  },
  {
    group: "Thrombolytics (Clot Busters)",
    color: "blood",
    drugs: [
      {
        name: "tPA & Thrombolytics",
        summary: "tPA/alteplase: convert plasminogen → plasmin, lyse clots. Used in STEMI, ischemic stroke (≤4.5h), massive PE. CI: recent surgery/bleed",
        tier: 1,
        aka: "Alteplase, Tenecteplase · Streptokinase",
        tags: ["STEMI", "Ischemic Stroke", "Massive PE"],
        moa: "Convert **plasminogen → plasmin** → dissolves fibrin clots systemically",
        use: "Ischemic stroke (within **4.5 hours**), STEMI (if PCI unavailable), massive PE",
        se: "**Bleeding** (intracranial hemorrhage most feared)",
        ci: "Recent surgery (<14 days), active bleeding, prior ICH, BP >185/110",
        pk: "tPA: fibrin-specific",
        pearl: "**Stroke window:** Must get non-contrast CT head first to rule out hemorrhage. Window is **4.5 hours** from symptom onset."
      }
    ]
  },
  {
    group: "Gout",
    color: "blood",
    drugs: [
      {
        name: "Allopurinol & Febuxostat",
        summary: "Inhibit xanthine oxidase → ↓ uric acid synthesis. For chronic gout prevention. Allopurinol + azathioprine/6-MP = fatal toxicity",
        tier: 1,
        aka: "Allopurinol, Febuxostat",
        tags: ["Gout", "Tumor Lysis"],
        moa: "Inhibit **xanthine oxidase** → ↓ uric acid production",
        use: "Chronic gout prevention, tumor lysis syndrome",
        se: "**Stevens-Johnson syndrome** (Allopurinol), precipitates acute gout flare if started during attack",
        ci: "Concurrent **azathioprine or 6-MP** (causes fatal toxicity)",
        pk: "Do NOT start during an acute attack",
        pearl: "Xanthine oxidase blocks 6-MP breakdown; blocking XO leads to **6-MP toxicity** (myelosuppression)."
      },
      {
        name: "Colchicine",
        summary: "Inhibits microtubule polymerization → ↓ neutrophil migration. Treats acute gout + pericarditis. Does NOT lower uric acid",
        tier: 1,
        aka: "Colcrys",
        tags: ["Acute Gout", "Pericarditis"],
        moa: "Inhibits **microtubule polymerization** → ↓ neutrophil migration",
        use: "Acute gout flare, pericarditis",
        se: "GI distress (diarrhea), myelosuppression",
        ci: "Severe renal/hepatic impairment",
        pk: "Start within 24–36 hrs of onset",
        pearl: "**Colchicine does NOT lower uric acid**."
      },
      {
        name: "Probenecid",
        summary: "Blocks urate reabsorption in proximal tubule → ↑ urinary uric acid excretion. For chronic gout. Inhibits penicillin secretion (↑ levels)",
        tier: 2,
        aka: "Benemid",
        tags: ["Gout", "Uricosuric"],
        moa: "Blocks **URAT1** in proximal tubule → ↓ uric acid reabsorption → ↑ urinary uric acid excretion",
        use: "Chronic gout in under-excreters. Also inhibits renal secretion of **penicillin** (↑ levels)",
        se: "Uric acid kidney stones, GI upset",
        ci: "**Aspirin** (blocks uricosuric effect), renal failure",
        pk: "Only effective in under-excreters",
        pearl: "**Probenecid + Penicillin:** Once used to stretch penicillin supplies. High-yield: avoid aspirin—it competes for the same transporter and negates the drug's effect."
      },
    ]
  }

],
neuro: [
{
    group: "Sedatives & Analgesics",
    color: "neuro",
    drugs: [
      {
        name: "Benzodiazepines",
        summary: "Enhance GABA-A Cl⁻ influx (↑ frequency). Diazepam/lorazepam: status epilepticus. Reversal: flumazenil. CI: combined with alcohol",
        tier: 1,
        aka: "Diazepam, Lorazepam, Midazolam (short-acting) · Alprazolam, Clonazepam (long-acting) · Flumazenil (reversal)",
        tags: ["Anxiety", "Seizures", "Alcohol Withdrawal"],
        moa: "Positive allosteric modulators of **GABA-A receptors** → ↑ frequency of Cl- channel opening (vs barbiturates: ↑ duration)",
        use: "Anxiety, panic disorder, alcohol withdrawal (prevents seizures/delirium tremens), seizures (lorazepam IV for status epilepticus), procedural sedation, muscle relaxation (diazepam)",
        se: "**CNS depression** (sedation, confusion, anterograde amnesia), respiratory depression (especially with opioids/alcohol), tolerance, dependence. Withdrawal: **life-threatening** (rebound seizures, autonomic instability)",
        ci: "Pregnancy (cleft palate), myasthenia gravis, severe respiratory depression",
        pk: "Short-acting: triazolam, midazolam, oxazepam (TOM). Long-acting: diazepam, chlordiazepoxide (used for detox). Flumazenil: benzo reversal (short-acting — monitor for re-sedation)",
        pearl: "**Benzo vs Barbiturate MOA on GABA-A:** Benzos → ↑ FREQUENCY of Cl- opening. Barbiturates → ↑ DURATION of Cl- opening. Barbiturates can directly activate GABA-A at high doses (→ no ceiling effect → fatal respiratory depression). Benzos have a ceiling effect (safer)."
      },
      {
        name: "Opioid Analgesics",
        summary: "μ-receptor agonists → analgesia + miosis + respiratory depression. Constipation has NO tolerance — always add a laxative",
        tier: 1,
        aka: "Morphine, Oxycodone, Hydromorphone, Fentanyl, Codeine, Tramadol",
        tags: ["Pain", "Palliative Care", "Anesthesia"],
        moa: "Agonists at **μ (mu), κ (kappa), δ (delta) opioid receptors** (all Gi-coupled) → ↓ cAMP → ↓ neural firing, ↓ Ca²⁺ influx → ↓ pain transmission, euphoria, sedation",
        use: "Moderate-severe acute pain (post-op, trauma), chronic cancer pain, dyspnea in terminal illness, cough suppression (codeine). Fentanyl: procedural sedation, anesthesia adjunct, transdermal patch for chronic pain",
        se: "**Classic triad of opioid toxicity:** miosis (pinpoint pupils) + respiratory depression + CNS depression. Also: constipation (NO tolerance develops — always treat prophylactically), nausea, urinary retention, biliary colic (↑ sphincter of Oddi pressure), histamine release (flushing, pruritus — especially morphine), physical dependence",
        ci: "Head injury (CO2 retention → cerebral vasodilation → ↑ ICP). **MAOIs + meperidine** (serotonin syndrome — meperidine is serotonergic). Use caution in obstructive sleep apnea",
        pk: "Fentanyl: 100× more potent than morphine. Codeine: prodrug → CYP2D6 activation (ultrarapid metabolizers → toxicity; poor metabolizers → no effect). Tramadol: weak μ agonist + inhibits NE/serotonin reuptake",
        pearl: "**Constipation is the one opioid SE with no tolerance.** All other SEs (sedation, nausea, respiratory depression) diminish with continued use — constipation persists indefinitely. Always prescribe a stimulant laxative (senna, bisacodyl) with opioids. Meperidine + MAOIs = serotonin syndrome (unique to meperidine — other opioids are safe with MAOIs)."
      },
      {
        name: "NSAIDs (Non-Opioid Analgesics)",
        summary: "Reversibly inhibit COX-1/2 → ↓ prostaglandins. GI ulcers (↓ PGE2), renal failure, inhibit platelet aggregation. Ketorolac: IV/IM",
        tier: 1,
        aka: "Ibuprofen, Naproxen, Ketorolac, Indomethacin (non-selective) · Celecoxib (COX-2 selective)",
        tags: ["Pain", "Fever", "Inflammation", "Gout"],
        moa: "Inhibit **COX-1 and COX-2** → ↓ PGE2, PGI2, TXA2. COX-1: constitutive (GI protection). COX-2: inducible (inflammation/pain)",
        use: "Pain, inflammation, fever, dysmenorrhea. Indomethacin: gout, closes **PDA**. Ketorolac: IV/IM analgesic",
        se: "**GI ulcers/bleeding** (↓ PGE2), **renal toxicity** (afferent vasoconstriction → ↓ GFR), **platelet dysfunction**. Aspirin-exacerbated respiratory disease",
        ci: "Renal failure, peptic ulcer, 3rd trimester of pregnancy (closes PDA)",
        pk: "COX-2 selective (celecoxib): ↓ GI risk but ↑ CV risk (↑ MI/stroke)",
        pearl: "**Renal Physiology:** In dehydration/CHF, PGE2 maintains GFR by dilating the afferent arteriole. NSAIDs block this → afferent constriction → **Acute Kidney Injury**."
      },
      {
        name: "Naloxone, Naltrexone & Buprenorphine",
        summary: "Naloxone: reverses opioid OD but t½ < opioid → re-narcotization. Buprenorphine (partial agonist) + methadone: OUD maintenance",
        tier: 1,
        aka: "Naloxone (Narcan) · Naltrexone (Vivitrol) · Buprenorphine (Suboxone with naloxone) · Methadone",
        tags: ["Opioid Overdose", "Opioid Use Disorder", "Alcohol Use Disorder"],
        moa: "Naloxone: competitive **μ-receptor antagonist** (pure antagonist — no agonist activity) → rapidly reverses opioid effects. Naltrexone: long-acting pure antagonist (oral/IM). Buprenorphine: **partial μ-agonist** (ceiling effect on respiratory depression) + κ-antagonist → mitigates withdrawal without full euphoria",
        use: "Naloxone: opioid overdose reversal (IV/IM/intranasal/auto-injector). Naltrexone: opioid use disorder (blocks euphoria from opioids), alcohol use disorder (↓ cravings — blocks endogenous opioid reward). Buprenorphine ± naloxone (Suboxone): opioid use disorder maintenance. Methadone: OUD maintenance, chronic pain",
        se: "Naloxone: precipitates acute withdrawal in opioid-dependent patients (agitation, tachycardia, vomiting, seizures). **Re-narcotization** (t½ ~1 hr — shorter than most opioids → patient may re-sedate after naloxone wears off — monitor for 4–6 hrs or redose). Naltrexone: hepatotoxicity (high doses), must be opioid-free ≥7 days before starting (precipitates withdrawal). Buprenorphine: milder withdrawal/abuse potential than full agonists",
        ci: "Naltrexone: active opioid dependence (precipitates withdrawal), acute hepatitis/liver failure. Methadone: QT prolongation (torsades risk), CYP interactions",
        pk: "Naloxone t½ ~1 hr (much shorter than fentanyl/methadone → must redose or infuse). Buprenorphine: very high affinity for μ-receptor — displaces other opioids. Methadone: extremely long t½ (24–36 hrs) → once daily, but unpredictable accumulation",
        pearl: "**Naloxone t½ trap:** Patient resuscitated from fentanyl overdose with naloxone → discharged after seeming OK → found unresponsive 90 minutes later. Fentanyl t½ >> naloxone t½ → re-narcotization. Always observe patients for minimum 2× the opioid's duration of action after naloxone."
      },
    ]
  },
{
    group: "Sleep & Anesthesia",
    color: "neuro",
    drugs: [
      {
        name: "Non-Benzodiazepine Hypnotics (Z-drugs) & Ramelteon",
        summary: "Zolpidem: GABA-A agonist (BZ1-selective) → hypnotic only, minimal amnesia. Ramelteon: MT1/MT2 melatonin agonist → circadian rhythm regulation. No abuse potential for ramelteon",
        tier: 2,
        aka: "Zolpidem (Ambien), Eszopiclone (Lunesta), Zaleplon · Ramelteon (Rozerem)",
        tags: ["Insomnia", "Sleep Disorders", "Non-habit Forming"],
        moa: "**Z-drugs (zolpidem/eszopiclone):** selective agonists at **BZ1 (ω1) GABA-A receptor subunits** → hypnotic effect without significant anxiolytic/muscle relaxant activity. **Ramelteon:** binds **MT1 and MT2 melatonin receptors** in suprachiasmatic nucleus → regulates circadian rhythm and promotes sleep onset",
        use: "Z-drugs: insomnia (short-term). Ramelteon: insomnia with difficulty falling asleep; circadian rhythm sleep disorders; only sleep aid approved for long-term use without restriction; preferred in elderly and patients with substance use history",
        se: "Z-drugs: parasomnias (**sleep-walking, sleep-eating, sleep-driving** — unique to Z-drugs), rebound insomnia, next-day sedation. **Less tolerance and dependence** than benzos but still DEA Schedule IV. Ramelteon: minimal — mild dizziness, no dependence, no abuse potential",
        ci: "Z-drugs: sleep apnea (can worsen), hepatic impairment (accumulation). Ramelteon: severe hepatic impairment; concurrent fluvoxamine (CYP1A2 inhibitor → ↑ ramelteon levels dramatically)",
        pk: "Zolpidem: rapid onset (15 min), short t½ (~2–3 hr). Eszopiclone: longer duration. Zaleplon: ultra-short (t½ ~1 hr). Ramelteon: peak 45 min; CYP1A2 metabolism",
        pearl: "**Z-drug vs benzo for sleep:** Both work on GABA-A, but Z-drugs are BZ1-selective → hypnotic-preferring with minimal anxiolytic/muscle relaxant effects. **Parasomnias are Z-drug-specific** (patient wakes with no memory of midnight driving). Ramelteon has no abuse potential (Schedule-free) — best choice in elderly, addiction history, or sleep apnea."
      },
      {
        name: "Propofol, Etomidate & Ketamine",
        summary: "Propofol: GABA-A potentiator, green/milky appearance, propofol infusion syndrome. Etomidate: adrenal suppression (single dose). Ketamine: dissociative NMDA antagonist — maintains airway reflexes",
        tier: 1,
        aka: "Propofol (Diprivan) · Etomidate (Amidate) · Ketamine (Ketalar)",
        tags: ["IV Anesthesia", "Procedural Sedation", "RSI"],
        moa: "**Propofol:** potentiates **GABA-A** (↑ Cl⁻ influx) → rapid sedation/hypnosis. **Etomidate:** GABA-A agonist (at distinct binding site from benzos). **Ketamine:** **NMDA receptor antagonist** → dissociative anesthesia — patients appear awake (eyes open, nystagmus) but are unresponsive to pain; preserves sympathetic tone + airway reflexes",
        use: "Propofol: IV induction and maintenance of anesthesia, procedural sedation (ICU, endoscopy), refractory status epilepticus. Etomidate: RSI in hemodynamically unstable patients (minimal cardiovascular depression). Ketamine: pediatric procedural sedation, analgesia, RSI in bronchospasm/hemodynamic instability, induction in trauma (↑ BP)",
        se: "**Propofol:** pain on injection (inject in large vein), apnea, hypotension, bradycardia. **Propofol infusion syndrome** (prolonged high-dose infusion → metabolic acidosis, rhabdomyolysis, cardiac failure — rare but fatal). Green discoloration of urine (benign). **Etomidate:** **adrenal suppression** (inhibits 11β-hydroxylase — even a single induction dose can suppress cortisol for 24 hours). Myoclonus. **Ketamine:** emergence reactions/hallucinations (give benzodiazepine concurrently), ↑ secretions, ↑ ICP (controversial), ↑ IOP, cardiovascular stimulation",
        ci: "Propofol: egg/soy allergy (contains lecithin and soybean oil — true anaphylaxis can occur). Etomidate: caution in septic shock (adrenal suppression worsens outcomes). Ketamine: ↑ ICP (relative), uncontrolled HTN, psychosis",
        pk: "Propofol: rapid redistribution and hepatic metabolism. Extremely lipophilic → rapid onset and offset. Needs lipid vehicle (milky white). Etomidate: ester hydrolysis, rapid offset. Ketamine: IM or IV, longer duration",
        pearl: "**Ketamine in asthma/bronchospasm:** Ketamine is the only induction agent that causes bronchodilation (stimulates catecholamine release → β2 activation). Drug of choice for RSI in severe bronchospasm. Also: etomidate is preferred for RSI in hypotensive patients — only induction agent with minimal cardiovascular depression."
      },
      {
        name: "Inhaled Anesthetics",
        summary: "Halothane → hepatitis. Isoflurane/desflurane/sevoflurane: standard agents. Halothane + succinylcholine → malignant hyperthermia (treat with dantrolene). Nitrous oxide: fills closed air spaces",
        tier: 1,
        aka: "Halothane · Isoflurane, Desflurane, Sevoflurane (newer halogenated agents) · Nitrous Oxide (N₂O)",
        tags: ["General Anesthesia", "Malignant Hyperthermia", "MAC"],
        moa: "Mechanism not fully understood. Primarily enhance **GABA-A** inhibition + inhibit **NMDA receptors** → reduced neuronal excitability → loss of consciousness, analgesia, amnesia. MAC (minimum alveolar concentration) = potency measure — lower MAC = more potent",
        use: "Maintenance of general anesthesia. Nitrous oxide: analgesia (dental procedures), adjunct to other agents, labor analgesia",
        se: "**Halothane:** **halothane hepatitis** (immune-mediated — sensitization with repeated exposure → fulminant liver failure). **All halogenated agents:** trigger **malignant hyperthermia (MH)** in susceptible patients (RYR1 mutation → uncontrolled Ca²⁺ release from SR → hyperthermia, rigidity, acidosis, rhabdomyolysis). **Nitrous oxide:** expands closed gas spaces (bowel, pneumothorax — avoid if present), inhibits B12/methionine synthesis → megaloblastic anemia with chronic exposure. All agents: dose-dependent cardiovascular/respiratory depression",
        ci: "History of malignant hyperthermia (all halogenated agents CI). Nitrous oxide: pneumothorax, bowel obstruction, middle ear surgery. Halothane: repeat exposure or liver disease",
        pk: "MAC inversely proportional to potency. Blood-gas solubility determines speed of onset/offset: low solubility (desflurane, N₂O) = fast on/off; high solubility (halothane) = slow on/off",
        pearl: "**Malignant Hyperthermia (MH):** Triggered by halogenated agents + succinylcholine. RYR1 mutation → uncontrolled SR Ca²⁺ release → sustained muscle contraction → hyperthermia, CO₂ production, rigidity, hyperkalemia, rhabdomyolysis. Treatment: **dantrolene** (blocks RYR1) + cooling + supportive care. Malignant is a misnomer — not related to cancer. Classic Step 1 killer scenario."
      },
    ]
  },
{
    group: "Psychiatric Agents",
    color: "neuro",
    drugs: [
      {
        name: "SSRIs & SNRIs",
        summary: "First-line for depression/anxiety — block serotonin reuptake. SE: sexual dysfunction, serotonin syndrome with MAOIs, SIADH",
        tier: 1,
        aka: "SSRIs: Fluoxetine, Sertraline, Paroxetine, Citalopram · SNRIs: Venlafaxine, Duloxetine",
        tags: ["Depression", "Anxiety", "OCD", "PTSD"],
        moa: "SSRIs: inhibit **serotonin reuptake transporter (SERT)** → ↑ synaptic 5-HT. SNRIs: inhibit SERT + NET → ↑ 5-HT + NE",
        use: "First-line for depression, anxiety disorders, OCD (high-dose), PTSD, panic disorder, social phobia. Duloxetine: also diabetic neuropathy, fibromyalgia, stress urinary incontinence",
        se: "**GI upset** (nausea, diarrhea — most common, early), sexual dysfunction (most bothersome), insomnia, **serotonin syndrome** (especially + MAOIs or linezolid). Paroxetine: most anticholinergic. Fluoxetine: longest t½. Citalopram/escitalopram: QT prolongation",
        ci: "Within 2 weeks of MAOI use (serotonin syndrome). Paroxetine: pregnancy (cardiac malformations)",
        pk: "Fluoxetine: t½ 4–6 days (+ active metabolite norfluoxetine 4–16 days) — minimal discontinuation syndrome",
        pearl: "**Serotonin Syndrome triad:** altered mental status + autonomic instability + neuromuscular abnormalities (clonus, hyperreflexia, tremor). Triggered by SSRIs + MAOIs, or SSRIs + triptans, or linezolid (weak MAOI). Treat with cyproheptadine (5-HT2A antagonist) + supportive care."
      },
      {
        name: "Tricyclic Antidepressants (TCAs)",
        summary: "Block NE + serotonin reuptake + anticholinergic + α1-blockade. OD: wide QRS, hypotension, seizures — treat with sodium bicarb",
        tier: 1,
        aka: "Amitriptyline, Nortriptyline, Imipramine, Clomipramine, Desipramine",
        tags: ["Depression", "Neuropathic Pain", "Enuresis"],
        moa: "Block **NE and 5-HT reuptake**. Also block muscarinic, H1, and α1 receptors → explains side effects",
        use: "Depression (now second-line), neuropathic pain (amitriptyline), migraine prophylaxis, enuresis (imipramine), OCD (clomipramine), panic disorder",
        se: "**TCA toxicity:** anticholinergic (dry mouth, urinary retention, constipation, blurry vision) + antihistamine (sedation, weight gain) + α-blockade (orthostatic hypotension) + **cardiac sodium channel blockade → wide QRS, arrhythmias, QT prolongation → can cause Torsades/VF**",
        ci: "Post-MI, arrhythmias, BPH, narrow-angle glaucoma, elderly (high fall/confusion risk)",
        pk: "",
        pearl: "**TCA overdose is an emergency:** wide QRS on ECG = Na+ channel blockade. Treat with **sodium bicarbonate IV** (alkalinize + increase Na+ → reverses Na+ channel blockade). Anti-muscarinic symptoms + QRS widening = TCA until proven otherwise."
      },
      {
        name: "MAO Inhibitors (MAOIs)",
        summary: "Last-line antidepressants — dangerous interactions: tyramine (hypertensive crisis), meperidine (serotonin syndrome), many others",
        tier: 2,
        aka: "Phenelzine, Tranylcypromine (irreversible) · Selegiline (MAO-B selective, Parkinson's) · Moclobemide (reversible)",
        tags: ["Atypical Depression", "Parkinson's Disease"],
        moa: "Inhibit **monoamine oxidase** → ↓ breakdown of NE, 5-HT, DA, and tyramine",
        use: "Atypical depression (last-line due to interactions), Parkinson's (selegiline — MAO-B selective), social phobia",
        se: "**Tyramine reaction (hypertensive crisis):** aged cheese, wine, cured meats → ↑ tyramine → ↑ NE → severe HTN. **Serotonin syndrome** with SSRIs, meperidine, dextromethorphan. Orthostatic hypotension",
        ci: "Concurrent SSRIs, TCAs, meperidine, sympathomimetics, tyramine-rich foods",
        pk: "Must wait **2 weeks** after stopping MAOI before starting SSRI (and vice versa, except fluoxetine — 5 weeks)",
        pearl: "**Washout period:** MAOI → SSRI requires 2-week washout. SSRI (fluoxetine) → MAOI requires 5-week washout (due to fluoxetine's long t½). Selegiline at low doses is MAO-B selective (safe), but at high doses loses selectivity → same interactions."
      },
      {
        name: "Atypical Antidepressants",
        summary: "Bupropion: smoking cessation, no sexual SE, lowers seizure threshold. Mirtazapine: ↑ appetite/sedation. Trazodone: sleep, priapism",
        tier: 1,
        aka: "Bupropion · Mirtazapine · Trazodone",
        tags: ["Depression", "Smoking Cessation", "Insomnia"],
        moa: "Bupropion: inhibits **DA and NE reuptake**. Mirtazapine: blocks presynaptic α2, H1, 5-HT2/3 → ↑ NE and 5-HT release. Trazodone: 5-HT2A antagonist + weak SERT inhibitor",
        use: "Bupropion: depression, smoking cessation (Wellbutrin/Zyban), ADHD, sexual dysfunction from SSRIs. Mirtazapine: depression + insomnia + poor appetite. Trazodone: insomnia (low-dose), depression",
        se: "Bupropion: **lowers seizure threshold** (contraindicated in eating disorders/seizure disorder), no sexual dysfunction, no weight gain. Mirtazapine: weight gain, sedation (H1 block). Trazodone: **priapism**, orthostatic hypotension, sedation",
        ci: "Bupropion: seizure disorder, anorexia/bulimia (↓ seizure threshold)",
        pk: "",
        pearl: "**Bupropion = only antidepressant for smoking cessation** (with varenicline). Unique: **no sexual dysfunction, no weight gain** — choose bupropion when patient complains of SSRI-related sexual dysfunction. Also used for ADHD. Contraindicated in bulimia/anorexia (seizures)."
      },
    ]
  },
{
    group: "Mood Stabilizers & Antiepileptics",
    color: "neuro",
    drugs: [
      {
        name: "Lithium",
        summary: "Mood stabilizer for bipolar — narrow therapeutic window, monitor levels. Toxicity: tremor→ataxia→seizures. Teratogen (Ebstein's anomaly)",
        tier: 1,
        aka: "Lithium carbonate",
        tags: ["Bipolar Disorder", "Mania", "SIADH"],
        moa: "Not fully understood. Inhibits **inositol monophosphatase** → ↓ inositol → ↓ IP3/DAG signaling. Inhibits GSK-3β",
        use: "Bipolar disorder (acute mania + maintenance), augmentation of antidepressants, SIADH treatment",
        se: "**LITHIUM:** Large urine output (nephrogenic DI), Intention tremor, Thyroid enlargement (hypothyroidism), Hyperparathyroidism, Interstitial nephritis, Urination polyuria, Malformations (Ebstein anomaly — fetal cardiac), teratogenic",
        ci: "Pregnancy (Ebstein anomaly), renal failure, sodium depletion",
        pk: "**Narrow therapeutic index** (0.6–1.2 mEq/L). Renally excreted — competes with Na+ in PCT. Hyponatremia (thiazides) → ↑ Li reabsorption → toxicity",
        pearl: "**Lithium toxicity:** coarse tremor, ataxia, confusion, seizures, arrhythmias. Triggers: NSAIDs (↓ GFR → ↑ Li), thiazides (↑ Li reabsorption), ACEi/ARBs (↓ GFR), dehydration. Treatment: **normal saline** (Na+ competes with Li+ for reabsorption). No antidote — dialysis for severe toxicity."
      },
      {
        name: "Valproate",
        summary: "Broad-spectrum AED + bipolar + migraine prophylaxis. SE: hepatotoxicity, pancreatitis, teratogen (neural tube defects — CI in pregnancy)",
        tier: 1,
        aka: "Valproic acid, Divalproex (Depakote)",
        tags: ["Epilepsy", "Bipolar", "Migraine Prophylaxis"],
        moa: "Blocks **Na+ channels** (use-dependent), ↑ GABA levels (↓ GABA transaminase), may block T-type Ca2+ channels",
        use: "Broad-spectrum AED: absence + myoclonic + generalized tonic-clonic seizures. Bipolar disorder (acute mania + maintenance). Migraine prophylaxis",
        se: "**Teratogenic (neural tube defects** — highest risk of all AEDs — give folic acid). Hepatotoxicity (check LFTs). Pancreatitis. Weight gain. Hair loss. **Inhibits CYP enzymes** → ↑ other drug levels",
        ci: "Pregnancy (if alternatives exist), liver disease",
        pk: "Strong CYP inhibitor — raises levels of many drugs",
        pearl: "**Valproate + lamotrigine = dangerous.** Valproate inhibits CYP → doubles lamotrigine levels → lamotrigine toxicity (Stevens-Johnson syndrome). Reduce lamotrigine dose when adding valproate."
      },
      {
        name: "Phenytoin",
        summary: "Blocks Na+ channels — tonic-clonic/focal seizures. Zero-order kinetics → small dose = huge level increase. Gingival hyperplasia, teratogenic",
        tier: 1,
        aka: "Dilantin · Fosphenytoin (IV prodrug)",
        tags: ["Epilepsy", "Status Epilepticus", "Focal Seizures"],
        moa: "Blocks **voltage-gated Na+ channels** (use-dependent) → stabilizes inactivated state → ↓ high-frequency neuronal firing. Also blocks T-type Ca2+ channels at high doses",
        use: "Tonic-clonic and focal (partial) seizures. IV phenytoin/fosphenytoin: status epilepticus (second-line after benzos). NOT effective for absence seizures (may worsen)",
        se: "**Dose-related CNS toxicity:** nystagmus (first sign) → ataxia → diplopia → lethargy → coma (correlates with rising plasma levels). Chronic: **gingival hyperplasia**, hirsutism, coarsening of facial features, megaloblastic anemia (↓ folate), peripheral neuropathy, **teratogenic (fetal hydantoin syndrome)**. CYP inducer",
        ci: "Pregnancy (fetal hydantoin syndrome — cleft palate, digit/nail hypoplasia). Absence seizures (worsens). Sinus bradycardia/AV block (IV form)",
        pk: "**Zero-order (saturable) kinetics at therapeutic levels** — enzyme saturated → small dose increase → disproportionate ↑ in plasma levels → sudden toxicity. Highly protein-bound — levels altered by hypoalbuminemia",
        pearl: "**Zero-order kinetics trap:** Patient on phenytoin stable for years → add a CYP inhibitor (e.g., fluconazole) → phenytoin levels spike → nystagmus/ataxia. Also: phenytoin + valproate interaction — valproate displaces phenytoin from protein binding AND inhibits CYP → ↑↑ free phenytoin toxicity."
      },
      {
        name: "Carbamazepine",
        summary: "Na+ channel blocker — focal seizures + trigeminal neuralgia (drug of choice) + bipolar. SE: aplastic anemia, SIADH, SJS (HLA-B*1502 in Asians)",
        tier: 1,
        aka: "Tegretol · Oxcarbazepine (Trileptal) — similar class",
        tags: ["Epilepsy", "Trigeminal Neuralgia", "Bipolar"],
        moa: "Blocks **voltage-gated Na+ channels** (use-dependent) → ↓ high-frequency firing. Same basic mechanism as phenytoin but different pharmacology and toxicity profile",
        use: "Focal (partial) seizures and secondary generalized tonic-clonic. **Trigeminal neuralgia** (drug of choice — first-line). Bipolar disorder (acute mania + maintenance). Glossopharyngeal neuralgia",
        se: "**Agranulocytosis/aplastic anemia** (rare but serious — monitor CBC). **SIADH** (hyponatremia — especially in elderly). Diplopia, ataxia, dizziness (dose-related). Stevens-Johnson syndrome (especially HLA-B*1502 in Asian patients). Hepatotoxicity. CYP3A4 inducer + **auto-induces its own metabolism**",
        ci: "Bone marrow suppression (prior), MAOIs (hypertensive crisis), porphyria. HLA-B*1502 testing before use in Asian patients (SJS risk)",
        pk: "Auto-induction: over first weeks, carbamazepine ↑ its own CYP3A4 metabolism → t½ shortens from ~35 hrs to ~15 hrs — may require dose increases. Major drug interactions: induces OCP → contraceptive failure",
        pearl: "**Carbamazepine + OCP = contraceptive failure.** CBZ is a potent CYP inducer → ↑ estrogen metabolism → OCP failure → unintended pregnancy. Always counsel patients on this. Also: CBZ-induced SIADH is a classic boards vignette — elderly epilepsy patient with seizures + low Na+."
      },
      {
        name: "Lamotrigine",
        summary: "Broad-spectrum AED + bipolar maintenance. SJS risk especially with valproate (valproate doubles levels → must halve dose)",
        tier: 1,
        aka: "Lamictal",
        tags: ["Epilepsy", "Bipolar Maintenance", "Absence Seizures"],
        moa: "Blocks **voltage-gated Na+ channels** + inhibits glutamate release → broad-spectrum anticonvulsant effect. Also some Ca2+ channel blockade",
        use: "Broad-spectrum AED: focal seizures, generalized tonic-clonic, **absence seizures** (alternative to ethosuximide). **Bipolar disorder maintenance** (especially depression phase — prevents depressive episodes more than mania). Lennox-Gastaut syndrome",
        se: "**Stevens-Johnson syndrome / TEN** (life-threatening rash — risk ↑ dramatically if dose titrated too fast or combined with valproate). Dizziness, headache, diplopia, ataxia (dose-related). Insomnia",
        ci: "Rapid dose titration (must titrate slowly over weeks to minimize SJS risk). Valproate co-administration requires 50% dose reduction",
        pk: "**Valproate doubles lamotrigine levels** (inhibits glucuronidation) → must halve lamotrigine dose when adding valproate. Enzyme inducers (CBZ, phenytoin) halve lamotrigine levels → must increase dose",
        pearl: "**Lamotrigine + valproate = SJS risk.** Valproate inhibits glucuronidation of lamotrigine → ↑ levels → ↑ rash risk. Must start lamotrigine at 25 mg every other day (not standard 25 mg/day) when on valproate. Lamotrigine is the preferred AED in pregnancy for bipolar disorder when valproate is contraindicated."
      },
      {
        name: "Ethosuximide",
        summary: "Blocks T-type Ca²⁺ channels — first-line for absence seizures ONLY. No use in other seizure types",
        tier: 1,
        aka: "Zarontin",
        tags: ["Absence Seizures", "Childhood Epilepsy"],
        moa: "Selectively blocks **T-type (low-voltage activated) Ca2+ channels** in thalamic neurons → interrupts the 3-Hz spike-and-wave discharge that characterizes absence seizures",
        use: "**Absence seizures (petit mal) — ONLY**. First-line for pure absence epilepsy in children. NOT effective for generalized tonic-clonic or focal seizures",
        se: "GI upset (nausea, vomiting — most common, take with food), drowsiness, headache, **Stevens-Johnson syndrome** (rare), hiccups",
        ci: "Generalized tonic-clonic seizures if used alone (absence may coexist with GTC → use valproate instead, which covers both)",
        pk: "Good oral absorption. t½ ~40–50 hours in adults. Not protein bound. Excreted renally",
        pearl: "**Ethosuximide is the ONLY antiepileptic for pure absence seizures.** If the child has ONLY absence seizures → ethosuximide. If they have absence + GTC → valproate (covers both). If valproate is contraindicated (pregnancy) → lamotrigine is the alternative for absence. T-type Ca2+ channels are the unique mechanism — no other AED targets only this channel."
      },
    ]
  },
{
    group: "Antipsychotics",
    color: "neuro",
    drugs: [
      {
        name: "Antipsychotics — First Generation (FGAs)",
        summary: "D2 blockers — haloperidol for acute psychosis. SE: EPS (akathisia/dystonia/Parkinsonism) + tardive dyskinesia + NMS + hyperprolactinemia",
        tier: 1,
        aka: "Haloperidol, Chlorpromazine, Fluphenazine, Thioridazine",
        tags: ["Schizophrenia", "Acute Psychosis", "Tourette's"],
        moa: "Block **D2 receptors** (dopamine) in mesolimbic pathway. Also block muscarinic, α1, H1 receptors",
        use: "Schizophrenia (positive symptoms), acute psychosis, Tourette syndrome (haloperidol), antiemesis (prochlorperazine), hiccups (chlorpromazine)",
        se: "**EPS (Extrapyramidal Symptoms):** Acute dystonia (hours–days, treat with benztropine or diphenhydramine), Akathisia (days–weeks, restlessness), Parkinsonism (weeks–months), Tardive dyskinesia (months–years, potentially irreversible). **NMS:** hyperthermia + rigidity + altered MS + autonomic instability (treat with dantrolene + bromocriptine). Thioridazine: retinal pigmentation, prolonged QT",
        ci: "Parkinson's (worsens), QT prolongation",
        pk: "High-potency (haloperidol): more EPS, less anticholinergic. Low-potency (chlorpromazine): more sedation, anticholinergic, α-blockade",
        pearl: "**NMS vs Serotonin Syndrome:** NMS = D2 blockade → lead-pipe rigidity + hyperthermia. SS = ↑ serotonin → hyperreflexia + clonus + tremor. NMS: treat with dantrolene (muscle relaxant) + bromocriptine (D2 agonist). SS: treat with cyproheptadine + discontinue serotonergic agents."
      },
      {
        name: "Antipsychotics — Second Generation (SGAs / Atypicals)",
        summary: "D2 + 5-HT2 blockade — clozapine: treatment-resistant schizophrenia but agranulocytosis (weekly CBC). Olanzapine: most metabolic SE",
        tier: 1,
        aka: "Clozapine, Olanzapine, Quetiapine, Risperidone, Aripiprazole, Ziprasidone",
        tags: ["Schizophrenia", "Bipolar", "Treatment-Resistant"],
        moa: "Block **D2 AND 5-HT2A receptors** (lower D2 affinity than FGAs). Clozapine: additionally blocks D4",
        use: "Schizophrenia (positive + negative symptoms). Olanzapine/quetiapine: bipolar mania. Clozapine: **treatment-resistant schizophrenia** or suicidality",
        se: "**Clozapine: agranulocytosis** (1–2% — must monitor weekly CBC), seizures, myocarditis. All SGAs: **metabolic syndrome** (weight gain, ↑ glucose → T2DM, hyperlipidemia) — olanzapine/clozapine worst. Less EPS than FGAs. Prolonged QT (ziprasidone worst)",
        ci: "Clozapine: history of agranulocytosis, uncontrolled seizures",
        pk: "",
        pearl: "**Clozapine requires weekly CBC** monitoring for agranulocytosis — this is a major barrier to use. However, it's the only drug for treatment-resistant schizophrenia and significantly reduces suicidality. Atypicals have LESS tardive dyskinesia but MORE metabolic syndrome than typicals."
      },
    ]
  },
{
    group: "Additional Antiepileptics",
    color: "neuro",
    drugs: [
      {
        name: "Topiramate",
        summary: "Broad-spectrum AED: blocks Na+ + enhances GABA + blocks AMPA/kainate — also used for migraine prophylaxis and weight loss. SE: cognitive dulling ('Dopamax'), kidney stones, metabolic acidosis",
        tier: 1,
        aka: "Topamax",
        tags: ["Epilepsy", "Migraine Prophylaxis", "Weight Loss"],
        moa: "Multiple mechanisms: (1) blocks voltage-gated **Na+ channels**; (2) enhances **GABA-A** activity; (3) inhibits **AMPA/kainate glutamate receptors**; (4) inhibits carbonic anhydrase → metabolic acidosis + ↓ renal stone precipitation",
        use: "Broad-spectrum epilepsy (partial and generalized, including Lennox-Gastaut). **Migraine prophylaxis** (FDA-approved). Obesity/weight management (in combination with phentermine as Qsymia)",
        se: "**Cognitive dulling** ('Dopamax' — word-finding difficulty, slowed processing), **nephrolithiasis** (calcium phosphate stones — carbonic anhydrase inhibition → alkaline urine → ↑ stone risk), **metabolic acidosis**, weight loss (often desirable), paresthesias, glaucoma (acute angle-closure)",
        ci: "Pregnancy (oral cleft risk). Concurrent valproate (↑ hyperammonemia risk). Carbonic anhydrase inhibitors (additive acidosis)",
        pk: "Renal excretion. Enzyme inducer at higher doses. Interacts with OCPs (↓ effectiveness — add barrier method)",
        pearl: "**Topiramate mnemonics:** 'TOPiramate TOPs it off' — weight loss + cognition. The unique combination of weight loss + migraine prophylaxis makes topiramate especially useful in obese migraineurs. The cognitive side effects are notorious — 'Dopamax' nickname from patients. Always ask patients about word-finding difficulties at follow-up."
      },
      {
        name: "Levetiracetam",
        summary: "Binds SV2A (synaptic vesicle protein) → modulates neurotransmitter release. Broad-spectrum, first-line for many epilepsies. SE: behavioral changes (irritability, depression) — notable in kids",
        tier: 1,
        aka: "Keppra",
        tags: ["Epilepsy", "Status Epilepticus", "Broad-Spectrum AED"],
        moa: "Binds **SV2A (synaptic vesicle glycoprotein 2A)** → modulates vesicular neurotransmitter release (exact mechanism incompletely understood). Does NOT enhance GABA or block Na+ channels — unique mechanism among AEDs",
        use: "Broad-spectrum: partial seizures, generalized tonic-clonic, juvenile myoclonic epilepsy. IV form used for acute seizure control and status epilepticus. Often used adjunctively",
        se: "**Behavioral/psychiatric SEs**: irritability, depression, aggression, hostility (especially in children and patients with psychiatric history). Somnolence, dizziness. Relatively low teratogenic risk (increasingly used in pregnancy when needed)",
        ci: "Behavioral/psychiatric history (relative — higher risk of psychiatric SEs). Renal failure (dose adjustment needed — renally cleared)",
        pk: "Renally excreted — dose-reduce in renal failure. Minimal drug interactions (not a CYP inducer or inhibitor — major advantage over phenytoin/carbamazepine). IV and oral formulations",
        pearl: "**Levetiracetam's major advantage is its minimal drug interactions** — no CYP induction/inhibition. Unlike older AEDs (phenytoin, carbamazepine), levetiracetam doesn't reduce OCP efficacy or interact with warfarin. The psychiatric SE profile is the main limitation — always screen for baseline mood/behavior."
      },
      {
        name: "Gabapentin, Tiagabine & Vigabatrin",
        summary: "Gabapentin: GABA analog, acts on voltage-gated Ca²⁺ channels — NOT GABA-A. Neuropathic pain + adjunct epilepsy. Vigabatrin: irreversible GABA-T inhibitor → permanent visual field defects",
        tier: 2,
        aka: "Gabapentin (Neurontin) · Pregabalin (Lyrica) · Tiagabine (Gabitril) · Vigabatrin (Sabril)",
        tags: ["Neuropathic Pain", "Epilepsy", "GABA Pathway"],
        moa: "**Gabapentin/Pregabalin:** GABA analogs but do NOT act on GABA receptors — instead bind **α2δ subunit of voltage-gated Ca²⁺ channels** → ↓ Ca²⁺-mediated neurotransmitter release. **Tiagabine:** inhibits **GABA transporter (GAT-1)** → ↓ GABA reuptake → ↑ synaptic GABA. **Vigabatrin:** **irreversible inhibitor of GABA transaminase (GABA-T)** → ↓ GABA catabolism → ↑ GABA levels",
        use: "Gabapentin/pregabalin: neuropathic pain (diabetic neuropathy, postherpetic neuralgia), fibromyalgia, adjunct epilepsy, anxiety (off-label). Tiagabine: adjunct partial seizures. Vigabatrin: infantile spasms (West syndrome), refractory partial seizures",
        se: "Gabapentin/pregabalin: sedation, dizziness, ataxia, weight gain, peripheral edema, abuse potential (pregabalin — Schedule V). Tiagabine: absence status epilepticus (can precipitate). **Vigabatrin: irreversible bilateral peripheral visual field defects** (irreversible concentric constriction — visual field testing required every 3–6 months — limits use to refractory cases)",
        ci: "Vigabatrin: pre-existing visual field defects. Gabapentin/pregabalin: caution with respiratory depression risk (opioids/benzos)",
        pk: "Gabapentin: renal excretion, no protein binding, no drug interactions (advantage). Vigabatrin: irreversible enzyme inhibitor",
        pearl: "**Vigabatrin = permanent visual field loss.** This is the critical toxicity — irreversible concentric narrowing ('tunnel vision'). Reserved for infantile spasms and refractory cases because the visual toxicity risk is so significant. Gabapentin pearl: despite the name, it does NOT act on GABA receptors — acts on α2δ subunit of Ca²⁺ channels. Classic Step 1 trap."
      },
    ]
  },
{
    group: "COMT Inhibitors (Parkinson's)",
    color: "neuro",
    drugs: [
      {
        name: "Entacapone & Tolcapone (COMT Inhibitors)",
        summary: "Extend levodopa effect by blocking COMT (peripheral breakdown of levodopa). Tolcapone: hepatotoxic — monitor LFTs. Entacapone: preferred (no hepatotoxicity). Both cause orange-brown urine",
        tier: 2,
        aka: "Entacapone (Comtan) · Tolcapone (Tasmar) · Stalevo = levodopa + carbidopa + entacapone",
        tags: ["Parkinson's Disease", "COMT Inhibitor", "Wearing-Off Effect"],
        moa: "Inhibit **catechol-O-methyltransferase (COMT)** → ↓ peripheral breakdown of **levodopa** by COMT → ↑ bioavailability of levodopa → more reaches brain → extends 'on' time. Given WITH levodopa/carbidopa — no benefit as monotherapy",
        use: "Adjunct to levodopa/carbidopa in Parkinson's disease with 'wearing-off' phenomenon (motor fluctuations — 'on/off' effect). Tolcapone: also has central COMT inhibition (crosses BBB partially)",
        se: "Both: **orange-brown discoloration of urine** (harmless — catechol metabolites), dyskinesia (↑ dopaminergic effect from increased levodopa), GI upset, diarrhea. **Tolcapone: hepatotoxicity** (fatal hepatic failure cases — requires LFT monitoring every 2–4 weeks). Entacapone: no significant hepatotoxicity (preferred agent)",
        ci: "Tolcapone: liver disease, elevated LFTs. Concurrent non-selective MAOIs (↑ catecholamine levels → hypertensive crisis)",
        pk: "Entacapone: peripheral COMT only (doesn't cross BBB). Tolcapone: peripheral + central COMT inhibition. Both taken with each dose of levodopa",
        pearl: "**Entacapone vs Tolcapone choice:** Both extend levodopa effectiveness, but entacapone is preferred in clinical practice because tolcapone has caused fatal fulminant hepatitis. Tolcapone is reserved for patients failing entacapone. The urine discoloration is a key distinguishing clinical detail — warn patients upfront or they'll discontinue thinking there's hematuria."
      },
    ]
  },
{
    group: "Parkinson's Disease & Movement Disorders",
    color: "neuro",
    drugs: [
      {
        name: "Levodopa / Carbidopa",
        summary: "Gold standard for Parkinson's — carbidopa blocks peripheral conversion so more L-DOPA reaches brain. Long-term: dyskinesias + on/off",
        tier: 1,
        aka: "L-DOPA/Carbidopa (Sinemet) · Pramipexole, Ropinirole (dopamine agonists) · Selegiline (MAO-B inhibitor)",
        tags: ["Parkinson's Disease", "Dopaminergic", "Movement Disorder"],
        moa: "Levodopa: crosses BBB → converted to **dopamine** by DOPA decarboxylase in CNS. Carbidopa: peripheral DOPA decarboxylase inhibitor → prevents peripheral conversion → ↓ side effects, ↑ CNS levodopa. Pramipexole/ropinirole: direct D2/D3 receptor agonists (no conversion needed)",
        use: "Levodopa/carbidopa: gold standard for Parkinson's (most effective for motor symptoms — rigidity, bradykinesia, tremor). Dopamine agonists: younger patients (↓ dyskinesia risk), restless leg syndrome. Selegiline: early/mild PD (MAO-B inhibitor → ↓ dopamine breakdown). Amantadine: mild PD, drug-induced dyskinesia",
        se: "Levodopa: **dyskinesias** (involuntary movements — dose-limiting, especially with long-term use), wearing-off ('on-off' phenomenon), nausea, hypotension, psychosis (↑ dopamine → hallucinations). **Dopamine agonists:** impulse control disorders (gambling, hypersexuality), daytime somnolence, nausea, orthostatic hypotension. On/off phenomenon worsens over time",
        ci: "Levodopa: narrow-angle glaucoma, MAOIs (hypertensive crisis). Dopamine agonists + dopamine-blocking antipsychotics (antagonize each other)",
        pk: "Carbidopa inhibits peripheral (not central) DOPA decarboxylase — cannot cross BBB. This is why it's combined with levodopa. Without carbidopa, ≤1% of levodopa reaches the brain",
        pearl: "**Parkinson's drug hierarchy for Step 1:** Levodopa/carbidopa = gold standard. Young patient → consider dopamine agonist first (delay dyskinesias). Anticholinergics (benztropine) → tremor-predominant PD. Drug-induced Parkinsonism (antipsychotics) → benztropine or reduce antipsychotic dose. **Never use dopamine-blocking drugs** (haloperidol, metoclopramide) in PD — will worsen symptoms dramatically."
      },
    ,
      {
  name: "Dopamine Agonists (Parkinson's)",
  summary: "Pramipexole/ropinirole: non-ergot D2/D3 agonists — first-line in young PD patients, impulse control disorders SE. Ergot-derived (bromocriptine) avoided due to fibrosis. Also used in RLS",
  tier: 1,
  aka: "Non-ergot: Pramipexole (Mirapex), Ropinirole (Requip), Rotigotine (patch) · Ergot-derived: Bromocriptine, Pergolide (withdrawn)",
  tags: ["Parkinson's Disease", "RLS", "Hyperprolactinemia"],
  moa: "**Direct agonism at dopamine D2 (and D3) receptors** in striatum → simulate dopaminergic signaling without requiring conversion from levodopa. Non-ergot agents: selective for D2/D3. Ergot agents (bromocriptine): D2 agonist + partial D1 agonist + α-adrenergic/serotonin effects",
  use: "Parkinson's disease: monotherapy in **early/mild PD** (especially younger patients — delay levodopa to postpone motor complications). Adjunct to levodopa in advanced PD. **Restless legs syndrome** (RLS — ropinirole/pramipexole, FDA approved). Bromocriptine: **hyperprolactinemia** (prolactinoma), acromegaly, type 2 DM (Cycloset). Neuroleptic malignant syndrome treatment",
  se: "**Impulse control disorders** (gambling, hypersexuality, compulsive eating/shopping — especially pramipexole — dopaminergic reward pathway activation). Orthostatic hypotension (first-dose). Nausea, hallucinations, confusion (more than levodopa). **Sudden sleep attacks** (without warning — warn patients about driving). Ergot agents: **pulmonary/retroperitoneal fibrosis**, Raynaud's phenomenon, valvular heart disease (pergolide withdrawn)",
  ci: "Ergot-derived agents: history of fibrotic disorders, peripheral vascular disease, CAD. Non-ergot: caution in psychosis (↑ dopamine), severe renal impairment (pramipexole — renally cleared)",
  pk: "Pramipexole: renal excretion — dose-reduce in renal failure. Ropinirole: hepatic metabolism. Rotigotine: transdermal patch — useful for dysphagia. Bromocriptine: hepatic",
  pearl: "**Non-ergot vs ergot DA agonists:** Non-ergot agents (pramipexole, ropinirole) have replaced ergot-derived agents due to fibrosis risk with ergots. The classic **impulse control disorder** side effect (especially pathological gambling) is strongly associated with dopamine agonists — not with levodopa alone. Always screen PD patients on dopamine agonists for behavioral changes. In **RLS**, the conundrum is **augmentation** — dopamine agonists paradoxically worsen RLS over time if dose escalated too much."
}
    ]
  }
],

micro: [
{
    group: "Cell Wall Inhibitors",
    color: "micro",
    drugs: [
      {
        name: "Natural Penicillins",
        summary: "Pen G: first-line for syphilis (all stages), Group A Streptococcus, Neisseria meningitidis. Benzathine PCN G: neurosyphilis requires IV Pen G",
        tier: 1,
        aka: "Penicillin G (IV/IM), Penicillin V (oral), Benzathine penicillin G (long-acting IM)",
        tags: ["Gram-Positive", "Streptococcus", "Treponema", "Syphilis"],
        moa: "Bind **penicillin-binding proteins (PBPs)** → inhibit transpeptidation of peptidoglycan cross-links → cell wall lysis; β-lactam ring essential for activity",
        use: "**Group A Streptococcus** (pharyngitis, rheumatic fever prophylaxis), **Syphilis** (benzathine PCN G is drug of choice for all stages), Streptococcus pneumoniae, Neisseria meningitidis, oral anaerobes",
        se: "**IgE-mediated anaphylaxis** (0.01-0.05%), maculopapular rash; **Jarisch-Herxheimer reaction** when treating syphilis (fever/chills from treponemal lysis — treat with supportive care)",
        ci: "Penicillin allergy; cross-reactivity with cephalosporins is roughly 1-2%",
        pk: "Penicillin G: IV for serious infections. Benzathine PCN G: single IM injection lasts 2-4 weeks. Pen V: acid-stable formulation for oral use",
        pearl: "**Syphilis treatment by stage:** All stages require benzathine penicillin G. Neurosyphilis requires IV penicillin G for 10-14 days because benzathine PCN G does NOT achieve adequate CSF levels."
      },
      {
        name: "Anti-Staphylococcal Penicillins",
        summary: "Nafcillin/oxacillin: narrow spectrum for MSSA only. First-line for MSSA (superior to vancomycin). Nafcillin causes neutropenia and is hepatically cleared",
        tier: 1,
        aka: "Nafcillin, Oxacillin (IV), Dicloxacillin (oral)",
        tags: ["Gram-Positive", "Staphylococcus", "MSSA", "Endocarditis"],
        moa: "Bind PBPs; **bulky side chain resists staphylococcal β-lactamase** → active against penicillinase-producing Staphylococcus; narrow spectrum strictly for Gram-positives",
        use: "**MSSA infections only** (skin/soft tissue, bacteremia, native valve endocarditis, osteomyelitis, septic arthritis); Drug of choice for MSSA; NOT effective against MRSA",
        se: "Nafcillin: **neutropenia**, hypokalemia, **interstitial nephritis** (unique to nafcillin), and hepatotoxicity. Oxacillin: hepatotoxicity more common",
        ci: "MRSA (all penicillins ineffective due to altered PBP2a); Penicillin allergy",
        pk: "Nafcillin: hepatically cleared (safe in renal failure unlike most β-lactams). Oxacillin: biliary/hepatic clearance. Dicloxacillin: oral formulation",
        pearl: "**MSSA vs MRSA treatment:** MSSA requires nafcillin/oxacillin. MRSA requires vancomycin or daptomycin. If a culture returns as MSSA on a patient receiving vancomycin, always de-escalate to nafcillin/oxacillin."
      },
      {
        name: "Aminopenicillins",
        summary: "Ampicillin covers Listeria (cephalosporins do not) and enterococcus. Amoxicillin has higher oral bioavailability. Ampicillin rash in EBV is not a true allergy",
        tier: 1,
        aka: "Ampicillin (IV/oral), Amoxicillin (oral), Amoxicillin-clavulanate (Augmentin), Ampicillin-sulbactam (Unasyn)",
        tags: ["Gram-Positive", "Gram-Negative", "Listeria", "Enterococcus", "Helicobacter pylori", "UTI"],
        moa: "Bind PBPs with extended Gram-negative coverage. Clavulanate/sulbactam: **β-lactamase inhibitors** (suicide inhibitors) → overcome β-lactamase-producing organisms",
        use: "Ampicillin: **Listeria monocytogenes** (critical for empiric meningitis coverage), **Enterococcus**, Haemophilus influenzae. Amoxicillin: **Helicobacter pylori** (triple therapy), Lyme disease. Augmentin: community-acquired pneumonia, bite wounds, sinusitis",
        se: "**Ampicillin rash in EBV (mononucleosis):** diffuse maculopapular rash in nearly 100% of EBV patients given ampicillin (NOT a true IgE allergy); GI upset (clavulanate causes significant diarrhea)",
        ci: "Penicillin allergy; Ampicillin contraindicated in suspected EBV infection to avoid rash",
        pk: "Amoxicillin has superior oral bioavailability compared to ampicillin; Clavulanate and sulbactam possess no intrinsic antibacterial activity",
        pearl: "**The Listeria gap:** Listeria monocytogenes has intrinsic resistance to all cephalosporins because it lacks the target PBP. Empiric regimens for neonatal or elderly meningitis must include ampicillin."
      },
      {
        name: "Extended-Spectrum Penicillins",
        summary: "Piperacillin-tazobactam: broadest penicillin covering Pseudomonas, anaerobes, and Gram-negatives. Standard for hospital-acquired infections and febrile neutropenia",
        tier: 1,
        aka: "Piperacillin-tazobactam (Zosyn), Ticarcillin-clavulanate (Timentin)",
        tags: ["Gram-Positive", "Gram-Negative", "Pseudomonas", "Anaerobes", "Nosocomial/Hospital-Acquired"],
        moa: "Bind PBPs with the broadest spectrum covering Gram-positives, Gram-negatives (including **Pseudomonas aeruginosa**), and anaerobes; tazobactam/clavulanate act as β-lactamase inhibitors",
        use: "**Hospital-acquired infections**, polymicrobial infections (intra-abdominal, diabetic foot), and **febrile neutropenia**. Empiric coverage in critically ill or immunocompromised patients",
        se: "Hypokalemia (penicillin anion causes urinary potassium wasting), platelet dysfunction at high doses, hypersensitivity, and increased C. difficile risk",
        ci: "Penicillin allergy; NOT effective against MRSA or many resistant Klebsiella (KPC) strains",
        pk: "IV administration only; dose-extended infusions (4-hour) optimize pharmacodynamics against resistant organisms; renally cleared",
        pearl: "**Pseudomonas resistance:** Piperacillin covers Pseudomonas well, but tazobactam is a poor inhibitor of the AmpC β-lactamases produced by Pseudomonas. Serious infections often require double coverage with an aminoglycoside."
      },
      {
        name: "Cephalosporins",
        summary: "Higher generation = increased Gram-negative coverage and CNS penetration. Ceftriaxone for meningitis. Ceftaroline (5th gen) is the only cephalosporin covering MRSA",
        tier: 1,
        aka: "1st: Cephalexin. 2nd: Cefuroxime. 3rd: Ceftriaxone, Ceftazidime. 4th: Cefepime. 5th: Ceftaroline",
        tags: ["Gram-Positive", "Gram-Negative", "MRSA", "Pseudomonas", "Meningitis", "Pneumonia", "UTI"],
        moa: "Bind PBPs. Progressive generations offer **increased Gram-negative coverage, CNS penetration, and beta-lactamase stability** while losing some Gram-positive efficacy",
        use: "1st gen: surgical prophylaxis (Cefazolin). 2nd gen: respiratory tract, intra-abdominal. 3rd gen: **Meningitis** and gonorrhea (Ceftriaxone). 4th/Ceftazidime: **Pseudomonas aeruginosa**. 5th gen: **MRSA**",
        se: "Hypersensitivity (cross-reactivity with penicillin ~1-2%); Ceftriaxone causes **biliary sludge** and displaces bilirubin in neonates; all carry C. difficile risk",
        ci: "Severe penicillin anaphylaxis; Ceftriaxone contraindicated in neonates with hyperbilirubinemia",
        pk: "Ceftriaxone features excellent CNS penetration, allows once-daily dosing, and is cleared via the biliary tract (safe in renal failure)",
        pearl: "**The LAME exception:** No cephalosporins cover Listeria, Atypicals (Chlamydia/Mycoplasma), MRSA (except 5th gen), or Enterococci. Ampicillin or vancomycin must be added for these organisms."
      },
      {
        name: "Carbapenems & Monobactams",
        summary: "Imipenem: broad-spectrum, always given with cilastatin, lowers seizure threshold. Aztreonam: narrow Gram-negative spectrum, safe in severe penicillin allergy",
        tier: 2,
        aka: "Imipenem, Meropenem, Ertapenem, Aztreonam (Monobactam)",
        tags: ["Gram-Negative", "Pseudomonas", "Broad-Spectrum", "Penicillin-Allergy"],
        moa: "Carbapenems: Bind PBPs, highly resistant to most β-lactamases. Aztreonam: Binds **PBP3** exclusively (target only present in Gram-negative bacteria)",
        use: "Carbapenems: Life-threatening, **multi-drug resistant infections** (ESBL Klebsiella, Pseudomonas). Aztreonam: severe Gram-negative infections in patients with **severe penicillin anaphylaxis**",
        se: "Imipenem: **CNS toxicity and seizures** (highest risk among β-lactams), GI distress, and rash. Meropenem carries a much lower seizure risk",
        ci: "Imipenem contraindicated in patients with prior seizure disorders",
        pk: "Imipenem is rapidly degraded by renal dehydropeptidase I and must always be administered with **Cilastatin** (enzyme inhibitor)",
        pearl: "**Aztreonam allergy rule:** Because it lacks the bicyclic ring structure of other β-lactams, aztreonam has NO cross-reactivity with penicillins. It is completely safe for a patient with a documented penicillin anaphylaxis."
      },
      {
        name: "Vancomycin",
        summary: "Binds D-Ala-D-Ala for cell wall inhibition. Drug of choice for MRSA. Causes Red Man Syndrome via rapid histamine release",
        tier: 1,
        aka: "Vancomycin",
        tags: ["Gram-Positive", "MRSA", "C. difficile", "Enterococcus"],
        moa: "Binds the **D-Ala-D-Ala terminus** of peptidoglycan precursors → inhibits transglycosylase → prevents cell wall synthesis; distinct target from penicillins prevents cross-resistance",
        use: "**MRSA** (IV formulation), severe Gram-positive infections, **Clostridioides difficile colitis** (oral formulation acts locally in GI tract), and empiric Gram-positive coverage in penicillin allergy",
        se: "**Red Man Syndrome:** flushing, erythema, and pruritus caused by rapid infusion mast cell degranulation (prevented by slow infusion or antihistamines); also causes **nephrotoxicity** and ototoxicity",
        ci: "Concurrent use with highly nephrotoxic or ototoxic drugs if possible",
        pk: "Monitored via trough levels (target 15-20 µg/mL); exclusively active against Gram-positive bacteria; renally cleared",
        pearl: "**Mechanism of Resistance:** Vancomycin-resistant enterococci (VRE) alter their cell wall target from D-Ala-D-Ala to D-Ala-D-Lac. Treat VRE with linezolid or daptomycin."
      }
    ]
  },
{
    group: "Protein Synthesis Inhibitors",
    color: "micro",
    drugs: [
      {
        name: "Aminoglycosides",
        summary: "30S inhibitors requiring oxygen (ineffective against anaerobes). OTAN side effects: Ototoxicity, Teratogenicity, ATN nephrotoxicity, Neuromuscular block",
        tier: 1,
        aka: "Gentamicin, Tobramycin, Amikacin, Streptomycin, Neomycin",
        tags: ["Gram-Negative", "Aerobes", "Pseudomonas", "Synergy", "Tuberculosis"],
        moa: "Bind **30S ribosomal subunit** → cause misreading of mRNA → defective proteins → cell death; require oxygen-dependent active transport for cellular uptake",
        use: "Severe **Gram-negative aerobic infections**. Tobramycin: Pseudomonas aeruginosa. Gentamicin: synergistic coverage for endocarditis with β-lactams. Streptomycin: Tuberculosis, plague. Neomycin: oral bowel prep",
        se: "**OTAN:** **Ototoxicity** (irreversible, exacerbated by loop diuretics), **Teratogenicity** (cranial nerve VIII deafness), Aminoglycoside renal toxicity (**Acute Tubular Necrosis**), and Neuromuscular blockade",
        ci: "Myasthenia gravis, pregnancy, and concurrent use of loop diuretics (increases ototoxicity risk)",
        pk: "Demonstrate concentration-dependent killing; once-daily dosing preferred to maximize peak and minimize trough toxicity",
        pearl: "**The Anaerobe Rule:** Aminoglycosides cannot kill anaerobes because they require oxygen to cross the bacterial membrane. In mixed intra-abdominal infections, always add metronidazole or clindamycin."
      },
      {
        name: "Tetracyclines",
        summary: "30S bacteriostatic agents. Doxycycline is first-line for RMSF, Lyme disease, and atypicals. Avoid in children under 8 due to dental staining",
        tier: 1,
        aka: "Tetracycline, Doxycycline, Minocycline",
        tags: ["Atypical Organisms", "Chlamydia", "Lyme", "Tick-Borne Illness", "Mycoplasma"],
        moa: "Bind the **30S ribosomal subunit** → block aminoacyl-tRNA binding to the A site → bacteriostatic effect",
        use: "Chlamydia trachomatis, Mycoplasma pneumoniae, **Rickettsia rickettsii** (Rocky Mountain spotted fever), **Borrelia burgdorferi** (Lyme disease), acne vulgaris",
        se: "**Dental staining** (yellow-brown discoloration), photosensitivity, esophageal ulceration, **Fanconi syndrome** (from expired tetracycline), and pseudotumor cerebri",
        ci: "Children under 8 years old, pregnancy, and renal failure (note: doxycycline is an exception and safe in renal failure)",
        pk: "Doxycycline is safe in renal failure due to biliary excretion; tetracyclines are chelated by calcium, milk, antacids, and iron, blocking oral absorption",
        pearl: "**RMSF exception:** Doxycycline is first-line for Rocky Mountain spotted fever even in children under 8. The high mortality risk of untreated RMSF outweighs the risk of temporary dental staining."
      },
      {
        name: "Macrolides",
        summary: "50S inhibitors. Azithromycin for atypical pneumonia, pertussis, and chlamydia. Associated with QT prolongation and CYP3A4 inhibition",
        tier: 1,
        aka: "Azithromycin (Z-pak), Clarithromycin, Erythromycin",
        tags: ["Gram-Positive", "Atypical Organisms", "Pneumonia", "Chlamydia", "Pertussis", "Helicobacter pylori"],
        moa: "Bind the **50S ribosomal subunit (23S rRNA)** → inhibit the translocation step of protein synthesis → bacteriostatic",
        use: "**Atypical pneumonia** (Mycoplasma, Chlamydia, Legionella), Community-acquired pneumonia. Azithromycin: pertussis, MAC prophylaxis, Chlamydia. Clarithromycin: Helicobacter pylori eradication",
        se: "GI hypermotility (erythromycin is a motilin receptor agonist); **QT prolongation** across the class; profound **CYP3A4 inhibition** (erythromycin and clarithromycin)",
        ci: "Concurrent use with other QT-prolonging drugs or CYP3A4 substrates like statins",
        pk: "Azithromycin concentrates intracellularly with a very long half-life, allowing short 5-day courses; clarithromycin and erythromycin are potent CYP450 inhibitors",
        pearl: "**Neonatal risk:** Erythromycin administered to neonates or infants strongly correlates with the development of hypertrophic pyloric stenosis because it stimulates the motilin receptor."
      },
      {
        name: "Clindamycin",
        summary: "50S inhibitor targeting anaerobes and MRSA skin infections. Potent suppressor of bacterial toxins. Classic risk factor for C. difficile colitis",
        tier: 1,
        aka: "Clindamycin",
        tags: ["Gram-Positive", "Anaerobes", "MRSA", "Toxin Suppression"],
        moa: "Binds the **50S ribosomal subunit** → inhibits peptidyl transferase → bacteriostatic; severely inhibits bacterial toxin synthesis",
        use: "**Anaerobic infections** above the diaphragm (aspiration pneumonia, lung abscesses, oral infections); skin/soft tissue **MRSA** infections; suppression of toxin production in necrotizing fasciitis or Toxic Shock Syndrome",
        se: "**Clostridioides difficile colitis** (most strongly associated antibiotic due to disruption of normal gut flora), GI upset, and metallic taste",
        ci: "History of C. difficile infection; inadequate for CNS infections due to poor penetration",
        pk: "Excellent bone penetration makes it useful for osteomyelitis; strictly targets Gram-positive organisms and anaerobes",
        pearl: "**Toxin suppression mechanism:** In necrotizing fasciitis, a β-lactam is used to kill the bacteria, while clindamycin is specifically added to shut down the 50S ribosome and halt the synthesis of tissue-destroying exotoxins."
      },
      {
        name: "Misc. Antibacterials",
        summary: "Linezolid (50S) for VRE/MRSA causes serotonin syndrome. Daptomycin (membrane) causes myopathy and is inactivated by surfactant. Chloramphenicol causes Gray baby syndrome",
        tier: 2,
        aka: "Linezolid, Daptomycin, Chloramphenicol",
        tags: ["Gram-Positive", "MRSA", "VRE", "Meningitis"],
        moa: "Linezolid: binds **50S subunit**. Daptomycin: inserts into cell membrane → depolarizes → rapid cell death. Chloramphenicol: binds 50S peptidyltransferase",
        use: "Linezolid and Daptomycin: **multidrug-resistant Gram-positive infections (MRSA, VRE)**. Chloramphenicol: meningitis in developing countries, severe rickettsial infections in pregnancy",
        se: "Linezolid: **Serotonin syndrome** (acts as a weak MAOI), bone marrow suppression, optic neuropathy. Daptomycin: **Myopathy and rhabdomyolysis**. Chloramphenicol: **Gray baby syndrome** (premature infants lack UDP-glucuronosyltransferase), aplastic anemia",
        ci: "Linezolid contraindicated with concurrent SSRI/MAOI use; Daptomycin strictly contraindicated for pneumonia",
        pk: "Daptomycin is bound and **completely inactivated by pulmonary surfactant**, making it useless for MRSA pneumonia",
        pearl: "**The Linezolid interaction:** If a hospital patient on fluoxetine develops pneumonia, is given linezolid, and subsequently presents with tremor, hyperthermia, and confusion, they are experiencing serotonin syndrome."
      }
    ]
  },
{
    group: "DNA, Folate & Membrane",
    color: "micro",
    drugs: [
      {
        name: "Fluoroquinolones",
        summary: "Inhibit DNA gyrase. Broad-spectrum for UTI, pyelonephritis, and pneumonia. Carries black box warnings for tendon rupture and QT prolongation",
        tier: 1,
        aka: "Ciprofloxacin, Levofloxacin, Moxifloxacin",
        tags: ["Gram-Negative", "UTI", "Pneumonia", "Pseudomonas", "Atypical Organisms"],
        moa: "Inhibit **DNA gyrase (topoisomerase II)** and topoisomerase IV → prevent DNA unwinding → induce double-strand DNA breaks → bactericidal",
        use: "**Urinary tract infections**, pyelonephritis, **Pseudomonas aeruginosa** (ciprofloxacin). Respiratory infections (levofloxacin/moxifloxacin for S. pneumoniae and atypicals). GI pathogens (Salmonella, Shigella)",
        se: "**Tendinopathy and Achilles tendon rupture** (risk increases in elderly and those on corticosteroids), cartilage damage, **QT prolongation**, CNS effects (seizures, dizziness), and photosensitivity",
        ci: "Children and adolescents (due to cartilage damage), pregnancy, myasthenia gravis, and concurrent QT-prolonging drugs",
        pk: "Excellent oral bioavailability; absorption is severely reduced by chelation with antacids containing magnesium, calcium, or aluminum",
        pearl: "**Tendon rupture mechanism:** Fluoroquinolones inhibit human collagen synthesis, leading to structural weakness in tendons. Always suspect this in an older patient on prednisone who suddenly develops heel pain after starting an antibiotic."
      },
      {
        name: "Metronidazole",
        summary: "Covers anaerobes and protozoa. Generates toxic free radicals. Causes a severe disulfiram-like reaction with alcohol",
        tier: 1,
        aka: "Flagyl",
        tags: ["Anaerobes", "C. difficile", "Protozoal Infections", "Bacterial Vaginosis"],
        moa: "Forms **toxic free radical metabolites** strictly in anaerobic environments → induces DNA strand breaks → bactericidal against anaerobes and protozoa",
        use: "**Anaerobic bacteria** below the diaphragm (intra-abdominal, pelvic infections), **Clostridioides difficile** (mild cases), **Protozoa** (Giardia, Trichomonas, Entamoeba histolytica), and bacterial vaginosis",
        se: "**Disulfiram-like reaction with alcohol** (severe flushing, vomiting, palpitations), metallic taste in mouth, peripheral neuropathy with prolonged use, and dark urine",
        ci: "First trimester of pregnancy (teratogenic in animal models)",
        pk: "Excellent tissue and CSF penetration; prodrug requires reduction by anaerobic pathways to become active",
        pearl: "**The alcohol rule:** Patients must strictly avoid alcohol during metronidazole treatment and for 48 hours after the last dose to prevent the accumulation of acetaldehyde and the subsequent disulfiram-like reaction."
      },
      {
        name: "TMP-SMX (Trimethoprim-Sulfamethoxazole)",
        summary: "Sequential antifolate blockade. Used for PCP prophylaxis, uncomplicated UTI, and community MRSA. Elevates creatinine without altering GFR",
        tier: 1,
        aka: "Bactrim, Septra",
        tags: ["Gram-Negative", "MRSA", "UTI", "PCP", "Pneumocystis jirovecii", "Folate Antagonist"],
        moa: "Sequential **antifolate** mechanism. SMX inhibits **dihydropteroate synthase**. TMP inhibits **dihydrofolate reductase (DHFR)**. Together they provide synergistic bactericidal blockade of folate synthesis",
        use: "First-line for **uncomplicated UTI**, **Pneumocystis jirovecii (PCP) prophylaxis and treatment**, **community-acquired MRSA** skin infections, Listeria, Nocardia, and Toxoplasma prophylaxis",
        se: "**Megaloblastic anemia** (antifolate effect), hemolytic anemia in G6PD deficiency, **Stevens-Johnson syndrome** (sulfonamide reaction), hyperkalemia (TMP blocks ENaC), and artificially elevated creatinine",
        ci: "Sulfonamide allergy, third trimester of pregnancy (competes with bilirubin for albumin causing kernicterus), and concurrent methotrexate use",
        pk: "Excreted renally; TMP blocks the tubular secretion of creatinine, raising serum creatinine levels without actually damaging the kidney or altering true GFR",
        pearl: "**HIV Prophylaxis:** Initiate TMP-SMX for PCP prophylaxis when CD4 counts drop below 200. At CD4 below 100, the same drug provides concurrent prophylaxis against Toxoplasma gondii encephalitis."
      }
    ]
  },
{
    group: "Antimycobacterials",
    color: "micro",
    drugs: [
      {
        name: "Tuberculosis Drugs (RIPE)",
        summary: "RIPE therapy for active TB. Isoniazid requires Vitamin B6 to prevent neuropathy. Rifampin causes orange body fluids and induces CYP450. Ethambutol causes optic neuritis",
        tier: 1,
        aka: "Rifampin, Isoniazid (INH), Pyrazinamide, Ethambutol",
        tags: ["Mycobacterium tuberculosis", "Tuberculosis", "Latent TB", "MAC"],
        moa: "Rifampin: inhibits **RNA polymerase**. INH: inhibits **mycolic acid synthesis**. Pyrazinamide: disrupts membrane potential. Ethambutol: inhibits **arabinosyl transferase**",
        use: "**Active Mycobacterium tuberculosis:** 4-drug regimen for 2 months, followed by INH and Rifampin for 4 months. Latent TB: INH monotherapy for 9 months",
        se: "Rifampin: **orange/red body fluids**, severe CYP450 induction, hepatotoxicity. INH: **peripheral neuropathy** (requires B6), drug-induced lupus, hepatotoxicity. Pyrazinamide: hyperuricemia. Ethambutol: **optic neuritis** (red-green color blindness)",
        ci: "Ethambutol contraindicated in young children who cannot report changes in visual acuity",
        pk: "Isoniazid requires activation by the mycobacterial KatG catalase-peroxidase enzyme; mutations in KatG confer INH resistance",
        pearl: "**The Pyridoxine Rule:** Isoniazid competitively depletes Vitamin B6 (pyridoxine) leading to defective neurotransmitter synthesis. You must always co-administer Vitamin B6 with INH to prevent severe peripheral neuropathy."
      },
      {
        name: "Leprosy Drugs",
        summary: "Dapsone inhibits folate synthesis for leprosy treatment and PCP prophylaxis. Classic trigger for hemolysis in G6PD deficiency",
        tier: 3,
        aka: "Dapsone",
        tags: ["Mycobacterium", "Leprosy", "PCP Prophylaxis", "G6PD"],
        moa: "Acts as a competitive antagonist of **dihydropteroate synthase**, disrupting folate synthesis in a manner structurally similar to sulfonamides",
        use: "**Mycobacterium leprae** (combined with rifampin for tuberculoid forms); secondary alternative for Pneumocystis jirovecii (PCP) prophylaxis in sulfa-allergic patients",
        se: "**Hemolytic anemia in G6PD deficiency**, methemoglobinemia, and agranulocytosis",
        ci: "Severe G6PD deficiency (screening mandatory before initiation)",
        pk: "Metabolized in the liver via acetylation",
        pearl: "**G6PD crisis presentation:** Dapsone is a potent oxidative stressor. Administering it to a G6PD-deficient patient will result in acute fatigue, dark urine, jaundice, and the appearance of bite cells and Heinz bodies on a peripheral blood smear."
      }
    ]
  },
{
    group: "Antifungals",
    color: "micro",
    drugs: [
      {
        name: "Amphotericin B",
        summary: "Nicknamed 'Amphoterrible' for profound nephrotoxicity and infusion reactions. Drug of choice for systemic mycoses and Mucormycosis",
        tier: 1,
        aka: "Amphotericin B deoxycholate, Liposomal amphotericin B (AmBisome)",
        tags: ["Systemic Fungi", "Cryptococcus", "Mucormycosis", "Histoplasma"],
        moa: "Binds **ergosterol** in the fungal cell membrane → forms destructive pores → membrane leakage and cell death. Exhibits selective toxicity because human cell membranes utilize cholesterol",
        use: "**Severe systemic fungal infections**. Cryptococcus neoformans meningitis (combined with flucytosine), Histoplasma, Blastomyces, Coccidioides; Drug of choice for **Mucormycosis**",
        se: "**Nephrotoxicity** (causes distal RTA, severe hypokalemia, and hypomagnesemia); **Infusion-related reactions** (fevers, rigors, hypotension prevented by antipyretics and antihistamines); anemia due to decreased erythropoietin production",
        ci: "Relative contraindication in pre-existing renal failure (requires switch to liposomal formulation)",
        pk: "Liposomal Amphotericin B is preferred due to significantly lower rates of nephrotoxicity. Requires aggressive IV saline pre-hydration to protect the kidneys",
        pearl: "**Cryptococcal induction:** Amphotericin B is always combined with flucytosine for the first 2 weeks of Cryptococcal meningitis treatment to achieve synergy and rapid sterilization of the CSF."
      },
      {
        name: "Azole Antifungals",
        summary: "Inhibit ergosterol synthesis. Voriconazole is First-line for Aspergillus. Fluconazole covers Candida. Notorious for CYP3A4 inhibition and teratogenicity",
        tier: 1,
        aka: "Fluconazole, Itraconazole, Voriconazole, Ketoconazole",
        tags: ["Candida", "Aspergillus", "Endemic Fungi", "CYP450"],
        moa: "Inhibit **lanosterol 14α-demethylase (a fungal CYP51 enzyme)** → prevent conversion of lanosterol to ergosterol → alters membrane fluidity; fungistatic effect",
        use: "Fluconazole: **Candida albicans**, Cryptococcal maintenance therapy. Voriconazole: **Aspergillus fumigatus** (drug of choice). Itraconazole: Endemic dimorphic fungi (Histoplasma, Blastomyces)",
        se: "**Hepatotoxicity** across the class; **CYP3A4 inhibition** causing severe drug interactions; QT prolongation. Voriconazole specifically causes visual disturbances (photopsia) and photosensitivity",
        ci: "Pregnancy (all azoles are teratogenic); concurrent use with other QT-prolonging agents",
        pk: "Because they target a fungal cytochrome P450 enzyme, azoles inherently cross-react and inhibit human CYP450 enzymes, significantly raising the serum levels of statins, tacrolimus, and warfarin",
        pearl: "**Fluconazole limits:** Fluconazole has absolutely no activity against Aspergillus or Mucor. If a patient presents with invasive aspergillosis, voriconazole is the required treatment."
      },
      {
        name: "Echinocandins & Flucytosine",
        summary: "Caspofungin: targets glucan synthase, first-line for invasive Candida, lacks CNS penetration. Flucytosine: targets DNA synthesis, used only in combination for Cryptococcus",
        tier: 2,
        aka: "Echinocandins (Caspofungin, Micafungin), Flucytosine (5-FC)",
        tags: ["Candida", "Aspergillus", "Cryptococcus"],
        moa: "Echinocandins: inhibit **β-1,3-glucan synthase** → disrupt fungal cell wall (target lacks a human equivalent). Flucytosine: converted to **5-fluorouracil (5-FU)** inside fungal cells → disrupts DNA and RNA synthesis",
        use: "Echinocandins: **first-line for invasive Candidiasis** in critically ill or neutropenic patients. Flucytosine: exclusively used in combination with Amphotericin B for **Cryptococcal meningitis**",
        se: "Echinocandins: exceptionally well tolerated (mild histamine release). Flucytosine: **dose-dependent bone marrow suppression** (leukopenia, thrombocytopenia) and GI toxicity",
        ci: "Echinocandins: inadequate for CNS infections (fails to cross blood-brain barrier). Flucytosine: renal failure leads to toxic accumulation",
        pk: "Echinocandins are administered via IV only and lack significant CYP450 interactions. Flucytosine resistance develops rapidly if used as monotherapy",
        pearl: "**The safest antifungal class:** Echinocandins have the lowest toxicity profile among systemic antifungals because human cells completely lack a cell wall and glucan synthase."
      },
      {
        name: "Dermatophyte Drugs",
        summary: "Griseofulvin (disrupts microtubules) and Terbinafine (inhibits squalene epoxidase) used for severe systemic ringworm and nail fungal infections",
        tier: 3,
        aka: "Griseofulvin, Terbinafine",
        tags: ["Dermatophytes", "Onychomycosis", "Tinea", "CYP450"],
        moa: "Griseofulvin: disrupts **microtubule function** and mitosis, depositing in keratin-rich tissues. Terbinafine: inhibits **squalene epoxidase** → triggers toxic accumulation of squalene within fungal cells",
        use: "Oral therapy for severe or refractory dermatophyte infections (tinea corporis/capitis) and **onychomycosis** (fungal nail infections)",
        se: "Terbinafine: hepatotoxicity and taste disturbances. Griseofulvin: teratogenic, carcinogenic, and induces confusion or headaches",
        ci: "Griseofulvin: pregnancy and porphyria. Both require baseline liver function testing prior to initiation",
        pk: "Griseofulvin is a classic CYP450 inducer, reducing the efficacy of oral contraceptives and warfarin",
        pearl: "**Treatment escalation:** Mild tinea infections are managed with topical clotrimazole. Oral agents like terbinafine are reserved for tinea capitis (scalp) and onychomycosis where topical creams cannot penetrate the hair shaft or nail bed."
      }
    ]
  },
{
    group: "Antivirals",
    color: "micro",
    drugs: [
      {
        name: "NRTIs & NNRTIs",
        summary: "Core backbone of HIV ART. Tenofovir and Emtricitabine used for PrEP. AZT used for perinatal transmission. Abacavir requires HLA-B*5701 testing to prevent fatal hypersensitivity",
        tier: 1,
        aka: "NRTIs: Tenofovir, Emtricitabine, Abacavir, Zidovudine (AZT). NNRTIs: Efavirenz",
        tags: ["HIV", "ART", "PrEP", "Perinatal"],
        moa: "NRTIs: **nucleoside analogs** incorporated into viral DNA → induce chain termination of reverse transcriptase (require intracellular phosphorylation). NNRTIs: **allosteric reverse transcriptase inhibitors** (do not require phosphorylation)",
        use: "Backbone of modern combination ART regimens. **PrEP:** tenofovir combined with emtricitabine. **Perinatal prevention:** AZT administered to mother during labor and neonate postpartum to reduce transmission",
        se: "AZT: **bone marrow suppression** and myopathy. Tenofovir: nephrotoxicity and decreased bone density. Abacavir: **severe hypersensitivity reaction associated with HLA-B*5701**. Efavirenz: vivid nightmares, CNS disturbances, and teratogenicity",
        ci: "Abacavir absolutely contraindicated in HLA-B*5701 positive individuals. Efavirenz contraindicated in first trimester of pregnancy",
        pk: "All NRTIs require intracellular phosphorylation by host kinases to achieve the active triphosphate form. Efavirenz is a potent CYP3A4 inducer",
        pearl: "**The Abacavir requirement:** HLA-B*5701 testing is strictly mandatory before initiating abacavir. Re-challenging a patient who previously developed fever and rash on abacavir can result in rapid, fatal anaphylaxis."
      },
      {
        name: "Protease & Integrase Inhibitors",
        summary: "Integrase inhibitors (dolutegravir) are the preferred 3rd agent in ART. Protease inhibitors cause lipodystrophy. Ritonavir is utilized purely as a pharmacokinetic CYP3A4 booster",
        tier: 1,
        aka: "Protease Inhibitors: Ritonavir, Atazanavir, Darunavir. Integrase Inhibitors: Dolutegravir, Raltegravir",
        tags: ["HIV", "ART", "CYP450"],
        moa: "Protease Inhibitors: inhibit **HIV protease** → prevent cleavage of Gag-Pol polyprotein → yield immature, non-infectious virions. Integrase Inhibitors: inhibit **HIV integrase** → block insertion of viral cDNA into the host chromosome",
        use: "Serve as the required third component of combination ART. **Integrase inhibitors** are now the preferred first-line agents due to higher potency and resistance barriers",
        se: "Protease Inhibitors: **lipodystrophy** (central fat accumulation and peripheral lipoatrophy), severe insulin resistance, and hyperlipidemia. Integrase Inhibitors: weight gain and historically associated with neural tube defects",
        ci: "Ritonavir carries extensive CYP3A4 drug interactions. Avoid St. John's Wort, which lowers PI concentrations",
        pk: "**Ritonavir boosting:** Ritonavir is a potent CYP3A4 inhibitor administered at low doses not for its antiviral properties, but to intentionally inhibit the metabolism of co-administered protease inhibitors, extending their half-life",
        pearl: "**Integrase inhibitor side effects:** While generally better tolerated than PIs, integrase inhibitors (the '-tegravir' class) are uniquely associated with isolated elevations in creatine kinase (CK)."
      },
      {
        name: "HIV Entry Inhibitors",
        summary: "Maraviroc acts as a CCR5 antagonist. Enfuvirtide inhibits gp41. Viral tropism testing is mandatory before utilizing Maraviroc",
        tier: 3,
        aka: "Maraviroc, Enfuvirtide",
        tags: ["HIV", "ART", "Salvage Therapy"],
        moa: "Maraviroc: binds the **human CCR5 co-receptor** on host T cells and macrophages → prevents HIV gp120 binding. Enfuvirtide: binds **viral gp41** → blocks viral fusion to the host membrane",
        use: "Reserved for HIV salvage therapy in patients harboring multi-drug resistant viral strains",
        se: "Maraviroc: hepatotoxicity and severe rash. Enfuvirtide: painful skin injection site reactions occurring in nearly 100% of patients",
        ci: "Maraviroc contraindicated if the patient's HIV strain utilizes the CXCR4 receptor",
        pk: "Enfuvirtide cannot be taken orally and requires subcutaneous injection twice daily",
        pearl: "**The Tropism Assay:** HIV strains use either CCR5, CXCR4, or a combination of both to enter host cells. Maraviroc is strictly a CCR5 antagonist and is entirely ineffective against CXCR4-tropic strains."
      },
      {
        name: "Herpes & CMV Antivirals",
        summary: "Acyclovir treats HSV/VZV and requires viral thymidine kinase for activation. Ganciclovir treats CMV and causes severe myelosuppression. Foscarnet targets resistant strains",
        tier: 1,
        aka: "Acyclovir, Valacyclovir, Ganciclovir, Valganciclovir, Foscarnet",
        tags: ["HSV", "VZV", "CMV", "Retinitis"],
        moa: "Acyclovir: initially phosphorylated by **viral thymidine kinase** → inhibits **viral DNA polymerase** and induces chain termination. Ganciclovir: analogous mechanism utilizing CMV kinase. Foscarnet: directly inhibits viral DNA polymerase without requiring kinase activation",
        use: "Acyclovir: **Herpes simplex virus** (encephalitis, genital herpes) and Varicella-zoster virus. Ganciclovir: **Cytomegalovirus retinitis** and transplant prophylaxis. Foscarnet: acyclovir-resistant HSV or ganciclovir-resistant CMV",
        se: "Acyclovir: obstructive nephropathy from drug crystallization in renal tubules. Ganciclovir: **profound myelosuppression** (leukopenia, thrombocytopenia). Foscarnet: severe electrolyte wasting (calcium, magnesium) and nephrotoxicity",
        ci: "Concurrent administration of ganciclovir and AZT drastically amplifies bone marrow suppression",
        pk: "Valacyclovir and valganciclovir represent prodrug forms designed to achieve superior oral bioavailability",
        pearl: "**CMV Resistance:** Cytomegalovirus fundamentally lacks the thymidine kinase enzyme, rendering acyclovir completely ineffective against it. If a CMV strain mutates its UL97 kinase to become resistant to ganciclovir, the next therapeutic step is foscarnet."
      },
      {
        name: "Influenza Antivirals",
        summary: "Oseltamivir and Zanamivir act as neuraminidase inhibitors for Influenza A and B. Efficacy strictly requires administration within 48 hours of symptom onset",
        tier: 1,
        aka: "Oseltamivir (Tamiflu), Zanamivir",
        tags: ["Influenza", "Neuraminidase"],
        moa: "Inhibit viral **neuraminidase** → prevent the cleavage of sialic acid residues → block the release of newly formed progeny influenza virions from the host cell",
        use: "Treatment and post-exposure prophylaxis for **Influenza A and B strains**",
        se: "Oseltamivir: primarily GI upset and nausea. Zanamivir: bronchospasm and respiratory irritation",
        ci: "Zanamivir contraindicated in patients with underlying asthma or COPD",
        pk: "Oral administration for oseltamivir; inhaled route for zanamivir",
        pearl: "**The 48-Hour Window:** The therapeutic window for neuraminidase inhibitors is exceptionally narrow. If a patient presents on day 3 or 4 of influenza symptoms, the correct action is supportive care alone."
      },
      {
        name: "Ribavirin & Interferons",
        summary: "Ribavirin induces severe hemolytic anemia and acts as a massive teratogen. Interferon-alpha utilized for Hepatitis B and Kaposi sarcoma",
        tier: 3,
        aka: "Ribavirin, Interferon-alpha (IFN-α)",
        tags: ["RSV", "Hepatitis B", "Hepatitis C"],
        moa: "Ribavirin: inhibits **IMP dehydrogenase** leading to depleted intracellular GTP pools. Interferon-alpha: **recombinant cytokine** that activates host ribonuclease L to degrade viral mRNA",
        use: "Ribavirin: severe **Respiratory Syncytial Virus (RSV)** via inhalation. Interferon-alpha: chronic Hepatitis B and Kaposi sarcoma",
        se: "Ribavirin: **dose-dependent hemolytic anemia** and severe teratogenicity. Interferon-alpha: severe flu-like symptoms, **profound depression and suicidality**, and drug-induced lupus",
        ci: "Ribavirin absolutely contraindicated in pregnancy (category X); requires strict contraception for 6 months post-treatment. Interferon-alpha contraindicated in patients with major depressive disorder",
        pk: "Hepatitis C is now managed with modern Direct-Acting Antivirals (DAAs), making ribavirin and interferon largely historical for that indication",
        pearl: "**Extreme teratogenicity:** Ribavirin is such a potent teratogen that it is contraindicated even in the male partners of pregnant women due to seminal accumulation."
      }
    ]
  },
{
    group: "Antiparasitics",
    color: "micro",
    drugs: [
      {
        name: "Antimalarials",
        summary: "Chloroquine eliminates blood schizonts. Primaquine specifically targets liver hypnozoites (P. vivax/ovale) and causes hemolysis in G6PD deficient patients",
        tier: 1,
        aka: "Chloroquine, Mefloquine, Primaquine",
        tags: ["Parasites", "Protozoal Infections", "Malaria", "Plasmodium", "G6PD"],
        moa: "Chloroquine: blocks Plasmodium **heme polymerase** → toxic free heme accumulates and destroys the parasite. Primaquine: eradicates dormant **liver hypnozoites**",
        use: "Treatment and prophylaxis of **malaria**. Chloroquine for sensitive Plasmodium falciparum. Primaquine must be added to regimens for P. vivax and P. ovale to prevent relapse",
        se: "Chloroquine: retinal toxicity and severe pruritus. Mefloquine: prominent neuropsychiatric effects and vivid dreams. Primaquine: **hemolytic anemia in G6PD deficiency**",
        ci: "Primaquine contraindicated in pregnancy and G6PD deficiency (screening required before initiation)",
        pk: "Global resistance to chloroquine is prevalent due to parasitic mutations in the PfCRT efflux pump",
        pearl: "**The Relapse Mechanism:** If a traveler is successfully treated for an acute malarial fever but presents months later with a recurrent infection, they were infected with P. vivax or P. ovale and failed to receive primaquine."
      },
      {
        name: "Anti-helminthics",
        summary: "Mebendazole (microtubule inhibitor) for nematodes. Praziquantel (calcium influx) for flukes and tapeworms. Pyrantel pamoate paralyzes pinworms",
        tier: 1,
        aka: "Mebendazole, Albendazole, Praziquantel, Pyrantel pamoate",
        tags: ["Parasites", "Worms", "Nematodes", "Trematodes", "Cestodes"],
        moa: "Mebendazole: inhibits parasitic **microtubule synthesis**. Praziquantel: increases **calcium membrane permeability** → triggers tetanic muscle contraction and paralysis. Pyrantel pamoate: acts as a depolarizing neuromuscular blocker",
        use: "Mebendazole: nematodes (Enterobius/pinworms, Ascaris). Praziquantel: trematodes (Schistosoma/flukes) and cestodes (Taenia/tapeworms). Pyrantel pamoate: pinworms and hookworms",
        se: "Generally well tolerated. Praziquantel causes headache and GI distress. Albendazole carries a risk of hepatotoxicity",
        ci: "Avoid mebendazole during the first trimester of pregnancy",
        pk: "Mebendazole exhibits poor systemic absorption, acting primarily within the GI tract lumen",
        pearl: "**Target matching:** Step 1 frequently tests the distinct mechanisms of these drugs. Microtubule disruption links to the bendazoles. Increased calcium permeability links to praziquantel."
      }
    ]
  }
],

gi: [
{
    group: "Gastrointestinal & Motility",
    color: "gi",
    drugs: [
      {
        name: "PPIs (Proton Pump Inhibitors)",
        summary: "Irreversibly inhibit H⁺/K⁺-ATPase — most potent acid suppression. Omeprazole: CYP2C19 inhibitor → clopidogrel interaction. Chronic: ↓ Mg²⁺/B12",
        tier: 1,
        aka: "Omeprazole, Lansoprazole, Pantoprazole, Esomeprazole (-prazole suffix)",
        tags: ["GERD", "PUD", "Zollinger-Ellison", "Helicobacter pylori"],
        moa: "Irreversibly inhibit **H+/K+ ATPase (proton pump)** on parietal cell canalicular surface → most potent acid suppression. Prodrug: activated in acidic environment",
        use: "GERD, peptic ulcer disease, H. pylori (triple/quadruple therapy), Zollinger-Ellison syndrome, NSAID-induced ulcer prevention, Barrett's esophagus, stress ulcer prophylaxis in ICU",
        se: "**Long-term use:** hypomagnesemia, C. difficile risk, ↑ pneumonia risk, ↓ B12 absorption, osteoporosis (↓ Ca2+ absorption), drug interactions (↓ clopidogrel activation by CYP2C19)",
        ci: "",
        pk: "All are prodrugs — must take 30–60 min before meals for best effect. CYP2C19 inhibitors (especially omeprazole) → may ↓ clopidogrel effectiveness",
        pearl: "**H. pylori triple therapy:** PPI + clarithromycin + amoxicillin (or metronidazole if PCN-allergic) × 14 days. Classic scenario: patient with recurrent peptic ulcers + H. pylori positive → treat with eradication therapy, not just acid suppression alone. Confirm eradication with urea breath test."
      },
      {
        name: "H2 Receptor Blockers",
        summary: "Famotidine/cimetidine: block H2 on parietal cells → ↓ acid. Cimetidine: CYP inhibitor + anti-androgenic (gynecomastia). Weaker than PPIs",
        tier: 2,
        aka: "Famotidine, Cimetidine, Ranitidine (-tidine suffix)",
        tags: ["GERD", "PUD", "Zollinger-Ellison"],
        moa: "Competitively block **H2 histamine receptors** on parietal cells → ↓ gastric acid secretion (less potent than PPIs)",
        use: "GERD (mild-moderate), peptic ulcers, Zollinger-Ellison, stress ulcer prophylaxis",
        se: "Cimetidine: **CYP450 inhibitor** (↑ warfarin, phenytoin, theophylline levels), anti-androgenic effects (gynecomastia, impotence), crosses BBB (confusion in elderly), crosses placenta",
        ci: "",
        pk: "Famotidine: safest (least drug interactions). Cimetidine: most drug interactions",
        pearl: "**Cimetidine is the problem child of H2 blockers** — only one with significant CYP inhibition and anti-androgenic effects. Boards love: cimetidine + warfarin = ↑ INR (bleeding). Always choose famotidine when interactions matter."
      },
      {
        name: "Ondansetron (5-HT3 Antagonist Antiemetics)",
        summary: "First-line for CINV/PONV — blocks 5-HT3 in gut + CTZ. No EPS (unlike metoclopramide). Key SE: QT prolongation (FDA black box)",
        tier: 1,
        aka: "Ondansetron (Zofran) · Granisetron, Palonosetron (-setron suffix)",
        tags: ["Chemotherapy-Induced Nausea", "PONV", "Gastroenteritis"],
        moa: "Selective **5-HT3 receptor antagonist** in the GI tract and CTZ (chemoreceptor trigger zone) → blocks serotonin-mediated nausea/vomiting signals from enterochromaffin cells and vagal afferents",
        use: "Chemotherapy-induced nausea and vomiting (CINV) — first-line. Post-operative nausea and vomiting (PONV). Radiation-induced nausea. Acute gastroenteritis (off-label). Hyperemesis gravidarum",
        se: "**QT prolongation** (dose-dependent — FDA warning, especially with IV doses and in cardiac patients). Headache (most common). Constipation. Serotonin syndrome (rare, only with other serotonergic drugs). Dizziness",
        ci: "Congenital long QT syndrome. Concurrent other QT-prolonging drugs (additive risk). Apomorphine (severe hypotension)",
        pk: "Well absorbed orally. Hepatic metabolism (CYP3A4, CYP2D6). Can be given IV, oral, or orally-disintegrating tablets (ODT — ideal for vomiting). Short acting — typically given before chemo and regularly for 1–3 days after",
        pearl: "**5-HT3 antagonists are NOT the same as D2 antagonists (metoclopramide, prochlorperazine)** — ondansetron causes no EPS (no D2 blockade) and no sedation. QT prolongation is the key concern. For CINV: use ondansetron + dexamethasone + NK1 antagonist (aprepitant) for highly emetogenic regimens."
      },
    ,
      {
  name: "Misoprostol & GI Mucosal Agents",
  summary: "Misoprostol (PGE1): NSAID-induced ulcer prevention + cervical ripening/medical abortion. Sucralfate: coats ulcers. Bismuth: H. pylori quadruple therapy + anti-diarrheal",
  tier: 1,
  aka: "Misoprostol (Cytotec) · Sucralfate (Carafate) · Bismuth subsalicylate (Pepto-Bismol) · Carbenoxolone",
  tags: ["PUD", "NSAID Gastroprotection", "Abortion", "Helicobacter pylori"],
  moa: "**Misoprostol:** synthetic **PGE1 analog** → activates prostaglandin receptors on gastric mucosa → ↑ mucus + HCO₃⁻ secretion, ↓ acid secretion, mucosal cytoprotection. On uterus: **cervical ripening** (softening/dilation) + **myometrial contractions**. **Sucralfate:** sulfated polysaccharide + aluminum → polymerizes in acidic environment → **adheres to ulcer base** → physical barrier against acid/pepsin/bile. **Bismuth:** antimicrobial against H. pylori + coats ulcers + bismuth sulfide → black stool",
  use: "Misoprostol: **prevention of NSAID-induced gastric ulcers** (especially with chronic NSAID use), **medical abortion** (with mifepristone, or alone), cervical ripening before procedures, postpartum hemorrhage (uterotonic). Sucralfate: PUD treatment, stress ulcer prophylaxis. Bismuth: component of H. pylori quadruple therapy (bismuth + tetracycline + metronidazole + PPI)",
  se: "Misoprostol: **diarrhea and cramping** (most common — prostaglandin GI effects), uterine hyperstimulation (obstetric use). Sucralfate: constipation (aluminum), ↓ absorption of other drugs (take 2 hrs apart from fluoroquinolones, phenytoin, digoxin). Bismuth: black stools/tongue (warn patients — not blood), **salicylate toxicity** (bismuth subsalicylate contains salicylate — avoid in children with viral illness: Reye syndrome risk)",
  ci: "**Misoprostol: PREGNANCY contraindicated** outside of abortion context (causes uterine contractions → abortion/uterine rupture). Sucralfate: renal failure (aluminum accumulation). Bismuth: children/teenagers with viral illness (Reye syndrome from salicylate component)",
  pk: "Misoprostol: oral, buccal, sublingual, vaginal routes. Short t½. Sucralfate: minimal systemic absorption (local action). Requires acid for activation — do not give with antacids/PPIs simultaneously",
  pearl: "**Misoprostol has two completely different clinical indications:** GI protection (NSAID co-prescription) and reproductive medicine (abortion, cervical ripening). Step 1 loves testing this duality. Key question: 'Why should misoprostol NOT be given to pregnant women for GI protection?' → Because its uterotonic effect can cause uterine rupture and abortion. Also note: mifepristone (anti-progestin) + misoprostol = medical abortion protocol."
},
      {
  name: "Antidiarrheals & Loperamide",
  summary: "Loperamide: peripheral opioid agonist (doesn't cross BBB) — reduces GI motility and secretions. Octreotide: somatostatin analog for VIPoma, carcinoid, variceal bleeding. Bismuth: traveler's diarrhea",
  tier: 2,
  aka: "Loperamide (Imodium) · Diphenoxylate/atropine (Lomotil) · Octreotide (Sandostatin) · Bismuth subsalicylate",
  tags: ["Diarrhea", "Carcinoid", "VIPoma", "IBD"],
  moa: "**Loperamide:** **μ-opioid receptor agonist** in enteric nervous system → ↓ GI motility (↓ peristalsis) + ↑ anal sphincter tone + ↓ intestinal secretions. **Does NOT cross BBB** (P-glycoprotein efflux + charged at physiologic pH) → no CNS/euphoric effects. **Octreotide:** **somatostatin analog** → inhibits secretion of GI hormones (VIP, glucagon, insulin, secretin, gastrin, GH) → ↓ diarrhea in secretory conditions. **Diphenoxylate:** opioid agonist (CNS-active, combined with atropine to discourage abuse)",
  use: "Loperamide: acute non-infectious diarrhea, chronic diarrhea (IBD). **Avoid in infectious/bloody diarrhea** (risk of toxic megacolon — don't slow gut when trying to expel pathogen). Octreotide: **VIPoma** (watery diarrhea), **carcinoid syndrome** (serotonin-mediated diarrhea/flushing), acute variceal bleeding (↓ portal pressure), acromegaly, dumping syndrome, insulinoma",
  se: "Loperamide: constipation, ileus, **QT prolongation** at high doses (cardiac Na⁺ channel block at supratherapeutic levels — abuse risk). **Avoid in E. coli O157:H7, C. difficile, shigella** (↑ HUS/toxic megacolon risk). Octreotide: cholelithiasis (↓ CCK → biliary stasis), hyperglycemia or hypoglycemia, bradycardia, local injection site reactions",
  ci: "Loperamide: bloody diarrhea, fever, C. difficile colitis, infectious diarrhea. Octreotide: caution in diabetes (↓ counter-regulatory hormones)",
  pk: "Loperamide: P-glycoprotein substrate — inhibitors (quinidine, verapamil) can cause CNS penetration and respiratory depression at high doses. Octreotide: SQ or IV; longer-acting depot formulation (Sandostatin LAR) monthly IM injection",
  pearl: "**Loperamide and the BBB:** Despite being an opioid, loperamide does not cause euphoria or CNS effects at therapeutic doses because it is effluxed by P-glycoprotein at the blood-brain barrier. At very high doses (abuse), P-gp is overwhelmed → euphoria/respiratory depression. This is why loperamide abuse is a growing concern. Classic Step 1 pearl: **do NOT give antidiarrheals in C. difficile or hemorrhagic E. coli** — slowing transit extends toxin contact time and ↑ risk of HUS/toxic megacolon."
}
    ]
  }
],

endo: [
{
    group: "Diabetes",
    color: "endo",
    drugs: [
      {
        name: "Insulin & Insulin Secretagogues",
        summary: "Sulfonylureas (glipizide): close β-cell K⁺ channels → ↑ insulin release. Risk hypoglycemia + weight gain. Insulin: weight gain, hypoglycemia",
        tier: 1,
        aka: "Insulin (rapid: lispro/aspart; long: glargine/detemir) · Sulfonylureas (glipizide, glyburide) · Meglitinides (repaglinide)",
        tags: ["T1DM", "T2DM", "Hyperkalemia"],
        moa: "Insulin: binds IR (tyrosine kinase) → ↑ GLUT4 translocation → ↓ blood glucose. Sulfonylureas: close K-ATP channels on β-cells → depolarize → ↑ insulin release. Meglitinides: same but shorter-acting",
        use: "Insulin: T1DM (required), T2DM failing other agents, DKA/HHS, hyperkalemia (with glucose → shifts K+ into cells). Sulfonylureas: T2DM. Meglitinides: T2DM (take with meals only)",
        se: "All → **hypoglycemia** (most dangerous). Sulfonylureas: weight gain, hypoglycemia (longest risk with glyburide). Meglitinides: less hypoglycemia (short-acting)",
        ci: "Sulfonylureas: sulfa allergy, renal failure (↑ hypoglycemia risk)",
        pk: "Glargine/detemir: peakless basal insulin. Lispro/aspart: rapid-acting (take with meals). Glyburide: avoid in elderly/renal failure (active metabolites accumulate)",
        pearl: "**Insulin for hyperkalemia:** Insulin drives K+ into cells via Na/K-ATPase activation. Always give with **dextrose** to prevent hypoglycemia. Onset 20–30 minutes, effect lasts 4–6 hours — only temporizing, doesn't remove K+ from body (need Kayexalate or dialysis for definitive treatment)."
      },
      {
        name: "Metformin",
        summary: "First-line T2DM — inhibits hepatic gluconeogenesis, no hypoglycemia, weight-neutral. CI: renal failure (lactic acidosis), hold before contrast",
        tier: 1,
        aka: "Metformin (Glucophage)",
        tags: ["T2DM", "PCOS", "First-Line"],
        moa: "Activates **AMPK** → ↓ hepatic gluconeogenesis, ↑ peripheral insulin sensitivity, ↓ intestinal glucose absorption",
        use: "T2DM (first-line), prediabetes, PCOS (off-label — improves insulin resistance, restores ovulation), weight management",
        se: "**GI upset** (most common — diarrhea, nausea; take with food). **Lactic acidosis** (rare but fatal — especially in renal failure, liver failure, CHF, severe hypoxia). Vitamin B12 deficiency (long-term)",
        ci: "eGFR <30 (hold if <45 before contrast), liver failure, CHF, excessive alcohol use, surgery, contrast administration",
        pk: "No hypoglycemia as monotherapy. Weight-neutral or slight weight loss. Renally cleared",
        pearl: "**Contrast + metformin = hold metformin.** IV contrast can transiently reduce GFR → ↑ metformin accumulation → lactic acidosis. Hold metformin 24–48 hours before and after contrast, resume once renal function confirmed stable."
      },
      {
        name: "GLP-1 Agonists & DPP-4 Inhibitors",
        summary: "GLP-1 (semaglutide): ↓ weight + CV benefit in T2DM. DPP-4 inhibitors (sitagliptin): weight-neutral. GLP-1 SE: nausea, pancreatitis",
        tier: 2,
        aka: "GLP-1: Semaglutide, Liraglutide, Exenatide (-glutide) · DPP-4: Sitagliptin, Saxagliptin (-gliptin)",
        tags: ["T2DM", "Obesity", "CV Protection"],
        moa: "GLP-1 agonists: mimic **GLP-1** → ↑ glucose-dependent insulin secretion, ↓ glucagon, slow gastric emptying, ↑ satiety. DPP-4 inhibitors: inhibit **DPP-4** → ↑ endogenous GLP-1/GIP levels",
        use: "T2DM. GLP-1 agonists: weight loss, CV risk reduction (liraglutide/semaglutide shown to ↓ MACE), NASH. Semaglutide (Ozempic/Wegovy): obesity",
        se: "GLP-1: **GI (nausea, vomiting, diarrhea)** — most common, dose-dependent. Pancreatitis (rare). Thyroid C-cell tumors (murine data). DPP-4: nasopharyngitis, pancreatitis",
        ci: "GLP-1: personal/family history of medullary thyroid carcinoma or MEN2",
        pk: "GLP-1 agonists: glucose-dependent mechanism → minimal hypoglycemia risk as monotherapy. Semaglutide: weekly injection or oral",
        pearl: "**Semaglutide cardiovascular benefit:** LEADER (liraglutide) and SUSTAIN (semaglutide) trials showed significant reduction in MACE (MI, stroke, CV death) in T2DM with established CVD — beyond just glucose lowering."
      },
      {
        name: "SGLT2 Inhibitors",
        summary: "Block renal glucose reabsorption → glucosuria. CV + renal protection (empagliflozin/dapagliflozin). SE: UTI/genital yeast, DKA, Fournier's gangrene",
        tier: 1,
        aka: "Empagliflozin, Dapagliflozin, Canagliflozin (-gliflozin)",
        tags: ["T2DM", "HF", "CKD", "CV Protection"],
        moa: "Inhibit **SGLT2 (sodium-glucose cotransporter 2)** in proximal tubule → ↓ renal glucose reabsorption → glucosuria + osmotic diuresis + natriuresis",
        use: "T2DM, HF (↓ hospitalizations regardless of EF), CKD (↓ progression), CV risk reduction",
        se: "**UTI and genital mycotic infections** (glucosuria creates sugar-rich environment). **Euglycemic DKA** (DKA with near-normal glucose — classic board trap). Volume depletion. Bone fractures, lower limb amputations (canagliflozin — FDA warning)",
        ci: "T1DM (↑ DKA risk), eGFR <30",
        pk: "Insulin-independent mechanism. Weight loss and BP reduction",
        pearl: "**SGLT2 + surgery = euglycemic DKA.** Hold SGLT2 inhibitors 3–4 days before surgery. Blood glucose can be near-normal — don't be fooled: check ketones."
      },
      {
        name: "Thiazolidinediones (TZDs)",
        summary: "Pioglitazone: PPAR-γ agonist → ↑ insulin sensitivity. SE: fluid retention, HF (CI in HF), weight gain, fractures, possible bladder cancer",
        tier: 2,
        aka: "Pioglitazone, Rosiglitazone (-glitazone)",
        tags: ["T2DM", "NASH", "Insulin Resistance"],
        moa: "Agonize **PPARγ** → ↑ adipocyte differentiation, ↑ GLUT4 expression → ↑ insulin sensitivity in adipose/muscle",
        use: "T2DM (improve insulin sensitivity). Pioglitazone: NASH (improves liver histology)",
        se: "**Fluid retention/edema** → contraindicated in HF. Weight gain. Hepatotoxicity. **Bone fractures** (↓ osteoblast activity). Bladder cancer risk (pioglitazone — prolonged use). Ovulation resumption in anovulatory women (unintended pregnancy)",
        ci: "**Heart failure (NYHA Class III/IV)** — fluid retention worsens HF. Active liver disease. Bladder cancer",
        pk: "",
        pearl: "**TZDs are contraindicated in HF** — they cause fluid retention by ↑ renal Na+ reabsorption (via PPARγ in kidney). Rosiglitazone (Avandia) was restricted due to ↑ MI risk. Pioglitazone: appears CV-neutral."
      },
    ]
  },
{
    group: "Bone & Mineral Metabolism",
    color: "endo",
    drugs: [
      {
        name: "Calcitonin",
        summary: "Salmon calcitonin: ↓ osteoclast activity → ↓ serum Ca²⁺. Used for Paget's, hypercalcemia, osteoporosis. Analgesic effect in vertebral fractures",
        tier: 2,
        aka: "Calcitonin salmon (Miacalcin, Fortical) — intranasal or SC injection",
        tags: ["Hypercalcemia", "Osteoporosis", "Paget's Disease"],
        moa: "Binds calcitonin receptors on **osteoclasts → inhibits osteoclast activity** → ↓ bone resorption → ↓ serum Ca²⁺. Also ↑ renal Ca²⁺ excretion. Analgesic mechanism unclear (possibly endorphin-mediated)",
        use: "Acute hypercalcemia (rapid-acting, used for first 24–48 hours alongside bisphosphonate). Paget's disease. Osteoporosis (intranasal — postmenopausal women who can't tolerate bisphosphonates). Analgesic for acute vertebral compression fractures",
        se: "Flushing, nausea, rhinitis (intranasal form), local injection site reactions. **Tachyphylaxis** (receptor downregulation with continued use — effectiveness wanes over time)",
        ci: "Hypocalcemia. Allergy to salmon protein",
        pk: "SC/IM or intranasal. Short duration of action (hours). Tachyphylaxis limits long-term anti-hypercalcemic use",
        pearl: "**Hypercalcemia acute management sequence:** (1) IV saline (volume repletion, ↑ Ca2+ excretion) → (2) Loop diuretics (furosemide — ↑ Ca2+ clearance) → (3) Calcitonin (fast-acting, days) → (4) Bisphosphonates (slower onset, longer duration). Calcitonin bridges the gap while bisphosphonates kick in."
      },
      {
        name: "Cinacalcet & Sevelamer",
        summary: "CKD mineral metabolism drugs — Cinacalcet: calcimimetic → ↓ PTH. Sevelamer: phosphate binder → ↓ hyperphosphatemia. Both treat CKD-mineral bone disease",
        tier: 2,
        aka: "Cinacalcet (Sensipar) · Sevelamer (Renagel, Renvela) · Calcium carbonate/acetate (other phosphate binders)",
        tags: ["CKD", "Secondary Hyperparathyroidism", "Hyperphosphatemia"],
        moa: "**Cinacalcet:** **calcimimetic** — allosterically activates calcium-sensing receptors (CaSR) on parathyroid chief cells → 'tricks' gland into sensing high Ca²⁺ → ↓ PTH secretion. **Sevelamer:** non-absorbable polymer → binds **dietary phosphate** in GI tract → ↓ phosphate absorption",
        use: "Cinacalcet: secondary hyperparathyroidism in CKD on dialysis; hypercalcemia in parathyroid carcinoma. Sevelamer: hyperphosphatemia in CKD (prevents vascular calcification and renal osteodystrophy)",
        se: "Cinacalcet: **hypocalcemia** (monitor Ca²⁺ levels), nausea, GI upset. Sevelamer: GI (constipation, nausea), may ↓ absorption of some drugs (fat-soluble vitamins, medications — take separately)",
        ci: "Cinacalcet: hypocalcemia",
        pk: "Cinacalcet: oral, hepatically metabolized (CYP3A4). Sevelamer: not absorbed — acts locally in GI tract",
        pearl: "**CKD mineral bone disease cascade:** ↓ GFR → ↓ phosphate excretion (hyperphosphatemia) → ↓ Vit D activation → ↓ Ca²⁺ absorption → ↑ PTH (secondary hyperparathyroidism) → bone resorption. Sevelamer ↓ phosphate; cinacalcet ↓ PTH; calcitriol replaces vitamin D. All three target different steps of the same cascade."
      },
    ]
  },
{
    group: "Fluid & Electrolyte Hormones",
    color: "endo",
    drugs: [
      {
        name: "ADH / Desmopressin (DDAVP) & Vaptans",
        summary: "ADH (vasopressin): V1 → vasoconstriction; V2 → water retention (aquaporin-2). DDAVP: V2-selective → diabetes insipidus. Vaptans (tolvaptan): V2 antagonist → ↑ free water excretion for SIADH",
        tier: 1,
        aka: "ADH (Vasopressin, Pitressin) · Desmopressin (DDAVP) · Tolvaptan, Conivaptan (Vaptans)",
        tags: ["Diabetes Insipidus", "SIADH", "Hemophilia A", "Bleeding"],
        moa: "**ADH/Vasopressin:** binds V1 receptors (vasoconstriction) and V2 receptors (↑ aquaporin-2 insertion in collecting duct → ↑ water reabsorption). **DDAVP:** V2-selective synthetic ADH → ↑ water reabsorption + ↑ vWF + factor VIII release (hemostatic effect). **Vaptans:** **V2 receptor antagonists** → block ADH action → ↑ free water excretion (electrolyte-sparing diuresis)",
        use: "DDAVP: central diabetes insipidus (drug of choice), nocturnal enuresis, mild hemophilia A and vWD (releases stored vWF/Factor VIII). Vasopressin: septic shock (vasopressor), variceal bleeding (splanchnic vasoconstriction). Tolvaptan: **SIADH** (hyponatremia from ↑ ADH), autosomal dominant polycystic kidney disease (ADPKD). Conivaptan: SIADH in hospital settings",
        se: "Vasopressin: hypertension, myocardial ischemia, vasoconstriction. DDAVP: hyponatremia (water retention — must restrict fluid), headache, flushing. Tolvaptan: **thirst, polyuria, hepatotoxicity** (boxed warning for ADPKD use), rapid correction of Na+ if not monitored (osmotic demyelination risk)",
        ci: "DDAVP: hyponatremia (worsens). Tolvaptan: anuria, liver failure. Rapid vaptan use without fluid monitoring → osmotic demyelination syndrome",
        pk: "DDAVP: intranasal, oral, IV. Tolvaptan: oral. Conivaptan: IV only (for in-hospital SIADH)",
        pearl: "**Central vs Nephrogenic DI:** Central DI: ↓ ADH production → DDAVP works (urine concentrates). Nephrogenic DI: kidneys don't respond to ADH → DDAVP fails. Treat nephrogenic DI with thiazide diuretics (paradoxically ↓ free water by volume depletion). Lithium → nephrogenic DI (blocks V2 receptor signaling)."
      },
    ]
  },
{
    group: "Pituitary & GI Hormone Agents",
    color: "endo",
    drugs: [
      {
        name: "Growth Hormone Axis Drugs",
        summary: "GH deficiency: somatropin (recombinant GH). GH excess (acromegaly): octreotide (SST analog → ↓ GH), pegvisomant (GH receptor antagonist), cabergoline",
        tier: 2,
        aka: "Somatropin (recombinant hGH) · Mecasermin (recombinant IGF-1) · Octreotide (somatostatin analog) · Pegvisomant (GH receptor antagonist)",
        tags: ["Acromegaly", "GH Deficiency", "Carcinoid", "VIPoma"],
        moa: "**Somatropin:** exogenous GH → binds GH receptor → ↑ IGF-1 production. **Mecasermin:** recombinant IGF-1 (for GH insensitivity/Laron syndrome). **Octreotide:** somatostatin analog → binds SSTR2/5 on somatotrophs → ↓ GH secretion; also ↓ glucagon, insulin, VIP. **Pegvisomant:** GH receptor antagonist → blocks IGF-1 generation",
        use: "Somatropin: GH deficiency (pediatric short stature, adult deficiency). Mecasermin: GH insensitivity syndrome. Octreotide: acromegaly, carcinoid tumors (↓ flushing/diarrhea), VIPoma (watery diarrhea), varices. Pegvisomant: acromegaly refractory to octreotide",
        se: "Somatropin: edema, glucose intolerance, arthralgias, ↑ cancer risk (theoretical). Octreotide: GI cramping, steatorrhea (↓ pancreatic secretion), cholelithiasis (↓ gallbladder motility), bradycardia, QT prolongation. Pegvisomant: hepatotoxicity (monitor LFTs)",
        ci: "Somatropin: active malignancy, diabetic retinopathy",
        pk: "All subcutaneous except acute octreotide (IV). Long-acting octreotide (LAR) monthly IM",
        pearl: "**Acromegaly treatment algorithm:** Surgery first (transsphenoidal resection). If GH levels remain elevated → octreotide/lanreotide. If IGF-1 still elevated despite maximal octreotide → add pegvisomant (directly blocks GH receptor regardless of GH levels). Octreotide also used for carcinoid syndrome — highest-yield application on boards."
      },
      {
        name: "Pramlintide",
        summary: "Amylin analog — slows gastric emptying, ↓ glucagon, ↑ satiety. Used as adjunct to insulin in T1DM and T2DM. Risk of severe hypoglycemia with insulin",
        tier: 2,
        aka: "Symlin",
        tags: ["T1DM", "T2DM", "Amylin Analog"],
        moa: "Synthetic analog of **amylin** (co-secreted with insulin from β-cells) → slows gastric emptying, ↓ glucagon secretion, ↑ satiety → lowers postprandial glucose",
        use: "Adjunct to insulin therapy in T1DM and insulin-requiring T2DM when postprandial glucose is inadequately controlled",
        se: "**Severe hypoglycemia** (when combined with insulin — must reduce mealtime insulin by 50% when starting). Nausea, vomiting (very common, dose-limiting). Anorexia",
        ci: "Hypoglycemia unawareness, gastroparesis (slows gastric emptying further), pediatric patients",
        pk: "SC injection at meals. Cannot be mixed with insulin in same syringe. Renally cleared",
        pearl: "**Pramlintide + insulin dose adjustment:** When adding pramlintide, always reduce mealtime insulin by 50% to prevent severe hypoglycemia — the drug's gastroparesis-like effect means glucose absorption slows, but insulin has already been injected. This is a classic drug interaction tested on boards."
      },
      {
        name: "Osmotic Laxatives",
        summary: "Lactulose: ↓ NH₃ for hepatic encephalopathy + constipation. Polyethylene glycol (PEG): bowel prep. Lactulose: acidifies colon → NH₄⁺ trapping",
        tier: 1,
        aka: "Lactulose · Polyethylene Glycol (PEG, MiraLAX) · Magnesium citrate · Sorbitol",
        tags: ["Hepatic Encephalopathy", "Constipation", "Bowel Prep"],
        moa: "**Lactulose:** non-absorbable disaccharide → metabolized by colonic bacteria to short-chain organic acids → (1) ↓ colonic pH → traps ammonia as NH₄⁺ (can't be absorbed) → ↓ serum NH₃. (2) ↑ colonic motility (osmotic + acidification). **PEG:** high-molecular-weight polymer → retains water in colon by osmosis → softens stool",
        use: "Lactulose: **hepatic encephalopathy** (first-line, target 2–3 soft bowel movements/day), constipation. PEG: constipation, bowel preparation for colonoscopy. Lactulose also reduces ammonia in renal failure patients",
        se: "Lactulose: **diarrhea, flatulence, bloating, abdominal cramping** — dose-dependent. Electrolyte disturbances with overuse. PEG: generally well-tolerated, minimal electrolyte effects",
        ci: "Lactulose: galactosemia (contains galactose). PEG bowel prep: GI obstruction, megacolon",
        pk: "Lactulose: not absorbed — acts locally. PEG: not absorbed — acts locally. All osmotic laxatives work in the colon",
        pearl: "**Lactulose for hepatic encephalopathy:** Goal is 2–3 soft stools per day. The mechanism is pH-dependent ammonia trapping — at acidic pH, NH₃ + H⁺ → NH₄⁺ (charged, not absorbed). Rifaximin is often added as adjunct (↓ ammonia-producing gut bacteria). Lactulose + rifaximin = standard regimen for prevention of recurrent HE."
      },
    ]
  },
{
    group: "Thyroid",
    color: "endo",
    drugs: [
      {
        name: "Levothyroxine (T4)",
        summary: "T4 replacement for hypothyroidism — titrate to TSH. Numerous drug interactions (antacids ↓ absorption). Toxicity = hyperthyroid symptoms",
        tier: 1,
        aka: "Synthroid, Levoxyl",
        tags: ["Hypothyroidism", "Myxedema Coma", "TSH Suppression"],
        moa: "Synthetic T4 (thyroxine) → converted peripherally to **active T3 (triiodothyronine)** via 5'-deiodinase → binds nuclear thyroid hormone receptors → ↑ metabolic rate, protein synthesis, growth",
        use: "Hypothyroidism (first-line), myxedema coma (IV), thyroid cancer (TSH suppression), after thyroid surgery/radioiodine ablation",
        se: "Symptoms of hyperthyroidism if overdosed: tachycardia, palpitations, heat intolerance, weight loss, osteoporosis (long-term), atrial fibrillation. **Subclinical hyperthyroidism in elderly → ↑ AF risk**",
        ci: "Untreated adrenal insufficiency (can precipitate adrenal crisis — cortisol corrects first before thyroid replacement). Acute MI with hyperthyroidism",
        pk: "Long t½ (~7 days). Take on empty stomach in morning (30–60 min before food). Multiple drug interactions: calcium, iron, cholestyramine, PPIs → ↓ absorption",
        pearl: "**Adrenal insufficiency + hypothyroidism:** If both present (e.g., panhypopituitarism), ALWAYS give glucocorticoids FIRST before starting levothyroxine. Thyroid hormone ↑ metabolism → ↑ cortisol clearance → can precipitate life-threatening adrenal crisis. Classic exam trap."
      },
      {
        name: "Methimazole / PTU (Antithyroid Drugs)",
        summary: "Block thyroid peroxidase → ↓ T3/T4 synthesis. PTU also blocks T4→T3 conversion — preferred in thyroid storm + 1st trimester. Agranulocytosis risk",
        tier: 1,
        aka: "Methimazole (MMI) · Propylthiouracil (PTU)",
        tags: ["Hyperthyroidism", "Graves Disease", "Thyroid Storm"],
        moa: "Both: inhibit **thyroid peroxidase** → ↓ organification of iodine → ↓ T3/T4 synthesis. PTU additionally: inhibits **peripheral conversion of T4 → T3** (deiodinase inhibition — makes it preferred in thyroid storm)",
        use: "Graves disease, hyperthyroidism (before surgery or radioiodine), thyroid storm. PTU: **first trimester of pregnancy** (MMI teratogenic → aplasia cutis, choanal atresia). MMI: all other cases of hyperthyroidism",
        se: "Both: **agranulocytosis** (rare but life-threatening — check WBC if fever/sore throat), skin rash, arthralgias, GI upset. PTU: hepatotoxicity (including acute liver failure — more than MMI). MMI: less hepatotoxicity, longer half-life",
        ci: "Agranulocytosis (prior history)",
        pk: "MMI: longer t½, once-daily dosing, preferred except in 1st trimester. PTU: shorter t½, three times daily. Both: 4–6 weeks to see full effect (existing thyroid hormone must be metabolized)",
        pearl: "**PTU in thyroid storm:** PTU is preferred over MMI because it ALSO blocks peripheral T4→T3 conversion, which is critical in thyroid storm (rapidly ↓ active T3 levels). Add propranolol (↓ sympathetic symptoms + also blocks T4→T3 conversion), steroids (↓ conversion), and iodine/ipodate. **Teratogenicity switch:** PTU in 1st trimester; switch to MMI in 2nd/3rd trimester (PTU liver failure risk)."
      },
    ]
  },
{
    group: "Corticosteroids",
    color: "endo",
    drugs: [
      {
        name: "Corticosteroids (Glucocorticoids)",
        summary: "Inhibit phospholipase A2 → ↓ all inflammatory mediators. Chronic use: Cushing's, osteoporosis, hyperglycemia, adrenal suppression — taper slowly",
        tier: 1,
        aka: "Prednisone, Prednisolone, Methylprednisolone (systemic) · Dexamethasone (high potency) · Hydrocortisone (also mineralocorticoid) · Budesonide, Fluticasone (inhaled/topical)",
        tags: ["Inflammation", "Autoimmune", "Adrenal Insufficiency", "Edema"],
        moa: "Bind **glucocorticoid receptors (GRs)** → translocate to nucleus → modulate gene transcription. Mechanism: ↓ phospholipase A2 (via lipocortin) → ↓ arachidonic acid → ↓ prostaglandins AND leukotrienes. Also ↓ COX-2, ↓ cytokines (IL-1, IL-6, TNF), ↓ T-cell activation, ↑ neutrophils (demarginate), ↓ lymphocytes/eosinophils",
        use: "Asthma/COPD exacerbations, allergic reactions/anaphylaxis adjunct, autoimmune diseases (RA, SLE, IBD, multiple sclerosis), organ transplant rejection, adrenal insufficiency (stress dosing), cerebral edema (dexamethasone), croup (nebulized/oral), PCP pneumonia (PaO2 <70), nausea (dexamethasone), meningitis (dexamethasone — ↓ neurological complications), Hodgkin lymphoma",
        se: "**Cushing's syndrome from long-term use:** HPA axis suppression (adrenal atrophy → adrenal crisis on abrupt withdrawal), **osteoporosis** (↓ osteoblast, ↑ octeoclast activity → give calcium + Vit D + bisphosphonate), hyperglycemia (↑ gluconeogenesis + insulin resistance), hypertension (mineralocorticoid activity), infections (immune suppression), peptic ulcers (↓ mucosal protection), myopathy (proximal), cataracts (posterior subcapsular), avascular necrosis (femoral head), psychiatric effects (euphoria, mania, depression), Cushingnoid features (moon face, buffalo hump, striae, central obesity), growth suppression in children, hypokalemia",
        ci: "Active systemic fungal infections (without antifungal therapy), live vaccines in immunosuppressed patients",
        pk: "Dexamethasone: NO mineralocorticoid activity (best for cerebral edema, croup, nausea). Hydrocortisone: significant mineralocorticoid activity (best for adrenal crisis). Budesonide: high local anti-inflammatory, minimal systemic absorption (hepatic first-pass). Prednisone: prodrug → prednisolone (active)",
        pearl: "**Never abruptly stop chronic corticosteroids.** Long-term use → HPA axis suppression → adrenal atrophy. Abrupt discontinuation → adrenal crisis (hypotension, fever, hyponatremia, hyperkalemia). Taper slowly. **Step 1 high-yield SEs to memorize:** Osteoporosis, Hyperglycemia, Hypertension, Cushingnoid features, Avascular necrosis, Myopathy, Cataracts (posterior subcapsular), Growth suppression (children), Peptic ulcers, Infection susceptibility."
      },
      {
        name: "Bisphosphonates & Osteoporosis Drugs",
        summary: "Alendronate: inhibit osteoclasts → ↓ fracture risk. Must take upright + full water to prevent esophagitis. Atypical femur fractures + osteonecrosis of jaw",
        tier: 2,
        aka: "Alendronate, Risedronate (oral) · Zoledronic acid (IV) · Denosumab · Teriparatide · Raloxifene",
        tags: ["Osteoporosis", "Hypercalcemia", "Paget's Disease"],
        moa: "Bisphosphonates: incorporated into bone → ingested by osteoclasts → inhibit **farnesyl pyrophosphate synthase** → ↓ osteoclast activity → ↓ bone resorption. Denosumab: anti-RANK-L antibody → ↓ osteoclast differentiation. Teriparatide: recombinant PTH → ↑ bone formation. Raloxifene: SERM → ↓ osteoclast activity",
        use: "Osteoporosis treatment/prevention, Paget's disease (bisphosphonates), hypercalcemia (IV zoledronic acid, pamidronate), malignant hypercalcemia, bone metastases",
        se: "Bisphosphonates: **esophagitis/esophageal ulcers** (take upright, full water, don't lie down 30–60 min), osteonecrosis of the jaw (ONJ), atypical femur fractures (long-term). Raloxifene: **↑ DVT/PE** risk, hot flashes. Teriparatide: contraindicated in Paget's disease and bone mets (↑ osteosarcoma risk in rats)",
        ci: "Bisphosphonates: renal failure (IV zoledronic acid), esophageal abnormalities. Teriparatide: Paget's disease, prior radiation to bone, bone metastases",
        pk: "Oral bisphosphonates: must be taken first thing in morning on empty stomach, with full glass of water, sitting upright for 30–60 minutes",
        pearl: "**Osteonecrosis of the jaw (ONJ):** occurs with prolonged bisphosphonate use (especially IV, especially in cancer patients). Triggered by dental procedures. Counsel patients to complete dental work BEFORE starting bisphosphonates."
      },
    ]
  },
  {
    group: "Reproductive Pharmacology",
    color: "endo",
    drugs: [
      {
      name: "Oral Contraceptives & Hormonal Contraception",
      summary: "Combined OCP (estrogen + progestin): inhibit LH surge → no ovulation. SERMs: tamoxifen (breast) + raloxifene (osteoporosis). Risks: DVT/PE, stroke (especially + smoking/age >35)",
      tier: 1,
      aka: "Combined OCP (ethinyl estradiol + levonorgestrel/norgestrel) · Progestin-only (mini-pill) · Levonorgestrel IUD · Emergency contraception (Plan B) · SERMs: Tamoxifen, Raloxifene, Clomiphene",
      tags: ["Contraception", "Breast Cancer", "Osteoporosis", "Endometriosis"],
      moa: "**Combined OCP:** estrogen + progestin → **negative feedback** on hypothalamus/pituitary → ↓ GnRH → ↓ FSH + ↓ LH → no LH surge → **no ovulation**. Also: progestin thickens cervical mucus (↓ sperm penetration), atrophies endometrium (↓ implantation). **SERMs:** selective estrogen receptor modulators — **tamoxifen: ER antagonist** in breast (blocks estrogen-driven growth) but **ER agonist** in bone/uterus. **Raloxifene:** ER antagonist in breast AND uterus, agonist in bone. **Clomiphene:** ER antagonist in hypothalamus → removes negative feedback → ↑ GnRH → ↑ FSH/LH → ovulation induction",
      use: "OCP: contraception, dysmenorrhea, endometriosis, PCOS, acne (reduce androgens). **Tamoxifen:** ER+ breast cancer (adjuvant therapy + prevention), gynecomastia. **Raloxifene:** osteoporosis (postmenopausal), breast cancer prevention (no uterine stimulation — safer than tamoxifen). **Clomiphene:** anovulatory infertility (PCOS)",
      se: "**OCP:** ↑ DVT/PE risk (estrogen → ↑ clotting factors — especially factor VIII, fibrinogen, ↓ protein S), ↑ stroke risk (migraine with aura contraindicated), HTN (estrogen → ↑ renin), nausea, breast tenderness, ↓ libido. **Tamoxifen:** **endometrial cancer** (uterine ER agonism), ↑ DVT/PE, hot flashes, teratogenic. **Raloxifene:** ↑ DVT, hot flashes (no endometrial cancer — uterine ER antagonism). **Clomiphene:** ovarian hyperstimulation, multiple gestation, visual changes (ER antagonism in retina)",
      ci: "OCP: **age >35 + smoker** (↑↑ stroke/MI risk), migraine with aura, history of DVT/PE/stroke, estrogen-sensitive malignancy, pregnancy, uncontrolled HTN. Tamoxifen: pregnancy (teratogenic), history of DVT",
      pk: "Progestin-only ('mini-pill'): fewer cardiovascular risks, safe in breastfeeding women. Emergency contraception (levonorgestrel/Plan B): high-dose progestin taken within 72h — primarily delays/inhibits ovulation (not abortifacient). Ella (ulipristal): progesterone receptor modulator, effective up to 5 days",
      pearl: "**Tamoxifen vs Raloxifene SERM comparison:** Both block estrogen in breast (anti-cancer). Tamoxifen STIMULATES uterus (agonist → endometrial cancer risk). Raloxifene BLOCKS uterus (antagonist → no endometrial cancer risk). Both ↑ DVT. This 3-way comparison (breast/uterus/bone) is a **classic Step 1 table question**. Raloxifene is the preferred SERM for osteoporosis prevention in women at breast cancer risk because it doesn't increase endometrial cancer risk."
    },
      {
      name: "Androgens, Anti-Androgens & 5α-Reductase Inhibitors",
      summary: "Finasteride/dutasteride: ↓ DHT for BPH/male pattern baldness. Flutamide/enzalutamide: prostate cancer. Spironolactone: anti-androgenic (PCOS, hirsutism). Anabolic steroids: suppress HPG axis",
      tier: 1,
      aka: "5α-RI: Finasteride (Proscar/Propecia), Dutasteride · Anti-androgens: Flutamide, Bicalutamide, Enzalutamide, Spironolactone · Androgens: Testosterone, Oxandrolone, DHEA",
      tags: ["BPH", "Prostate Cancer", "PCOS", "Hirsutism"],
      moa: "**Finasteride/dutasteride:** inhibit **5α-reductase** → ↓ conversion of testosterone → DHT (dihydrotestosterone, the more potent androgen) → ↓ prostatic epithelial growth + ↓ hair follicle miniaturization. Finasteride: type 2 only. Dutasteride: type 1 + type 2. **Flutamide/bicalutamide:** **competitive androgen receptor antagonists** → block testosterone/DHT signaling in prostate. **Enzalutamide:** 2nd-generation — also inhibits AR nuclear translocation. **Spironolactone:** aldosterone antagonist (primary) + **AR antagonist** (secondary) + ↓ androgen synthesis",
      use: "Finasteride: **BPH** (shrinks prostate — takes 6–12 months for full effect, compare to α-blockers for immediate relief), **androgenetic alopecia** (male pattern baldness, 1mg). Dutasteride: BPH only. Flutamide/bicalutamide: **prostate cancer** (androgen-deprivation therapy). Spironolactone: **PCOS** (hirsutism, acne), trans women (feminizing hormone therapy), hyperaldosteronism",
      se: "Finasteride: **decreased libido, erectile dysfunction, gynecomastia** (↓ DHT → relative estrogen excess). **Lowers PSA by ~50%** (must adjust PSA interpretation). Dutasteride: same + longer half-life. **Flutamide:** hepatotoxicity, gynecomastia (AR block → ↑ estrogen action). Spironolactone: hyperkalemia, gynecomastia (men), irregular periods (women). **Anabolic steroids:** suppress HPG axis → testicular atrophy + infertility, hepatotoxicity (especially 17α-alkylated oral forms), polycythemia, dyslipidemia (↓ HDL), premature epiphyseal closure (adolescents)",
      ci: "Finasteride/dutasteride: **pregnancy** (teratogenic — feminizes male fetuses; women must not handle crushed tablets). Flutamide: hepatic disease. Spironolactone: hyperkalemia, Addison's disease, concurrent ACEi/ARB (↑ K⁺)",
      pk: "Finasteride t½ ~6h (type 2 5α-RI). Dutasteride t½ ~5 weeks (type 1+2 5α-RI — longer effect). Spironolactone: active metabolites (canrenone) contribute to effect. All oral except testosterone (IM, transdermal, subdermal)",
      pearl: "**5α-reductase inhibitors and PSA:** Finasteride/dutasteride lower PSA by ~50% independent of prostate cancer status. If a man on finasteride has a PSA of 2.0, his 'true' PSA is closer to 4.0 — must double the PSA when interpreting screening results. Failure of PSA to decline on finasteride is suspicious for cancer. Also: **flutamide is used before starting GnRH agonist** in prostate cancer — without it, initial testosterone flare from GnRH agonist can worsen bone pain/spinal cord compression ('flare reaction')."
    },
      {
      name: "GnRH Agonists & Antagonists",
      summary: "Leuprolide pulsatile → stimulates HPG. Continuous/depot → desensitizes → ↓ testosterone/estrogen. Used for prostate cancer, endometriosis, precocious puberty, IVF. Cetrorelix = direct antagonist",
      tier: 1,
      aka: "GnRH Agonists: Leuprolide (Lupron), Goserelin, Nafarelin · GnRH Antagonists: Cetrorelix, Ganirelix, Degarelix · Natural: GnRH (Gonadorelin)",
      tags: ["Prostate Cancer", "Endometriosis", "Precocious Puberty", "IVF"],
      moa: "**Pulsatile GnRH agonist:** mimics natural pulsatile GnRH secretion → stimulates FSH + LH release (used for fertility induction in hypogonadotropic hypogonadism). **Continuous GnRH agonist (depot):** constant stimulation → **down-regulation/desensitization of GnRH receptors** on pituitary gonadotrophs → ↓↓ FSH + LH → ↓↓ testosterone/estrogen ('medical castration' — reversible). Initial 1–2 weeks: ↑ testosterone (flare) before desensitization. **GnRH antagonists (cetrorelix, degarelix):** directly block GnRH receptors → immediate ↓ FSH/LH/testosterone — **no initial flare**",
      use: "**Prostate cancer:** leuprolide depot (continuous) → ↓ testosterone → androgen deprivation therapy. **Endometriosis/uterine fibroids:** ↓ estrogen → shrink lesions/fibroids. **Central precocious puberty:** ↓ LH/FSH → halt premature puberty. **IVF protocols:** cetrorelix/ganirelix prevent premature LH surge before egg retrieval. Fertility induction: pulsatile leuprolide pump (rare, for hypothalamic amenorrhea)",
      se: "**Continuous agonists:** menopausal symptoms (hot flashes, vaginal dryness), osteoporosis (↓ estrogen/testosterone → ↓ bone density — limit to 6 months or add 'add-back' estrogen therapy for endometriosis), sexual dysfunction, depression. **Initial testosterone flare** (agonists) — prevent with anti-androgen (flutamide) for 2 weeks before starting in prostate cancer. GnRH antagonists: **no flare** (immediate effect), injection site reactions",
      ci: "Agonists: undiagnosed vaginal bleeding, pregnancy (teratogenic). Use with caution in osteoporosis. In prostate cancer with spinal metastases: start anti-androgen before agonist to prevent flare-related cord compression",
      pk: "Leuprolide: depot IM injection (monthly, 3-monthly, 6-monthly formulations) for sustained effect. Nafarelin: intranasal spray. Degarelix: SC injection (antagonist, no flare, faster castration)",
      pearl: "**The 'paradox of continuous GnRH agonists'** is a classic Step 1 concept: the same molecule (GnRH agonist) that stimulates gonadotropin release when given in pulses causes profound suppression when given continuously. The pituitary receptor becomes desensitized and internalized — it is overstimulated into silence. Always remember: leuprolide for prostate cancer = **continuous** (suppress testosterone). Leuprolide for infertility = **pulsatile** (stimulate FSH/LH). Opposite effects from the same drug based entirely on dosing pattern."
    },
      {
      name: "Oxytocin & Tocolytics",
      summary: "Oxytocin: labor induction + PPH; risk SIADH (ADH-like). Tocolytics to delay preterm labor: terbutaline (β2), nifedipine (CCB), indomethacin (NSAID), magnesium (1st line < 32 wk)",
      tier: 1,
      aka: "Oxytocin (Pitocin) · Tocolytics: Terbutaline (β2 agonist), Nifedipine (CCB), Indomethacin (NSAID), Magnesium sulfate, Atosiban (oxytocin receptor antagonist)",
      tags: ["Labor", "Postpartum Hemorrhage", "Preterm Labor", "Obstetrics"],
      moa: "**Oxytocin:** binds **oxytocin receptors** (Gq) on uterine myometrium → ↑ intracellular Ca²⁺ → uterine contractions. Receptors upregulate at term → sensitization. Also acts on breast (milk ejection reflex). **Tocolytics:** **Terbutaline:** β2 agonist → ↑ cAMP → ↓ uterine smooth muscle Ca²⁺ → relaxation. **Nifedipine:** L-type Ca²⁺ channel blocker → ↓ myometrial contraction. **Indomethacin:** COX inhibitor → ↓ PGE2/PGF2α (prostaglandins drive uterine contractions). **Magnesium:** Ca²⁺ antagonist + ↓ uterine excitability → tocolysis + fetal neuroprotection",
      use: "Oxytocin: **induction of labor** (cervical ripening + contractions), **postpartum hemorrhage** (PPH — uterine atony, most common cause of PPH). Tocolytics: delay preterm labor (to allow corticosteroids for fetal lung maturity): Indomethacin (most evidence < 32 wk), Nifedipine (most used), Magnesium (fetal neuroprotection < 32 wk + tocolysis)",
      se: "**Oxytocin:** **SIADH/water intoxication** (ADH-like activity → hyponatremia — use NS diluent, not D5W). Uterine hyperstimulation → fetal distress (tachy systole). Hypotension (IV bolus). **Terbutaline:** tachycardia, hyperglycemia, hypokalemia (β2 → K⁺ shift). **Indomethacin:** **premature closure of ductus arteriosus** (↓ PGE2) → use only < 32 wk gestational age to avoid this complication. **Nifedipine:** hypotension, reflex tachycardia. **Magnesium toxicity:** loss of patellar reflexes (first sign, ~5 mEq/L) → respiratory depression (~10 mEq/L) → cardiac arrest → **antidote: calcium gluconate**",
      ci: "Indomethacin tocolysis: contraindicated after **32 weeks** (ductus arteriosus closure), oligohydramnios (renal PG effects). Oxytocin: complete previa, malpresentation, prior classical C-section",
      pk: "Oxytocin: IV infusion (titrated). Short t½. **Misoprostol** (PGE1) also used for uterine atony when oxytocin fails. Methylergonovine (ergot): strong uterotonic for PPH but contraindicated in hypertension",
      pearl: "**Magnesium toxicity progression and antidote:** 4 mEq/L: therapeutic. 5 mEq/L: loss of deep tendon reflexes (DTRs — first clinical sign). 7–10: respiratory depression. >10–15: cardiac arrest. **Antidote = calcium gluconate IV** (antagonizes Mg²⁺ at calcium channels). Always monitor DTRs and urine output (Mg is renally cleared — hold if UO < 30 mL/hr or absent DTRs). This progression is extremely high-yield for Step 1."
    },
      {
      name: "Fludrocortisone & Mineralocorticoid Axis",
      summary: "Fludrocortisone: synthetic mineralocorticoid for Addison's disease and CAH. Dexamethasone suppression test: screens for Cushing's. Cortisol vs aldosterone selectivity: CBG binding explains",
      tier: 1,
      aka: "Fludrocortisone (Florinef) · Dexamethasone (high/low-dose suppression test) · Cortisol · ACTH (cosyntropin stimulation test)",
      tags: ["Addison's Disease", "CAH", "Cushing's Syndrome", "Adrenal"],
      moa: "**Fludrocortisone:** potent **mineralocorticoid** (with some glucocorticoid activity) → binds mineralocorticoid receptors in distal tubule/collecting duct → ↑ ENaC expression → ↑ Na⁺ reabsorption + ↑ K⁺/H⁺ excretion. **Dexamethasone:** potent synthetic glucocorticoid that suppresses ACTH (negative feedback) → ↓ cortisol. **Dexamethasone DOES NOT cross-react** with cortisol assays → can give dexamethasone and still measure serum cortisol accurately. **Cosyntropin (synthetic ACTH):** stimulation test for adrenal insufficiency — failure to ↑ cortisol → primary adrenal insufficiency",
      use: "Fludrocortisone: **primary adrenal insufficiency (Addison's disease)** — replaces aldosterone. **Congenital adrenal hyperplasia (CAH) with salt-wasting** — 21-hydroxylase deficiency. Orthostatic hypotension. **Dexamethasone suppression test:** low-dose (1 mg overnight): screens for Cushing's (normal: cortisol suppresses to <1.8 µg/dL; Cushing's: fails to suppress). High-dose: distinguishes pituitary (suppresses) vs ectopic/adrenal (doesn't suppress) Cushing's",
      se: "Fludrocortisone: hypokalemia, hypertension, edema (Na⁺ retention), metabolic alkalosis. Excessive glucocorticoids (Cushing's): central obesity, buffalo hump, purple striae, hyperglycemia, osteoporosis, immune suppression, HTN, hypokalemia. HPA suppression with chronic glucocorticoid use → adrenal atrophy → must taper slowly to avoid Addisonian crisis",
      ci: "Fludrocortisone: hypertension (caution), hypernatremia, heart failure (Na⁺ retention worsens fluid overload)",
      pk: "Fludrocortisone: 10x more potent than aldosterone at mineralocorticoid receptor. Hydrocortisone (cortisol): has both glucocorticoid AND mineralocorticoid activity — used for both replacement in Addison's. Dexamethasone: minimal mineralocorticoid activity, maximal glucocorticoid/anti-inflammatory potency",
      pearl: "**The dexamethasone suppression test works because dexamethasone is not measured in cortisol assays.** Give dexamethasone → it suppresses ACTH (negative feedback) → ↓ cortisol in normal people. In Cushing's: ACTH/cortisol still secreted autonomously. High-dose test: pituitary tumors still respond to very high dexamethasone (relative autonomy); ectopic ACTH sources (lung, carcinoid) and adrenal tumors do not. This 2-step logic (low-dose screen → high-dose distinguish) is a very common Step 1 question framework."
    }
    ]
  }
],

pulm: [
{
    group: "Allergy & Pulmonary",
    color: "pulm",
    drugs: [
      {
        name: "SABAs & LABAs",
        summary: "Albuterol (SABA): rescue inhaler, β2 → bronchodilation, also used for hyperkalemia. LABAs (salmeterol): maintenance only, never as monotherapy in asthma",
        tier: 1,
        aka: "SABAs (Short-Acting): Albuterol, Levalbuterol · LABAs (Long-Acting): Salmeterol, Formoterol",
        tags: ["Asthma", "COPD", "Bronchospasm"],
        moa: "**β2-adrenergic agonists** → activate Gs → ↑ cAMP → PKA activation → bronchial smooth muscle relaxation. Also ↑ mucociliary clearance, ↑ mast cell stabilization",
        use: "Albuterol: acute bronchospasm rescue (Step 1 inhaler). Salmeterol/formoterol: add-on to ICS for Step 3+ asthma and COPD maintenance. LABAs also for exercise-induced bronchospasm prophylaxis",
        se: "Tachycardia, tremor, **hypokalemia** (β2 → Na/K-ATPase → K+ into cells). LABAs: **↑ asthma-related deaths if used as monotherapy without ICS** (FDA black box warning). Worsening control with overuse of SABAs (indicates poorly controlled asthma)",
        ci: "LABAs: NEVER as monotherapy in asthma (always with ICS). High-dose albuterol in CAD (tachycardia ↑ O2 demand)",
        pk: "Albuterol onset: 5 min, duration: 4–6 hrs. Salmeterol: 12-hr duration — NOT for acute rescue (slow onset). Formoterol: faster onset than salmeterol, also can be used as rescue in some regimens",
        pearl: "**LABAs black box:** Salmeterol (SMART trial) → ↑ asthma deaths when used without ICS. Must always be co-prescribed with ICS (or use combination inhaler: fluticasone/salmeterol = Advair). Never prescribe LABA as single agent in asthma."
      },
      {
        name: "Inhaled Corticosteroids (ICS)",
        summary: "Fluticasone/budesonide: controller therapy for persistent asthma — ↓ inflammation, ↓ exacerbations. SE: oral candidiasis (rinse mouth after use)",
        tier: 1,
        aka: "Fluticasone (Flovent), Budesonide (Pulmicort), Beclomethasone, Mometasone",
        tags: ["Asthma", "COPD Exacerbation", "Maintenance"],
        moa: "Bind **glucocorticoid receptors** → translocate to nucleus → ↓ pro-inflammatory gene expression → ↓ cytokines (IL-4, IL-5, IL-13), ↓ eosinophil recruitment, ↓ mucus production, ↓ airway hyperresponsiveness",
        use: "Step 2+ asthma maintenance (controller therapy). COPD with frequent exacerbations (add to LABA). NOT for acute bronchospasm",
        se: "**Oral candidiasis** (thrush — always tell patient to rinse mouth after use). Dysphonia (hoarseness). Minimal systemic effects vs. oral steroids (extensive first-pass). HPA suppression only at very high doses",
        ci: "Active oral/esophageal candidiasis. Avoid in acute status asthmaticus (not acute treatment)",
        pk: "Rinse mouth → prevents oropharyngeal deposition → ↓ candida. Budesonide: safest in pregnancy (FDA category B). Extensive first-pass hepatic metabolism → minimal systemic absorption",
        pearl: "**ICS is the most important controller medication in asthma.** It reduces inflammation, exacerbations, and asthma-related deaths. Step 1 pearl: patient asks if they should stop ICS when feeling well → NO, ICS prevents exacerbations and must be used daily."
      },
      {
        name: "Leukotriene Antagonists (LTRAs)",
        summary: "Montelukast: blocks LTD4 receptor — mild persistent asthma + allergic rhinitis. Good for aspirin-exacerbated asthma and exercise-induced",
        tier: 2,
        aka: "Montelukast (Singulair), Zafirlukast",
        tags: ["Asthma", "Allergic Rhinitis", "Aspirin-Exacerbated"],
        moa: "Block **cysteinyl leukotriene receptor (CysLT1)** → ↓ leukotriene-mediated bronchoconstriction, inflammation, mucus secretion, and eosinophil recruitment",
        use: "Step 2–3 asthma alternative/add-on. Aspirin-exacerbated respiratory disease (Samter's triad — best LTRA indication). Allergic rhinitis. Exercise-induced bronchoconstriction",
        se: "**Neuropsychiatric effects** (nightmares, depression, suicidal ideation — FDA black box warning, 2020). GI upset (mild). Generally well tolerated",
        ci: "Depression/suicidal history (use caution). No absolute contraindications, but FDA warns of neuropsychiatric risks",
        pk: "Once-daily oral. Not effective for acute bronchospasm. Takes days to weeks for full effect. Also blocks nasal symptoms (useful for combined asthma + allergic rhinitis)",
        pearl: "**Samter's Triad = Aspirin-exacerbated respiratory disease:** Asthma + nasal polyps + NSAID/aspirin sensitivity. Mechanism: COX inhibition → shunts arachidonic acid to 5-lipoxygenase → ↑↑ leukotrienes → bronchoconstriction. Montelukast is specifically indicated — blocks the leukotriene receptor that's being overactivated."
      },
      {
        name: "Omalizumab & Biologic Asthma Therapies",
        summary: "Omalizumab: anti-IgE monoclonal antibody — severe allergic asthma uncontrolled on ICS/LABA. Dupilumab: anti-IL-4/IL-13 for eosinophilic asthma",
        tier: 3,
        aka: "Omalizumab (anti-IgE) · Mepolizumab, Benralizumab (anti-IL-5) · Dupilumab (anti-IL-4/IL-13)",
        tags: ["Severe Asthma", "Biologics", "Eosinophilic Asthma"],
        moa: "Omalizumab: binds **free IgE** → ↓ IgE available to bind mast cell FcεRI → ↓ allergic cascade. Anti-IL-5 (mepolizumab/benralizumab): ↓ eosinophil survival and recruitment. Dupilumab: blocks IL-4Rα → ↓ IL-4 + IL-13 signaling",
        use: "Moderate-severe allergic asthma not controlled on high-dose ICS + LABA (Step 5+). Omalizumab: for IgE-mediated (allergic) asthma + elevated serum IgE. Anti-IL-5: eosinophilic asthma. Dupilumab: eosinophilic or oral steroid-dependent asthma + atopic dermatitis",
        se: "Injection site reactions. Omalizumab: rare anaphylaxis (must monitor 30 min post-injection). Anti-IL-5: upper respiratory infections. Dupilumab: conjunctivitis (common)",
        ci: "Omalizumab: total serum IgE must be in range. Not for acute attacks",
        pk: "All: subcutaneous injections every 2–4 weeks. Expensive — require prior authorization. Omalizumab: dose based on weight + baseline IgE levels",
        pearl: "**Omalizumab works specifically for allergic (IgE-mediated) asthma** — must have elevated total IgE and sensitivity to perennial allergens. If patient's asthma is eosinophilic rather than allergic, use anti-IL-5 biologics (mepolizumab). Biologic asthma therapy is Step 5 and reserved for refractory disease."
      },
      {
        name: "Cromolyn Sodium",
        summary: "Mast cell stabilizer — prophylaxis only, must be used BEFORE allergen/exercise exposure. Not for acute attacks. Safest asthma drug",
        tier: 3,
        aka: "Intal (inhaled), Nasalcrom (nasal)",
        tags: ["Asthma Prophylaxis", "Allergic Rhinitis", "Exercise-Induced"],
        moa: "Stabilizes **mast cell membranes** → inhibits degranulation → ↓ histamine, ↓ leukotrienes, ↓ prostaglandins. Exact mechanism unclear — may block Cl- channels. Does NOT bronchodilate",
        use: "Prophylaxis of asthma (must be used before allergen/exercise exposure — NOT for acute attacks). Allergic rhinitis (nasal spray). Exercise-induced bronchospasm prevention. Pediatric use (very safe profile)",
        se: "Minimal — throat irritation, cough. Very safe profile (no systemic absorption). Taste disturbance",
        ci: "Acute bronchospasm (no bronchodilator activity). Must be started days before anticipated exposure",
        pk: "Must be used 15–20 minutes before exercise or allergen exposure. No systemic absorption. Multiple daily dosing required. Largely replaced by ICS in clinical practice",
        pearl: "**Cromolyn = prophylaxis only, NOT treatment.** Classic board distinction: give cromolyn before allergen exposure to prevent the reaction, not after the reaction starts. Also: it is one of the safest drugs in asthma — no systemic effects, can be used in pregnancy and children."
      },
      {
        name: "Antihistamines",
        summary: "H1 blockers: 1st gen (diphenhydramine) crosses BBB → sedation + anticholinergic. 2nd gen (loratadine): non-sedating. Diphenhydramine reverses acute EPS",
        tier: 1,
        aka: "1st gen H1: Diphenhydramine, Chlorpheniramine, Promethazine · 2nd gen H1: Cetirizine, Loratadine, Fexofenadine · H2: Famotidine, Cimetidine",
        tags: ["Allergic Rhinitis", "Urticaria", "Motion Sickness"],
        moa: "H1 blockers: block **H1 histamine receptors** → ↓ vasodilation, ↓ bronchoconstriction, ↓ vascular permeability. 1st gen also block muscarinic, α1, and 5-HT receptors",
        use: "1st gen: allergic reactions, anaphylaxis adjunct, motion sickness, insomnia. 2nd gen: allergic rhinitis (preferred — less sedating). Promethazine: antiemesis. Diphenhydramine: Parkinson symptoms, EPS, anaphylaxis (adjunct to epi)",
        se: "1st gen: **sedation, anticholinergic effects** (dry mouth, urinary retention, constipation), cognitive impairment, QT prolongation. 2nd gen: minimal sedation (don't cross BBB)",
        ci: "1st gen: elderly (Beers Criteria — cognitive decline, falls), narrow-angle glaucoma, BPH",
        pk: "2nd gen advantage: **non-sedating** because they don't cross BBB.",
        pearl: "**1st gen vs 2nd gen antihistamines:** 1st gen crosses BBB → sedation, useful at night. 2nd gen (cetirizine, loratadine, fexofenadine) — use for daytime allergies. Key fact: diphenhydramine is also used for **acute EPS/drug-induced dystonia** (IV) because of its anticholinergic effect."
      },
    ]
  },
{
    group: "Vasoactive",
    color: "pulm",
    drugs: [
      {
        name: "Nitrates",
        summary: "Donate NO → venodilation → ↓ preload. CI: PDE5 inhibitors (fatal hypotension) + RV infarction. Tolerance requires nitrate-free interval daily",
        tier: 1,
        aka: "Nitroglycerin (sublingual, IV, patch) · Isosorbide dinitrate/mononitrate",
        tags: ["Angina", "ACS", "Hypertensive Emergency"],
        moa: "Donate **nitric oxide (NO)** → activates guanylate cyclase → ↑ cGMP → smooth muscle relaxation → vasodilation (predominantly venous > arterial) → ↓ preload (↓ O2 demand)",
        use: "Acute angina (sublingual NTG — fastest onset), ACS, chronic angina prevention (patches, long-acting), hypertensive emergency (IV NTG), acute decompensated HF (↓ preload), esophageal spasm",
        se: "**Headache** (most common — meningeal vasodilation), **hypotension**, reflex tachycardia, flushing. **Tolerance** with continuous exposure — requires nitrate-free interval (8 hrs/day). Methemoglobinemia (high dose)",
        ci: "**PDE5 inhibitors (sildenafil, tadalafil)** — severe, potentially fatal hypotension (both ↑ cGMP → synergistic vasodilation). Right ventricular infarction (↓ preload is deadly — RV needs filling pressure)",
        pk: "Sublingual: onset 1–2 min, duration 30 min. IV: titratable. Patch: 12–14 hrs on, then off to prevent tolerance",
        pearl: "**Nitrate tolerance:** The mechanism is depletion of sulfhydryl groups needed for NO generation. Monday disease: industrial workers exposed to nitrates all week → vasodilation tolerance. Weekend off → sulfhydryl groups replenish. Monday back to work → reflex vasoconstriction on withdrawal → angina/MI."
      },
      {
        name: "Prostaglandins, Prostacyclin, Bosentan & PDE5 Inhibitors",
        summary: "PAH drug classes: PGI2 analogs (prostacyclins) → vasodilation + ↓ platelet aggregation; endothelin antagonists (bosentan) → block ET-1 vasoconstriction; PDE5 inhibitors (sildenafil) → ↑ cGMP → pulmonary vasodilation. Also: PGE1/PGE2 for ductus arteriosus, ulcers, and labor induction",
        tier: 2,
        aka: "Prostacyclins: Epoprostenol (IV), Iloprost (inhaled), Treprostinil · Endothelin antagonist: Bosentan, Ambrisentan · PDE5 inhibitors: Sildenafil (Viagra/Revatio), Tadalafil (Cialis/Adcirca) · PGE1: Alprostadil, Misoprostol · PGE2: Dinoprostone",
        tags: ["Pulmonary HTN", "PAH", "Erectile Dysfunction", "Prostaglandins"],
        moa: "**Prostacyclins (PGI2 analogs):** Bind IP receptors → ↑ cAMP → pulmonary smooth muscle relaxation + inhibit platelet aggregation. **Bosentan:** Competitive antagonist of endothelin-1 (ET-1) receptors → blocks ET-1–mediated vasoconstriction and smooth muscle proliferation. **PDE5 inhibitors:** Inhibit PDE5 → prevent cGMP breakdown → ↑ cGMP → smooth muscle relaxation → pulmonary and penile vasodilation. **PGE1 (alprostadil/misoprostol):** Vasodilation, maintain ductus arteriosus, ↓ gastric acid. **PGE2 (dinoprostone):** Cervical ripening and uterine contraction",
        use: "**PDE5 inhibitors:** PAH, erectile dysfunction. **Prostacyclins:** PAH (epoprostenol IV most potent). **Bosentan:** PAH. **Alprostadil (PGE1):** Keep ductus arteriosus open in cyanotic CHD, erectile dysfunction. **Misoprostol:** NSAID-induced ulcer prevention, cervical ripening, postpartum hemorrhage. **Dinoprostone (PGE2):** Labor induction, cervical ripening",
        se: "**PDE5 inhibitors:** Hypotension (especially with nitrates — DANGEROUS), flushing, headache, visual disturbances (sildenafil — transient blue-tinge). **Bosentan:** **Hepatotoxicity** (monitor LFTs), teratogenic (contraception mandatory), anemia. **Prostacyclins:** Flushing, jaw pain, diarrhea, hypotension. **Misoprostol:** Diarrhea, uterine cramping (avoid in pregnancy except for intended induction)",
        ci: "**PDE5 inhibitors + nitrates = ABSOLUTE CI** (synergistic cGMP ↑ → severe/fatal hypotension). Bosentan: pregnancy (teratogen), severe hepatic impairment. Misoprostol: unintended pregnancy. Alprostadil: respiratory distress syndrome",
        pk: "Sildenafil: CYP3A4 substrate. Bosentan: CYP3A4/2C9 inducer — reduces OCP levels (add barrier method). Epoprostenol: t½ ~6 min — requires continuous IV infusion; abrupt discontinuation causes rebound PAH crisis",
        pearl: "**PAH three-pathway approach:** (1) NO pathway → PDE5 inhibitors ↑ cGMP; (2) Prostacyclin pathway → epoprostenol ↑ cAMP; (3) Endothelin pathway → bosentan blocks ET-1. The classic kill question: **sildenafil + nitrates = fatal hypotension** (both ↑ cGMP). Also: alprostadil keeps the ductus arteriosus open in cyanotic neonates — life-saving bridge to surgery."
      },
    ]
  },
{
    group: "Triptans & Migraine",
    color: "pulm",
    drugs: [
      {
        name: "Sumatriptan (Triptans)",
        summary: "5-HT1B/1D agonists → cranial vasoconstriction + ↓ CGRP — acute migraine. CI: CAD/stroke (vasoconstrictors, NOT dilators)",
        tier: 1,
        aka: "Sumatriptan · Rizatriptan, Zolmitriptan, Eletriptan (-triptan suffix)",
        tags: ["Migraine", "Cluster Headache", "Acute Treatment"],
        moa: "Selective **5-HT1B/1D receptor agonists** → (1) vasoconstriction of cranial blood vessels — ↓ meningeal vasodilation. (2) Inhibit release of CGRP and substance P from trigeminal nerve terminals → ↓ neurogenic inflammation. (3) Presynaptic inhibition of pain transmission",
        use: "Acute migraine (first-line for moderate-severe). Cluster headache (subcutaneous sumatriptan only). NOT for migraine prevention (no prophylactic role). Most effective when taken at headache onset",
        se: "**Coronary vasospasm/chest tightness** (serious — 5-HT1B on coronary arteries). Paresthesias, flushing, dizziness, neck tightness, triptan sensations (pressure/tightening in chest/throat — usually benign but must exclude cardiac). Serotonin syndrome if combined with MAOIs",
        ci: "**CAD, uncontrolled hypertension, history of stroke/TIA, Prinzmetal angina**, hemiplegic or basilar migraine, pregnancy (relative), within 24 hours of ergotamine use, concurrent MAOIs (serotonin syndrome)",
        pk: "Sumatriptan: subcutaneous (fastest — 10 min onset), intranasal, or oral. Most triptans: 2-hour time to peak effect. Avoid within 24 hours of ergotamines (additive vasospasm)",
        pearl: "**Triptan MOA pearl:** They are NOT vasodilators — they are vasoCONSTRICTORS of cerebral vessels. This is why they're contraindicated in CAD/stroke. Serotonin syndrome risk: triptans + MAOIs or linezolid. Don't confuse with ergotamines — both constrict cranial vessels but different receptor mechanisms."
      },
    ]
  }
],

onco: [
{
    group: "Antimetabolites & Cell Cycle Drugs",
    color: "onco",
    drugs: [
      {
        name: "Antimetabolites",
        summary: "MTX: DHFR inhibitor (rescue with leucovorin). 5-FU: inhibits thymidylate synthase. 6-MP: activated by HGPRT, inactivated by xanthine oxidase — toxic with allopurinol",
        tier: 1,
        aka: "Methotrexate, 5-Fluorouracil (5-FU), 6-Mercaptopurine (6-MP), Cytarabine",
        tags: ["Leukemia", "Solid Tumors", "Immunosuppression"],
        moa: "Methotrexate: inhibits **dihydrofolate reductase (DHFR)** → ↓ THF → ↓ thymidine/purines → ↓ DNA synthesis. 5-FU: inhibits **thymidylate synthase**. 6-MP: inhibits purine synthesis. All: S-phase specific",
        use: "MTX: ALL, osteosarcoma, choriocarcinoma, RA, psoriasis, ectopic pregnancy. 5-FU: colorectal, breast, head/neck cancers. 6-MP: ALL, IBD maintenance",
        se: "MTX: **myelosuppression, mucositis**, hepatotoxicity (cirrhosis with long-term use), pulmonary fibrosis, **teratogenic**. Rescue: **leucovorin (folinic acid)** — bypasses DHFR block. 5-FU: myelosuppression, mucositis, **hand-foot syndrome**",
        ci: "MTX: pregnancy, renal failure, pleural effusion/ascites (MTX accumulates in 'third spaces')",
        pk: "MTX: renally cleared — renal failure → toxicity. Leucovorin given 24 hours after high-dose MTX",
        pearl: "**MTX rescue with leucovorin:** High-dose MTX → give leucovorin 24 hours later. Leucovorin (5-formyl-THF) doesn't need DHFR → bypasses the block in normal cells. Classic board Q: What reverses MTX toxicity? → **Leucovorin** (NOT folic acid)."
      },
      {
        name: "Cytarabine, Cladribine & Gemcitabine",
        summary: "Pyrimidine analogs that inhibit DNA synthesis — Cytarabine: AML. Cladribine: hairy cell leukemia/MS. Gemcitabine: pancreatic/NSCLC. All cause myelosuppression; cytarabine causes cerebellar toxicity at high doses",
        tier: 2,
        aka: "Cytarabine (Ara-C, cytosine arabinoside) · Cladribine (2-CDA) · Gemcitabine (Gemzar)",
        tags: ["AML", "Hairy Cell Leukemia", "Pancreatic Cancer", "Antimetabolite"],
        moa: "**Cytarabine:** analog of deoxycytidine → inhibits **DNA polymerase** after phosphorylation → chain termination; S-phase specific. **Cladribine:** chlorinated purine analog → incorporates into DNA + inhibits DNA repair → especially toxic to lymphocytes/monocytes. **Gemcitabine:** difluoro-deoxycytidine analog → inhibits ribonucleotide reductase + DNA polymerase → S-phase arrest",
        use: "Cytarabine: AML (cornerstone of induction chemotherapy — 'Ara-C backbone'), ALL. Cladribine: hairy cell leukemia (often single course curative), CLL, MS (Mavenclad). Gemcitabine: pancreatic cancer (first-line), NSCLC, bladder cancer, breast cancer",
        se: "Cytarabine: myelosuppression, GI toxicity, **cerebellar toxicity at high doses** (ataxia, nystagmus, dysarthria — irreversible if not caught). Cladribine: profound myelosuppression, immunosuppression (opportunistic infections), fever. Gemcitabine: myelosuppression, pulmonary toxicity, HUS (rare), peripheral edema",
        ci: "Cytarabine: CNS toxicity at high doses — monitor cerebellar function",
        pk: "Cytarabine: CNS penetration (used for CNS leukemia). Cladribine: oral (Mavenclad) or IV. Gemcitabine: IV only",
        pearl: "**Cytarabine (Ara-C) cerebellar toxicity at high doses:** High-dose cytarabine (HD Ara-C) is used for AML consolidation. Before each dose, perform a neurological exam focused on cerebellar function (finger-to-nose, heel-to-shin, gait). Cerebellar signs → hold drug immediately. This distinguishes it from other antimetabolites."
      },
      {
        name: "Hydroxyurea",
        summary: "Inhibits ribonucleotide reductase → ↓ deoxyribonucleotide synthesis. Sickle cell disease: ↑ HbF. Also CML/polycythemia vera. SE: myelosuppression, macrocytosis",
        tier: 1,
        aka: "Hydroxyurea (Hydrea, Droxia)",
        tags: ["Sickle Cell Disease", "CML", "HbF Inducer", "Polycythemia Vera"],
        moa: "Inhibits **ribonucleotide reductase** → ↓ deoxyribonucleotide synthesis → ↓ DNA synthesis (S-phase specific). In sickle cell: mechanism of ↑ HbF production involves ↑ γ-globin gene expression (mechanism not fully understood — may involve demethylation)",
        use: "**Sickle cell disease:** ↑ HbF → dilutes HbS → ↓ sickling episodes, ↓ hospitalizations, ↓ ACS, possibly ↑ survival. CML (before TKIs available — now second-line). Polycythemia vera and essential thrombocythemia. Head/neck cancer (radiosensitizer)",
        se: "**Myelosuppression** (dose-limiting), **macrocytosis** (large RBCs — from impaired DNA synthesis; doesn't indicate B12/folate deficiency — just the drug's effect), leg ulcers, nail hyperpigmentation, teratogenic. GI upset",
        ci: "Pregnancy (teratogenic), severe myelosuppression",
        pk: "Oral, renally cleared. Monitor CBC every 2–4 weeks when initiating. HbF ↑ seen within 1–3 months",
        pearl: "**Hydroxyurea in sickle cell:** By ↑ HbF, sickling is reduced (HbF doesn't participate in the HbS polymer). HbF acts as a diluent. Key distinction: macrocytosis on hydroxyurea does NOT mean B12/folate deficiency — it's a direct drug effect on DNA synthesis. Don't reflexively check B12 or give folate supplements."
      },
      {
        name: "Alkylating Agents",
        summary: "Cyclophosphamide/ifosfamide: cross-link DNA, hemorrhagic cystitis prevented by mesna (bladder protection). Busulfan: pulmonary fibrosis. Nitrosoureas: cross BBB for CNS tumors",
        tier: 1,
        aka: "Cyclophosphamide, Ifosfamide · Cisplatin, Carboplatin · Busulfan, Chlorambucil · Nitrosoureas: Carmustine (BCNU), Lomustine (CCNU)",
        tags: ["Lymphoma", "Solid Tumors", "Transplant Conditioning", "Brain Tumor"],
        moa: "Cross-link **DNA strands** → prevent DNA replication. Cisplatin: forms intra-strand adducts. Cyclophosphamide: prodrug activated by CYP. **Nitrosoureas:** highly lipophilic alkylating agents that **cross the blood-brain barrier**; also inhibit DNA repair enzymes",
        use: "Cyclophosphamide: NHL, breast, ovarian, SLE, Wegener's. Cisplatin: testicular, lung, bladder, ovarian, head/neck. Busulfan: CML, bone marrow transplant conditioning. Chlorambucil: CLL. **Nitrosoureas (carmustine/lomustine): brain tumors** (glioblastoma, gliomas — specifically chosen for CNS penetration). Carmustine also used for CNS lymphoma, myeloma",
        se: "**Cyclophosphamide:** hemorrhagic cystitis (acrolein metabolite — prevent with **mesna** + hydration), SIADH, myelosuppression, gonadal toxicity, transitional cell carcinoma. **Cisplatin:** nephrotoxicity (hydrate!), ototoxicity, peripheral neuropathy, severe emesis. **Busulfan:** pulmonary fibrosis, hyperpigmentation. **Nitrosoureas:** delayed myelosuppression (nadir 4–6 weeks — later than other chemo agents), pulmonary fibrosis, nausea",
        ci: "",
        pk: "Cisplatin: nephrotoxic — always hydrate aggressively with NS. Cyclophosphamide: activated in liver. Nitrosoureas: highly lipophilic → readily cross BBB (designed feature)",
        pearl: "**Cyclophosphamide toxicity prevention:** MESNA (2-mercaptoethane sulfonate) binds acrolein in urine → prevents hemorrhagic cystitis. Ifosfamide: similar mechanism, higher risk of encephalopathy and hemorrhagic cystitis — always give mesna. **Nitrosoureas for brain tumors** — almost uniquely they can treat CNS malignancies due to BBB penetration. Carmustine wafers (Gliadel) can be implanted directly into the tumor cavity."
      },
      {
        name: "Microtubule-Targeting Agents",
        summary: "Vincristine (vinca): inhibits polymerization → peripheral neuropathy. Paclitaxel (taxane): stabilizes microtubules → neuropathy + neutropenia",
        tier: 1,
        aka: "Vincristine, Vinblastine (Vinca alkaloids) · Paclitaxel, Docetaxel (Taxanes)",
        tags: ["Leukemia", "Lymphoma", "Solid Tumors"],
        moa: "Vinca alkaloids: bind β-tubulin → **inhibit polymerization** → prevent mitotic spindle formation. Taxanes: bind tubulin → **inhibit depolymerization** → freeze spindle → mitotic arrest. Both: M-phase specific",
        use: "Vincristine: ALL, NHL, Hodgkin's, Wilms' tumor. Vinblastine: Hodgkin's, testicular, Kaposi's. Paclitaxel: breast, ovarian, lung, Kaposi's",
        se: "**Vincristine: peripheral neuropathy** (hallmark — paresthesias, areflexia, footdrop) + SIADH, minimal myelosuppression. **Vinblastine: myelosuppression** (hallmark) + peripheral neuropathy. Taxanes: peripheral neuropathy, myelosuppression, hypersensitivity reactions",
        ci: "",
        pk: "",
        pearl: "**Vincristine vs Vinblastine:** Vincristine = neuropathy (no myelosuppression). Vinblastine = bone marrow suppression (blast = bone marrow). Classic Step 1: 'Which vinca alkaloid does NOT cause myelosuppression?' → vincristine."
      },
      {
        name: "Topoisomerase Inhibitors",
        summary: "Etoposide (topo II): testicular/SCLC, secondary AML risk. Irinotecan (topo I): colorectal cancer, early diarrhea (atropine) + late diarrhea (loperamide)",
        tier: 1,
        aka: "Topo II: Etoposide · Topo I: Irinotecan, Topotecan",
        tags: ["Leukemia", "Lymphoma", "Solid Tumors"],
        moa: "Etoposide: inhibits **topoisomerase II** → stabilizes DNA-topo II cleavage complex → prevents DNA relegation → double-strand breaks. Irinotecan/Topotecan: inhibit **topoisomerase I** → prevent DNA re-ligation after single-strand nicking → replication fork collision → DNA breaks. Both: S/G2-phase activity",
        use: "Etoposide: testicular cancer (BEP regimen), lung (SCLC), lymphomas, leukemia conditioning. Irinotecan: colorectal cancer (FOLFIRI regimen), lung (SCLC). Topotecan: ovarian cancer (second-line), SCLC",
        se: "Etoposide: **myelosuppression**, alopecia, hypotension with rapid infusion, **secondary AML** (t(11q23) translocation — topo II damage → treatment-related leukemia). Irinotecan: **diarrhea** (early: cholinergic — treat with atropine; late: secretory — treat with loperamide), myelosuppression, nausea",
        ci: "Irinotecan: UGT1A1*28 polymorphism (Gilbert's-like — ↓ glucuronidation of active metabolite SN-38 → ↑↑ toxicity — dose-reduce)",
        pk: "Etoposide: oral or IV (oral bioavailability ~50%). Irinotecan: prodrug → active SN-38 by carboxylesterase. UGT1A1 testing increasingly recommended before irinotecan",
        pearl: "**Etoposide → secondary AML:** Topo II inhibitors cause characteristic t(11q23) MLL gene rearrangements → treatment-related AML (t-AML), typically 2–3 years after treatment. Presents as AML with monocytic features. This is a classic secondary malignancy question on boards — distinguish from alkylating agent-related AML (which takes 5–7 years)."
      },
      {
        name: "Anthracyclines",
        summary: "Doxorubicin: breast/lymphoma/sarcoma — dose-dependent dilated cardiomyopathy (irreversible). Prevent with dexrazoxane. Red/orange urine (not blood)",
        tier: 1,
        aka: "Doxorubicin (Adriamycin) · Daunorubicin · Epirubicin · Idarubicin",
        tags: ["Breast Cancer", "Leukemia", "Lymphoma"],
        moa: "Intercalate into DNA + inhibit **topoisomerase II** + generate **free radicals** (via iron chelation/redox cycling) → DNA strand breaks + oxidative damage. Iron-mediated free radicals particularly toxic to cardiac myocytes (limited antioxidant capacity)",
        use: "Doxorubicin: breast cancer, sarcomas, lymphomas (CHOP regimen = Cyclophosphamide, Hydroxydaunorubicin/doxorubicin, Oncovin/vincristine, Prednisone), ovarian, bladder. Daunorubicin: AML, ALL. Idarubicin: AML",
        se: "**Dose-dependent dilated cardiomyopathy** (hallmark — cumulative lifetime dose limit: doxorubicin ≤450–550 mg/m²). Myelosuppression, alopecia, mucositis, **red-orange urine** (not hematuria — drug color). Severe vesicant (tissue necrosis if extravasation)",
        ci: "Prior anthracycline-induced cardiomyopathy. Exceeding cumulative dose limits. Avoid combining with trastuzumab (synergistic cardiotoxicity)",
        pk: "Dexrazoxane: iron chelator given with doxorubicin → prevents free radical formation in cardiomyocytes → cardioprotection. Liposomal doxorubicin (Doxil): different toxicity profile — hand-foot syndrome predominates, less cardiotoxic",
        pearl: "**Cardiotoxicity prevention:** Dexrazoxane chelates iron → prevents doxorubicin-induced reactive oxygen species in the heart. Monitor LVEF (echo or MUGA) before and during anthracycline therapy. Irreversible cardiomyopathy — unlike trastuzumab (reversible). Cumulative dose = the key risk factor."
      },
      {
        name: "Bleomycin",
        summary: "Testicular cancer (BEP) + Hodgkin's (ABVD) — pulmonary fibrosis is hallmark toxicity. Avoid high FiO₂ intraoperatively. Minimal myelosuppression",
        tier: 1,
        aka: "Bleomycin sulfate",
        tags: ["Testicular Cancer", "Hodgkin Lymphoma", "BEP Regimen"],
        moa: "Chelates iron → forms Fe²⁺-bleomycin complex → generates **reactive oxygen species (free radicals)** → DNA single- and double-strand breaks. Cell-cycle specific (G2/M phase). Inactivated by bleomycin hydrolase (absent in lung and skin → explains organ-specific toxicity)",
        use: "Testicular cancer (BEP = Bleomycin + Etoposide + cisPlatin — curative even in metastatic disease). Hodgkin lymphoma (ABVD regimen). Squamous cell carcinoma. Pleurodesis (sclerosing agent)",
        se: "**Pulmonary fibrosis** (hallmark — dose-dependent, potentially fatal — monitor PFTs and DLCO; onset may be delayed). Skin reactions (hyperpigmentation, thickening, Raynaud's phenomenon). Mucositis. **Minimal myelosuppression** (unusual among chemo — bleomycin hydrolase present in bone marrow → inactivated there)",
        ci: "Renal failure (↑ pulmonary toxicity — renally cleared → accumulation). Prior bleomycin pulmonary toxicity. Cumulative dose limit (~400 units lifetime). High FiO2 intraoperatively (↑ free radical damage — avoid O2 >30% during/after bleomycin)",
        pk: "Renally excreted — dose-reduce in renal failure. Bleomycin hydrolase absent in lung and skin → drug accumulates in these tissues. PFTs (especially DLCO) must be monitored serially",
        pearl: "**Bleomycin + high FiO2 = pulmonary crisis.** Classic scenario: testicular cancer survivor goes for surgery → anesthesiologist gives high-flow O2 → acute respiratory failure. Bleomycin sensitizes lung to O2 toxicity — inform anesthesia of bleomycin history. Also: bleomycin is the one chemo drug with minimal bone marrow toxicity — useful in patients who can't tolerate myelosuppression."
      },
      {
        name: "Targeted Therapy & Monoclonal Antibodies",
        summary: "Imatinib: BCR-ABL inhibitor for CML (Ph+). Rituximab: anti-CD20 for B-cell lymphomas. Trastuzumab: HER2+ breast cancer, reversible cardiomyopathy. Alemtuzumab: anti-CD52 for CLL/MS",
        tier: 2,
        aka: "Imatinib (BCR-ABL) · Rituximab (anti-CD20) · Trastuzumab/Herceptin (HER2) · Bevacizumab (anti-VEGF) · Cetuximab (anti-EGFR) · Alemtuzumab (anti-CD52)",
        tags: ["CML", "B-cell Cancers", "HER2+ Breast", "Targeted Therapy"],
        moa: "Imatinib: inhibits **BCR-ABL tyrosine kinase** (Philadelphia chromosome). Rituximab: anti-**CD20** → B-cell lysis. Trastuzumab: blocks **HER2/ErbB2** receptor. Bevacizumab: anti-**VEGF** → ↓ angiogenesis. Cetuximab: anti-**EGFR**. **Alemtuzumab: anti-CD52** → depletes mature lymphocytes (T + B cells) and NK cells",
        use: "Imatinib: CML (Ph+), GIST. Rituximab: CD20+ B-cell lymphomas, CLL, RA, ITP. Trastuzumab: HER2+ breast/gastric cancer. Bevacizumab: colorectal, glioblastoma, NSCLC. Cetuximab: KRAS wild-type colorectal, head/neck. **Alemtuzumab: CLL (CD52+), relapsing-remitting multiple sclerosis**",
        se: "**Imatinib:** fluid retention/edema, myelosuppression. **Rituximab:** infusion reactions, PML reactivation (JC virus), HBV reactivation. **Trastuzumab:** **cardiomyopathy** (reversible, unlike doxorubicin). Bevacizumab: hypertension, impaired wound healing, GI perforation, DVT. **Alemtuzumab:** severe immunosuppression (profound lymphocyte depletion → opportunistic infections), autoimmune diseases (thyroid, ITP, anti-GBM nephritis)",
        ci: "Cetuximab: KRAS-mutated tumors (no response). Trastuzumab: avoid with anthracyclines (↑ cardiotoxicity). Alemtuzumab: active infections",
        pk: "",
        pearl: "**Philadelphia chromosome (t(9;22)) = BCR-ABL** tyrosine kinase → constitutively active → uncontrolled cell proliferation (CML, some ALL). Imatinib was revolutionary — first targeted cancer therapy. Resistance: T315I 'gatekeeper' mutation → switch to ponatinib (3rd gen TKI). **Alemtuzumab in MS** causes lasting lymphocyte depletion — autoimmune complications (especially thyroid) emerge months to years later."
      },
      {
        name: "Tyrosine Kinase Inhibitors (TKIs) — Targeted Oncology",
        summary: "Erlotinib/gefitinib: EGFR inhibitors for NSCLC (EGFR-mutated). Sorafenib/sunitinib: multi-kinase inhibitors for RCC/HCC. Vemurafenib: BRAF V600E inhibitor for melanoma. SE: skin rash correlates with efficacy",
        tier: 2,
        aka: "EGFR TKIs: Erlotinib (Tarceva), Gefitinib (Iressa) · Multi-kinase: Sorafenib (Nexavar), Sunitinib (Sutent) · BRAF inhibitor: Vemurafenib (Zelboraf)",
        tags: ["NSCLC", "Melanoma", "RCC", "Targeted Therapy"],
        moa: "**Erlotinib/Gefitinib:** inhibit **EGFR tyrosine kinase** (intracellular domain) → ↓ downstream RAS/MAPK and PI3K/AKT signaling; active only in EGFR-mutated tumors. **Sorafenib/Sunitinib:** multi-target kinase inhibitors — inhibit VEGFR, PDGFR, BRAF, FLT3 → ↓ angiogenesis + tumor cell signaling. **Vemurafenib:** selective **BRAF V600E kinase inhibitor** → ↓ MAPK signaling in BRAF-mutated melanoma",
        use: "Erlotinib/gefitinib: NSCLC with **EGFR mutation (exon 19/21)** — first-line. Sorafenib: hepatocellular carcinoma (first-line unresectable), RCC, thyroid cancer. Sunitinib: RCC (first-line), GIST (imatinib-resistant), pancreatic NETs. Vemurafenib: metastatic melanoma with **BRAF V600E mutation**",
        se: "All TKIs: **dermatologic toxicity** (acneiform rash, hand-foot syndrome — severity correlates with drug efficacy for EGFR inhibitors). QT prolongation, hepatotoxicity. Sunitinib/sorafenib: hypertension (VEGFR inhibition → ↓ NO production), hypothyroidism (sunitinib). **Vemurafenib:** paradoxical cutaneous squamous cell carcinoma (BRAF inhibitor activates RAS-MAPK in BRAF-WT cells), photosensitivity, QT prolongation",
        ci: "Erlotinib/gefitinib: KRAS-mutated tumors (no benefit — KRAS is downstream of EGFR). Vemurafenib: BRAF wild-type tumors",
        pk: "All oral agents. Hepatic CYP metabolism — numerous drug interactions. Must test for tumor mutation before prescribing (EGFR, BRAF, KRAS testing required)",
        pearl: "**Biomarker testing before TKIs is essential.** EGFR inhibitors only work in EGFR-mutated NSCLC. BRAF inhibitors only work in BRAF V600E+ melanoma. If KRAS is mutated, don't bother with cetuximab or erlotinib — RAS is constitutively active regardless of EGFR. The skin rash from EGFR TKIs is a good sign — higher-grade rash correlates with better response."
      },
    ]
  },
{
    group: "Immunosuppressants",
    color: "onco",
    drugs: [
      {
        name: "Azathioprine",
        summary: "Purine antimetabolite prodrug → 6-MP → inhibits de novo purine synthesis → ↓ lymphocyte proliferation. Used in transplant, autoimmune disease. DANGEROUS with allopurinol",
        tier: 1,
        aka: "Imuran · Prodrug of 6-mercaptopurine (6-MP)",
        tags: ["Transplant", "Autoimmune", "IBD", "RA"],
        moa: "**Prodrug** converted to **6-mercaptopurine (6-MP)** → further converted to 6-thioguanine nucleotides → inhibit de novo purine synthesis → suppress proliferation of **T and B lymphocytes** (lymphocytes rely on de novo synthesis, unlike most cells)",
        use: "Organ transplant rejection prophylaxis (with other agents), Crohn's disease, ulcerative colitis (steroid-sparing), rheumatoid arthritis, SLE, myasthenia gravis, autoimmune hepatitis",
        se: "**Myelosuppression** (leukopenia, thrombocytopenia, anemia — dose-limiting). **Hepatotoxicity** (↑ LFTs). Increased infection risk. GI upset. **Malignancy risk** (lymphoma, skin cancer with long-term use). Teratogenic",
        ci: "**Allopurinol / febuxostat co-administration** (xanthine oxidase inhibitors block 6-MP metabolism → massive 6-MP accumulation → severe myelosuppression — FATAL if missed). Pregnancy. Severe myelosuppression",
        pk: "**TPMT (thiopurine methyltransferase) genotype testing** before starting — TPMT deficiency → cannot metabolize 6-MP → severe myelosuppression. Metabolized by xanthine oxidase and TPMT. If allopurinol must be used, reduce azathioprine dose by 75%. Monitor CBC regularly",
        pearl: "**The azathioprine + allopurinol interaction is a classic Step 1 kill question.** Allopurinol inhibits xanthine oxidase → 6-MP cannot be cleared → toxic accumulation → fatal myelosuppression. TPMT testing is standard of care before initiation. Lymphocytes are uniquely dependent on de novo purine synthesis (no salvage pathway backup), which is why this drug selectively immunosuppresses."
      },
      {
  name: "Hydroxychloroquine",
  summary: "Antimalarial/DMARD for SLE and RA. Key SE: irreversible retinal toxicity (bull's-eye maculopathy) — annual eye screening required",
  tier: 2,
  aka: "Plaquenil",
  tags: ["SLE", "RA", "Lupus"],
  moa: "Accumulates in lysosomes → impairs antigen processing → ↓ TLR activation",
  use: "SLE (reduces flares/mortality), Rheumatoid Arthritis",
  se: "**Retinal toxicity** (bull's-eye maculopathy) — dose/duration dependent",
  ci: "G6PD deficiency, pre-existing retinal disease",
  pk: "Requires annual ophthalmology screening",
  pearl: "Safe in pregnancy and **disease-modifying in SLE**."
},
      {
        name: "Mycophenolate Mofetil",
        summary: "Prodrug → mycophenolic acid → inhibits IMPDH → blocks de novo guanosine synthesis → selective suppression of T and B lymphocytes. Mainstay of solid organ transplant. Major teratogen",
        tier: 1,
        aka: "CellCept · Myfortic (enteric-coated) · MMF",
        tags: ["Transplant", "Lupus Nephritis", "Autoimmune"],
        moa: "**Prodrug** hydrolyzed to **mycophenolic acid (MPA)** → selectively inhibits **inosine monophosphate dehydrogenase (IMPDH)** → blocks de novo guanosine nucleotide synthesis → cytostatic effect on **T and B lymphocytes** (which lack a guanosine salvage pathway)",
        use: "Solid organ transplant rejection prophylaxis (kidney, heart, liver — used with calcineurin inhibitor + corticosteroid). Lupus nephritis (first-line induction and maintenance). Myasthenia gravis. Steroid-sparing agent in various autoimmune conditions",
        se: "**GI toxicity** (diarrhea, nausea, cramping — most common; enteric-coated formulation reduces GI burden). **Myelosuppression** (leukopenia, anemia, thrombocytopenia). Increased infection risk (CMV, PCP). **Teratogenic** (cleft lip/palate, limb abnormalities, miscarriage — two forms of contraception mandatory)",
        ci: "**Pregnancy** (major teratogen — category D). Hypersensitivity to MMF. Caution with antacids/PPIs (↓ absorption via chelation)",
        pk: "Rapidly hydrolyzed to MPA after oral absorption. Enterohepatic recirculation prolongs effect. Renal excretion. Antacids and cholestyramine reduce absorption. **No dangerous allopurinol interaction** (unlike azathioprine). Monitor CBC and renal function",
        pearl: "**MMF vs Azathioprine:** Both target lymphocyte purine synthesis but via different enzymes — MMF inhibits IMPDH (guanosine pathway); azathioprine inhibits via 6-MP (overall purine synthesis). MMF has largely replaced azathioprine in transplant due to better efficacy and **no allopurinol interaction**. GI toxicity is MMF's main limitation — enteric-coated form helps. **Teratogenicity is a major Step 1 theme** — always flag in women of childbearing age and counsel on contraception."
      },
    ,
      {
  name: "Cyclosporine & Tacrolimus (Calcineurin Inhibitors)",
  summary: "Cyclosporine: binds cyclophilin → blocks calcineurin → ↓ IL-2 transcription. Tacrolimus: binds FKBP-12 → same end effect. Both: nephrotoxic. Cyclosporine: gingival hyperplasia, hirsutism. Tacrolimus: neurotoxic, diabetogenic",
  tier: 1,
  aka: "Cyclosporine (Neoral, Sandimmune) · Tacrolimus (FK506, Prograf) · Pimecrolimus (topical, Elidel)",
  tags: ["Transplant", "Autoimmune", "Nephrotoxicity", "IL-2 Inhibition"],
  moa: "**Cyclosporine:** binds intracellular **cyclophilin** → complex inhibits **calcineurin** (phosphatase) → calcineurin cannot dephosphorylate NFAT → **NFAT cannot enter nucleus** → ↓ transcription of **IL-2** and other cytokines → ↓ T-cell activation + proliferation. **Tacrolimus (FK506):** binds **FKBP-12** (FK binding protein) → FK506-FKBP12 complex inhibits **calcineurin** by same mechanism → ↓ IL-2. Same downstream target (calcineurin), different binding protein",
  use: "**Solid organ transplant rejection prophylaxis** (kidney, liver, heart — both are mainstays). Cyclosporine: also RA, psoriasis, uveitis, aplastic anemia. Tacrolimus: increasingly preferred over cyclosporine in transplant (better efficacy). Pimecrolimus/tacrolimus topical: atopic dermatitis (topical calcineurin inhibitors — avoid steroids on face)",
  se: "**Both nephrotoxic** (↓ renal blood flow via afferent arteriole vasoconstriction — monitor renal function + drug levels). **Hypertension** (renal effects). **Increased infection risk** (especially viral — CMV, EBV/PTLD). **Malignancy** (lymphoma — EBV-associated PTLD, skin cancers). **Cyclosporine-specific:** **gingival hyperplasia**, **hirsutism** (hypertrichosis), metabolic syndrome. **Tacrolimus-specific:** **neurotoxicity** (tremor, headache, seizures — tacrolimus crosses BBB more), **new-onset diabetes** (↓ insulin secretion from β-cells), fewer cosmetic effects than cyclosporine",
  ci: "Both: concurrent nephrotoxic agents (NSAIDs, aminoglycosides — additive nephrotoxicity). **Both are CYP3A4 substrates** — major drug interactions (azole antifungals, macrolides, rifampin, phenytoin, grapefruit juice). Tacrolimus: caution in patients with seizure disorders or diabetes",
  pk: "Both metabolized by **CYP3A4** — drug interactions are clinically critical. **Narrow therapeutic index** — **drug level monitoring** is mandatory (trough levels). Tacrolimus: 100x more potent than cyclosporine on molar basis. Both also inhibit P-glycoprotein → can increase levels of co-administered drugs",
  pearl: "**Cyclosporine vs Tacrolimus distinguishing features:** Same MOA (calcineurin inhibition), different binding proteins (cyclophilin vs FKBP). Unique to cyclosporine: **gingival hyperplasia** (also caused by phenytoin, CCBs — calcium channel connection?), **hirsutism**. Unique to tacrolimus: **neurotoxicity** (tremor, seizures), **diabetes** (β-cell toxicity). Both nephrotoxic and both major transplant drugs. When a board question says 'transplant patient develops tremors and new-onset DM' → **tacrolimus**. Gingival hyperplasia + transplant → **cyclosporine or phenytoin or CCBs**."
},
      {
  name: "mTOR Inhibitors (Sirolimus & Everolimus)",
  summary: "Sirolimus: binds FKBP-12 → inhibits mTOR (not calcineurin) → ↓ T-cell proliferation. Everolimus: same. Non-nephrotoxic via calcineurin pathway. Used in transplant, RCC, TSC. Key SE: hyperlipidemia, impaired wound healing",
  tier: 2,
  aka: "Sirolimus (Rapamycin, Rapamune) · Everolimus (Afinitor) · Temsirolimus (IV, for RCC)",
  tags: ["Transplant", "RCC", "TSC", "mTOR"],
  moa: "**Sirolimus/everolimus:** bind intracellular **FKBP-12** (same as tacrolimus) → sirolimus-FKBP12 complex inhibits **mTOR (mammalian target of rapamycin)** — a serine/threonine kinase that drives cell growth/proliferation. **mTOR inhibition → ↓ IL-2 receptor signaling** (blocks downstream of IL-2R, not IL-2 transcription) → ↓ T-cell cycle progression (G1→S). Also inhibits tumor cell proliferation (mTOR is frequently activated in cancers). **NOT a calcineurin inhibitor** — different mechanism from cyclosporine and tacrolimus despite same initial binding protein (FKBP)",
  use: "**Transplant:** sirolimus/everolimus (kidney transplant — often combined with calcineurin inhibitor + steroid). Everolimus: **renal cell carcinoma** (mTOR overactivation in VHL-mutant RCC), pancreatic NETs, HR+/HER2- breast cancer (with exemestane). Sirolimus: **tuberous sclerosis complex (TSC)** (mTOR constitutively activated by TSC1/TSC2 loss → sirolimus shrinks hamartomas, subependymal giant cell astrocytomas). Sirolimus-eluting stents (↓ restenosis)",
  se: "**Hyperlipidemia/hypertriglyceridemia** (mTOR involved in lipid metabolism — distinct from calcineurin inhibitor effects). **Impaired wound healing** (mTOR drives fibroblast proliferation — stop sirolimus before surgery). **Myelosuppression** (leukopenia, thrombocytopenia, anemia). **Interstitial pneumonitis/pulmonary toxicity** (everolimus — non-infectious lung inflammation). **Oral ulcers** (aphthous stomatitis). **Hyperglycemia**. **Non-nephrotoxic via the calcineurin pathway** (but can still affect kidneys indirectly at high doses — used to spare calcineurin inhibitors in protocols)",
  ci: "Avoid with strong CYP3A4 inhibitors/inducers (major drug interactions — same as calcineurin inhibitors). Impaired wound healing contraindication for perioperative use",
  pk: "CYP3A4 and P-glycoprotein substrate — extensive drug interactions. Long t½ (sirolimus ~60h) — weekly dosing possible. Everolimus shorter t½ (~28h). Drug level monitoring recommended",
  pearl: "**mTOR inhibitors vs calcineurin inhibitors: key distinction.** Both are used in transplant, both bind FKBP-12, but they inhibit completely different targets: tacrolimus → calcineurin → blocks IL-2 production; sirolimus → mTOR → blocks IL-2 signaling/response. **Sirolimus does NOT cause gingival hyperplasia, hirsutism (cyclosporine), or neurotoxicity/DM (tacrolimus).** Instead it causes hyperlipidemia and impaired wound healing. In TSC: mTOR is constitutively active (TSC1/2 suppresses mTOR normally) → sirolimus is the targeted treatment for TSC-related brain tumors, renal angiomyolipomas, and pulmonary LAM."
}
    ]
  }
],

toxicology: [
  {
    group: "Drug Toxicology & Antidotes",
    color: "neuro",
    drugs: [
      {
  name: "Drug Antidotes (High-Yield Pairs)",
  summary: "Classic antidote pairs: naloxone (opioids), flumazenil (benzos), N-acetylcysteine (acetaminophen), protamine (heparin), Vitamin K/FFP (warfarin), fomepizole (methanol/EG), atropine+pralidoxime (OPs)",
  tier: 1,
  aka: "Naloxone (Narcan) · Flumazenil (Romazicon) · N-Acetylcysteine (Mucomyst) · Protamine sulfate · Vitamin K / FFP / Idarucizumab · Fomepizole (4-MP) · Atropine + Pralidoxime (2-PAM) · Deferoxamine · Physostigmine · Digoxin immune Fab · Methylene blue",
  tags: ["Overdose", "Toxicology", "Reversal Agent", "Antidotes"],
  moa: "**Naloxone:** competitive μ-opioid receptor antagonist → displaces opioids. **Flumazenil:** competitive GABA-A benzodiazepine site antagonist. **N-acetylcysteine (NAC):** replenishes **glutathione** → conjugates NAPQI (toxic acetaminophen metabolite) → prevents hepatotoxicity. **Protamine:** positively-charged protein + negatively-charged heparin → ionic binding → neutralizes anticoagulation. **Fomepizole:** inhibits **alcohol dehydrogenase (ADH)** → prevents conversion of methanol/ethylene glycol to toxic metabolites (formate/oxalate). **Atropine:** muscarinic antagonist (blocks DUMBBELLS of OP poisoning). **Pralidoxime (2-PAM):** regenerates AChE if given before 'aging' (~24–48h). **Deferoxamine:** chelates iron. **Methylene blue:** reduces methemoglobin (Fe³⁺ → Fe²⁺) via NADPH-dependent reduction",
  use: "See table — each antidote is specific to its toxin. **Flumazenil caution:** can precipitate seizures in chronic benzo users (benzodiazepine withdrawal) and doesn't reverse respiratory depression from polypharmacy — use rarely in clinical practice (primarily diagnostic). **Idarucizumab:** reverses **dabigatran** (direct thrombin inhibitor). **Andexanet alfa:** reverses **factor Xa inhibitors** (rivaroxaban, apixaban)",
  se: "Naloxone: precipitates acute opioid withdrawal (agitation, vomiting, tachycardia, hypertension) — painful but not dangerous. Repeat dosing needed (short t½ ~30–80 min) — opioid may outlast antidote. Flumazenil: seizures in dependent patients. Protamine: hypotension, bradycardia, anaphylaxis (especially fish allergy or prior protamine/NPH insulin exposure). NAC: anaphylactoid reactions (IV formulation)",
  ci: "Flumazenil: chronic benzo dependence, TCA overdose (seizure risk — benzodiazepines are treatment). Pralidoxime: after AChE 'aging' (>24–48h for most organophosphates — enzyme-drug bond becomes irreversible)",
  pk: "**Naloxone t½ ~ 30–80 min** — shorter than most opioids → repeat dosing or infusion often required. All antidotes have unique pharmacokinetics; timing of administration is critical for pralidoxime (aging) and NAC (most effective within 8h of acetaminophen ingestion)",
  pearl: "**Organophosphate poisoning two-drug treatment:** Atropine (high doses, titrate to dry secretions — NOT to heart rate) + pralidoxime (regenerates AChE before 'aging'). The 'aging' process is irreversible binding of the OP-AChE complex that makes pralidoxime ineffective — soman ages fastest (~10 min), parathion ages in ~24h. **Critical drug interaction:** never give succinylcholine to OP-poisoned patients (AChE is already inhibited → prolonged paralysis). Also: **Digoxin Fab** fragments — indications are severe arrhythmia, K⁺ > 5.5, or digoxin level > 10 ng/mL."
},
      {
  name: "Acetaminophen Toxicity & N-Acetylcysteine",
  summary: "NAPQI (CYP2E1 metabolite) depletes glutathione → hepatic necrosis zone 3. N-acetylcysteine replenishes GSH. Rumack-Matthew nomogram guides treatment. Risk ↑ with fasting, alcoholism, CYP inducers",
  tier: 1,
  aka: "Acetaminophen (APAP, Tylenol, Paracetamol) · NAPQI (N-acetyl-p-benzoquinone imine) · N-acetylcysteine (NAC, Mucomyst, Acetadote)",
  tags: ["Overdose", "Hepatotoxicity", "Toxicology", "Antidote"],
  moa: "**Normal:** acetaminophen → 94% sulfation/glucuronidation → non-toxic conjugates. 4–5% → CYP2E1/3A4 → **NAPQI** → immediately conjugated with **glutathione (GSH)** → mercapturic acid → excreted. **Overdose:** GSH depleted → NAPQI accumulates → **covalently binds hepatocyte proteins** → oxidative stress → **centrilobular (zone 3) hepatic necrosis** (highest CYP2E1 activity, lowest GSH reserves). **NAC mechanism:** provides cysteine (precursor) → replenish GSH → conjugate NAPQI → prevent hepatocyte death",
  use: "N-acetylcysteine: treatment of acetaminophen overdose (most effective **within 8–10 hours** of ingestion — start before lab confirmation if index of suspicion high). Also used as mucolytic (inhaled — cystic fibrosis, COPD), contrast nephropathy prevention (IV/oral NAC pre-procedure — controversial evidence). **Rumack-Matthew nomogram:** plots serum APAP level vs. time since ingestion → determines treatment threshold",
  se: "Acetaminophen overdose: **Phase I (0–24h):** nausea, vomiting, malaise (NAPQI accumulating). **Phase II (24–72h):** RUQ pain, ↑ LFTs — appears to improve clinically (deceptive). **Phase III (72–96h):** peak hepatotoxicity, fulminant hepatic failure, coagulopathy, renal failure (proximal tubule NAPQI), encephalopathy. **Phase IV:** recovery (if survives) or death. NAC IV: anaphylactoid infusion reaction (slowing infusion rate helps)",
  ci: "Liver failure is the consequence, not a contraindication — treat regardless. Fomepizole (alcohol dehydrogenase inhibitor) is NOT used for APAP toxicity. **Risk factors for toxicity:** alcoholism (↑ CYP2E1 induction, ↓ GSH), fasting/malnutrition (↓ GSH), CYP inducers (rifampin, carbamazepine, phenytoin — lower toxic threshold)",
  pk: "Therapeutic dose: 325–1000mg q4–6h, max 4g/day (2g/day in liver disease/alcoholism). Toxic dose: >7.5–10g single ingestion in adults. Children: 150 mg/kg threshold. Minimal therapeutic index in at-risk populations",
  pearl: "**Zone 3 hepatic necrosis** is specific to acetaminophen toxicity (compare: zone 1 = phosphorus/heavy metals; zone 3 = acetaminophen, halothane, carbon tetrachloride). Zone 3 (centrilobular) has highest CYP2E1 activity and is most distant from portal blood supply (lowest O₂ + GSH). **Classic board trap:** patient with alcoholism takes 'normal' doses for days → toxicity. Ethanol chronically INDUCES CYP2E1 (↑ NAPQI production) AND depletes GSH → lower toxic threshold. **Acute** ethanol actually COMPETES with CYP2E1 → somewhat protective acutely but harmful with chronic use."
},
      {
  name: "Ethanol Metabolism, Disulfiram & Alcohol Antidotes",
  summary: "Ethanol → acetaldehyde (ADH) → acetate (ALDH). Disulfiram blocks ALDH → acetaldehyde accumulation → flushing/nausea/vomiting. Fomepizole: methanol/ethylene glycol (blocks ADH). Wernicke-Korsakoff: thiamine deficiency",
  tier: 1,
  aka: "Ethanol · Disulfiram (Antabuse) · Naltrexone (ReVia) · Acamprosate (Campral) · Fomepizole (4-methylpyrazole) · Thiamine (Vitamin B1)",
  tags: ["Alcohol", "Addiction", "Methanol", "Wernicke's"],
  moa: "**Ethanol metabolism:** Ethanol → (ADH, CYP2E1 chronic) → **acetaldehyde** → (ALDH) → **acetate** → → CO₂ + H₂O. Generates NADH → ↑ NADH:NAD⁺ ratio → ↓ gluconeogenesis (hypoglycemia) + ↓ fatty acid oxidation (fatty liver) + ↑ lactate. **Disulfiram:** irreversibly inhibits **ALDH** → acetaldehyde accumulates → flushing, nausea, vomiting, tachycardia, hypotension (disulfiram-like reaction). **Naltrexone:** μ-opioid receptor antagonist → ↓ euphoria/reward of alcohol. **Acamprosate:** NMDA antagonist + GABA-A modulator → ↓ glutamate excitotoxicity during abstinence → ↓ craving. **Fomepizole:** competitive inhibitor of **ADH** → prevents methanol/EG conversion to formate/oxalate",
  use: "Disulfiram: alcohol use disorder (aversion therapy — patient must be motivated, cannot drink). Naltrexone: alcohol use disorder (↓ craving, ↓ relapse) + opioid use disorder. Acamprosate: alcohol use disorder (maintaining abstinence — safe in liver disease, unlike naltrexone). **Fomepizole:** methanol poisoning (→ formate → metabolic acidosis + blindness) and ethylene glycol poisoning (→ oxalate → renal failure). Thiamine: **Wernicke's encephalopathy** (always give IV thiamine BEFORE glucose in alcoholic patients)",
  se: "Disulfiram: **severe reaction if alcohol ingested** (must warn patient about hidden alcohol in foods, medications, mouthwash). Hepatotoxicity. **Naltrexone:** precipitates acute opioid withdrawal if opioid-dependent — screen carefully. Hepatotoxicity at high doses. Acamprosate: diarrhea. GI upset. Safe in liver disease. Fomepizole: headache, nausea, dizziness",
  ci: "Disulfiram: **must be alcohol-free for ≥12h before starting**. Liver disease (hepatotoxicity), heart failure, psychosis. Naltrexone: current opioid use, acute hepatitis, liver failure",
  pk: "Disulfiram: long t½ (up to 2 weeks effect after stopping). Naltrexone: oral or monthly IM injection (Vivitrol — improves compliance). Acamprosate: renally excreted — dose-reduce in renal failure (unlike naltrexone — renally cleared). **Metronidazole has a disulfiram-like effect** (avoid alcohol with metronidazole, tinidazole, cefotetan, cefoperazone)",
  pearl: "**The Wernicke-Korsakoff continuum:** Thiamine (B1) deficiency in alcoholism → **Wernicke's encephalopathy** (acute — confusion + **ataxia + ophthalmoplegia** = 'confusion + can't walk + can't move eyes') → if untreated → **Korsakoff psychosis** (chronic irreversible — anterograde amnesia + confabulation, mamillary body damage). **Always give IV thiamine BEFORE glucose** — glucose bolus ↑ metabolic demand → depletes last thiamine → precipitates Wernicke's. In the ER, when giving D50 to any malnourished or alcoholic patient, give thiamine first."
}
    ]
  }
],

};
